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RESUMO  
A doença celíaca (DC) é uma enteropatia autoimune que ocorre em indivíduos 
geneticamente suscetíveis como resultado da ingestão de glúten. Para o diagnóstico clínico 
desta doença, a metodologia mais usada é o ensaio de imunoabsorção enzimática (ELISA), 
mas nos últimos anos muitos esforços tem sido feitos para melhorar os testes serológicos 
para a DC. Contudo, não existe um acordo geral no método imunoquímico a utilizar. 
Hoje em dia, os métodos baseados no uso de sensores eletroquímicos estão 
desempenhando um papel cada vez maior em diversos campos em que sistemas de 
medida precisos, rápidos e que permitam uma medida em tempo real são necessários. 
Relativamente à qualidade e custo, os sensores eletroquímicos podem ser uma melhor 
opção do que os métodos analíticos convencionais. Especialmente, os imunossensores 
eletroquímicos (IEs), que ao combinar a elevada especificidade dos métodos 
imunoquímicos tradicionais com o elevado limite de deteção das técnicas eletroquímicas, 
são poderosas ferramentas analíticas para o desenvolvimento de dispositivos mais 
rápidos, mais simples, mais sensíveis e de baixo custo que podem ser competitivos o 
suficiente e aplicados diariamente com êxito no diagnóstico clínico da DC. 
O principal objetivo desta tese de doutoramento foi o desenvolvimento, produção e 
otimização da melhor superfície transdutora de modo a obter IEs sensíveis, reprodutíveis 
e robustos para análise rotineira do diagnóstico clínico da DC. 
A primeira etapa deste trabalho consistiu na busca da superfície apropriada para a 
imobilização da quantidade adequada de material proteico na superfície transdutora dos 
sensores eletroquímicos, incluindo também a exploração das potencialidades dos 
nanomateriais. Para este propósito, elétrodos serigrafados de carbono foram 
nanoestruturados com nanopartículas de ouro, nanotubos de carbono, nanofibras de 
carbono, e, com sistemas híbridos de materiais de carbono e metal. A biofuncionalidade 
dos diferentes transdutores foi avaliada através da sua capacidade para adsorverem e 
reterem material proteico nas suas superfícies, e empregando, como modelo analito, o 
complexo altamente estável estreptravidina/biotina. As superfícies transductoras foram 
também caraterizadas por microscopia eletrónica de varrimento. Os elétrodos serigrafados 
de carbono modificados com os híbridos de nanotubos de carbono e nanopartículas de 
ouro revelaram ser os que propocionavam a superfície transductoras mais apropriada. 
Depois da seleção do transductor mais adequado, a fase sensora dos IEs foi construída 
com base na interação antigénio-anticorpo. IEs para a determinação de imunoglobulinas 
(IgG) classe A (IgA) e classe G (IgG) produzidas contra a gliadina (AGA) e contra a 
transglutaminase tecidual (anti-tTG) (i.e. os marcadores serológicos específicos para a 
DC) foram desenvolvidos e otimizados. Um IE de multi-deteção para a determinação 
simultânea de dois biomarcadores, AGA e anti-tTG, foram também desenvolvidos. Além 
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disso, a determinação de anticorpos humanos gerados contra a gliadina desamidada foi 
também efetuada. Os sensores desenvolvidos foram testados usando amostras de soro de 
pacientes de DC e indivíduos saudáveis. Finalmente, os métodos desenvolvidos foram 
validados por comparação com os métodos espetrofotométricos convencionalmente 
utilizados no diagnóstico serológico da DC.  
Os imunossensores construídos e optimizados nesta tese de doutoramento tem como 
vantagem o fato de serem ferramentas analíticas simples de usar e descartáveis, o que 
facilitará uma futura transferência destes sensores para aplicações point-of-care. 
 
 
Palavras-chave: doença celíaca, transglutaminase tecidual, gliadina, elétrodos 
serigrafados nanoestruturados, imunossensores eletroquímicos  
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ABSTRACT 
Celiac disease (CD) is an autoimmune enteropathy that occurs in genetically 
susceptible individuals as a result of gluten ingestion. For CD diagnostic purposes the 
most used methodology is the enzyme-linked immunosorbent assay (ELISA), and in the 
past few years many attempts have been made to improve CD serological tests. However, 
there is no general agreement on the immuno-based analytical method for CD screening.  
Nowadays, electrochemical sensing techniques are playing a growing role in various 
fields in which accurate, fast and online measuring systems are required. With regard to 
quality and cost, electrochemical sensors can be a better option than standard analytical 
methods. Especially electrochemical immunosensors (EIs), which combine the high 
specificity of traditional immunochemical methods with the low detection limits of 
modern electrochemical techniques, are powerful analytical tools to develop faster, 
simpler, more sensitive and low-cost devices that can be competitive enough to be 
successfully applied on a daily basis for CD clinical diagnosis. 
The main goal of this PhD thesis was the development, manufacturing and 
optimization of the best transducer surface to obtain sensitive, reproducible and robust 
EIs for routine analyses of CD clinical serological diagnosis.  
The first stage of this work consisted of the search for a suitable layer for immobilizing 
an adequate amount of protein material on the transducer's surface of electrochemical 
sensors, including the exploitation of the potentialities of nanomaterials. For this purpose, 
screen-printed carbon electrodes  were nanostructured with gold nanoparticles (NPAus), 
carbon nanotubes, and carbon nanofibers, and, with hybrid systems of the carbon/metal 
materials. The biofunctionality of the different transducers was evaluated by their ability 
to adsorb and retain protein material on their surface, employing the highly stable and 
efficient streptavidin/biotin complex as model analyte. The transducers' surfaces were also 
characterized by scanning electron microscopy. The screen-printed electrodes modified 
with the hybrid carbon nanotubes/gold nanoparticles revealed to provide the most 
suitable transducer surface. 
After the adequate electrode surface selection, the sensing phase of the EIs was 
constructed relying on antigen-antibody interactions. EIs for the determination of 
immunoglobulins (IgG) class A (IgA) and class G (IgG) against gliadin (AGA) and tissue 
transglutaminase (anti-tTG) (i.e. specific CD serological markers) were developed and 
optimized. A multiplexed EI for the simultaneous assessment of AGA and anti-tTG CD 
biomarkers was also developed. Moreover, the determination of human antibodies 
produced against deamidated gliadin was also assayed. The developed sensors were tested 
using serum samples from CD patients and healthy individuals.  
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Finally, the developed methodologies were validated by comparison with the 
established spectrophotometric immunoassays for CD serological diagnosis.   
The immunosensors, that were constructed and optimized within this doctoral thesis, 
have the advantage of being easy-to-use and disposable analytical tools, which facilitates a 
future transfer to point-of-care applications.  
 
 
Keywords: celiac disease, tissue transglutaminase, gliadin, nanostructured screen-
printed electrodes, electrochemical immunosensors 
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RÉSUME 
La maladie cœliaque (MC) est une entéropathie auto-immune qui apparait chez des 
personnes prédisposées génétiquement, due à une ingestion de gluten. La méthode la plus 
utilisée dans les diagnostiques cliniques est le test du dosage d'immunoabsorption par 
enzyme liée (ELISA), et ces dernières années, des études ont été réalisées dans le but 
d’améliorer les tests sérologiques de la MC. Cependant il n’y a pas de consensus au niveau 
des méthodes analytiques basées sur des réactions immunologiques pour la détection de la 
MC. 
De nos jours, les techniques de mesures électrochimiques jouent un rôle de plus en 
plus important dans divers domaines dans lesquels sont nécessaires des systèmes de 
mesures précis, rapides, et en temps réels. Au regard de la qualité et du coût, les capteurs 
électrochimiques peuvent être une meilleure option que les méthodes de référence 
actuelles. Plus particulièrement les immunocapteurs électrochimiques (IEs), qui 
combinent la grande spécificité des méthodes immunochimiques avec les limites de 
détection basses des techniques électrochimiques modernes, sont des outils analytiques 
très utiles pour développer des dispositifs plus rapides, plus simple, et à moindre coût, de 
manière à être  suffisamment compétitifs pour être appliqué avec succès dans les 
diagnostiques cliniques quotidiens de la maladie cœliaque.  
L’objectif principal de cette thèse de doctoract fut le développement, la fabrication et 
l’optimisation du meilleur transducteur pour obtenir des IEs sensibles, reproductibles et 
robustes pour le diagnostique routinier des marqueurs sérologiques de la maladie 
cœliaque. 
La première de ce travail fut la recherche d’une couche appropriée pour 
l’immobilisation d’une quantité adéquate de matériel protéique sur la superficie 
transductrice des capteurs électrochimiques, et dans le même temps l’exploration des 
propriétés des nanomatériaux. Pour cela des électrodes sérigraphiées de carbone furent 
nanostructurées avec des nanoparticules d’or, des nanotubes de carbones, des nano fibres 
de carbone et avec des systèmes hybrides fait de carbones et de métal. La bio 
fonctionnalité des différents transducteurs furent évaluées pour leurs capacité 
d’adsorption et rétention de matériels protéiques à sa surface, en utilisant comme modèle 
analytique, le complexe hautement stable et efficace, streptavidine/biotine. Les superficies 
transductrices furent caractérisées par microscopie électronique à balayage. Les électrodes 
sérigraphiées de carbone modifiées avec l’hybride de nanotubes de carbone et 
nanoparticules d’or se révéla être la superficie transductrice la plus adéquate. 
 Après avoir déterminée quelle était la meilleure superficie électrodique, la partie de 
détection des IEs  fut construite en se basant sur les interactions antigènes-anticorps. Les 
immunocapteurs électrochimiques pour la détermination d’immunoglobuline (IgG) de 
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classe A (IgA) et de classe G (IgG) générée contre gliadin (AGA) et transglutaminase 
tissulaire (anti-tTG) (i.e. marqueurs sérologiques spécifiques de la maladie cœliaque) 
furent développés et optimisés. Un IEs multiplexed, pour la détection simultanée des bio 
marqueurs de la maladie cœliaque AGA et anti tTG a également été développé. De plus, la 
détermination des anticorps humains produits contre la gliadine desamidée fut aussi 
testée. Les capteurs développés furent testés en utilisant des échantillons de sérum de 
patients atteints de la MC et de patients sains. Finalement, les méthodes développées 
furent validées en comparant les résultats obtenus avec ceux obtenus grâce aux 
immunotests spectrophotomètriques de référence pour les diagnostiques sérologiques de 
la MC. 
Les capteurs proposés, qui ont été construits et optimisés dans cette thèse, ont 
l’avantage d’être des outils analytiques faciles à utiliser et jetables, ce qui facilite  un futur 
transfert aux applications point-of-care. 
  
 
Mots-clés: la maladie cœliaque, transglutaminase tissulaire, la gliadine, électrodes 
sérigraphiées nanostructurées,  immunocapteurs électrochimique 
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RESUMEN 
La enfermedad celíaca (EC) es una enteropatía autoinmune que sufren individuos 
genéticamente susceptibles como resultado de la ingestión de gluten. Para el diagnóstico 
de esta enfermedad, los métodos más utilizados están basados en ensayos por 
inmunoabsorción ligado a enzimas,  llamados ensayo de inmunoabsorción enzimática 
(ELISA), pero en los últimos años la comunidad científica está haciendo esfuerzos para 
mejorar los tests serológicos de diagnóstico de la EC. Sin embargo, no existe un acuerdo 
sobre el tipo de método inmunoquímico a utilizar para el diagnóstico de la EC. 
Actualmente, los métodos basados en el uso de sensores electroquímicos están 
jugando un papel muy importante en varios campos en los que es necesario implantar 
métodos rápidos, fiables, y que puedan realizar medidas en línea. Teniendo en cuenta la 
calidad y el coste, los sensores electroquímicos pueden convertirse en una buena 
alternativa a los métodos estándar de análisis. Entre los diferentes sensores 
electroquímicos, cabe destacar los inmunosensores electroquímicos (IEs), ya que 
combinan la alta especificidad de las reacciones inmunológicas con los bajos límites de 
detección las técnicas electroquímicas, lo que los convierten en poderosas herramientas 
analíticas en el desarrollo de métodos más rápidos, más sencillos, más sensibles and de 
menor coste que los utilizados actualmente en el diagnóstico de la EC. 
El principal objetivo planteado en esta tesis doctoral fue el desarrollo, fabricación y 
optimización de la superficie del transductor para obtener inmunosensores 
electroquímicos para el diagnóstico serológico de la EC más sensibles, robustos y 
reproducibles y con una estabilidad aceptable que permita su comercialización. 
La primera parte de este trabajo consistió en la búsqueda de una inmovilización 
adecuada del material proteico en la superficie del transductor del sensor electroquímico, 
explotando la potenciabilidad de los nanomateriales. Para ello, electrodos  serigrafiados de 
carbono fueron nanoestructurados con nanopartículas de oro, nanotubos de carbono y 
nanofibras de carbono, además del uso de materiales nanohíbridos de carbono/metal. La 
biofuncionalidad de los diferentes transductores ha sido evaluada a través de su habilidad 
para absorber y retener material proteico en sus superficies, empleando para ello la 
reacción estreptavidina/biotina. Las superficies de los diferentes transductores también 
han sido caracterizadas utilizando microscopía de barrido electrónico. Las mejores 
superficies transductoras han resultado ser los electrodos  serigrafiados de carbono 
modificados con híbridos nanotubos de carbon/nanopartículas de oro. 
Después de seleccionar el transductor más adecuado, la interfase sensora de los EIs 
fue construida utilizando la reacción antígeno-anticuerpo. Así, en el caso que nos ocupa,  
los EIs desarrollados y puestos a punto en este trabajo determinan inmunoglobulinas  A 
(IgA) y G (IgG) anti-gliadina (AGA) y anti-transglutaminasa tisular (anti-tTG), 
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marcadores serológicos específicos de la EC. Además, un EI bianalito para la detección 
simultánea de los marcadores de la EC, AGA y anti-tTG, ha sido también desarrollado. Por 
último, se ha ensayado un inmunosensor electroquímico para la determinación de 
anticuerpos contra gliadina deaminada.  
Los diferentes sensores desarrollados han sido testados utilizando muestras de suero 
humano de pacientes celíacos y personas sanas. Finalmente los inmunosensores 
electroquímicos desarrollados han sido validados con otros inmunoensayos 
espectrofotométricos ya establecidos para el diagnóstico serológico de la EC. 
Los inmunosensores diseñados y optimizados en esta tesis doctoral tienen la ventaja de 
ser de fácil manejo y de un único uso, lo que facilitaría una futura implantación de estos 
sensores como dispositivos point-of-care.  
 
 
Palabras clave: enfermedad celíaca, la transglutaminasa tisular, la gliadina, electrodos 
serigrafiados nanoestructurados,  inmunosensores electroquímicos 
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ORGANIZATION AND STRUCTURE OF THE DISSERTATION 
The present work includes all scientific articles (5 published and 1 submitted to 
international peer-reviewed scientific journals) which resulted from this doctoral thesis.  
All articles are written in English and the original manuscript content, formatted in 
accordance with the specific rules of each journal, was maintained. Therefore, there are 
variations in the structure of the various articles presented along the chapters as well as in 
the references format. All the literature that is not integrated in the publications is 
presented according to the Vancouver norm as advised by the "rules of formatting 
dissertations and doctoral thesis" of the Faculty of Pharmacy, University of Porto. 
The texts that appear in Portuguese were prepared in accordance with the new spelling 
agreement. 
The thesis is divided in two main parts: Part I corresponds to the State of the Art 
and Part II called Research and Development, includes all the developed 
experimental research. 
Thus, in Part I, with a more theoretical approach, a general introduction to the 
subject of this dissertation is given in order to contextualize the work, addressing issues 
such as the problem of celiac disease, namely regarding the diagnostic. An overall view 
about electrochemical immunosensors principles as well as new analytical alternatives, 
such as new nanomaterials as transducer surfaces for sensing applications, are also 
presented. This brief introduction is followed by a description of the main goals of the 
work. In Part I of this thesis are also presented two chapters, Chapter 1 and Chapter 2, 
that correspond to reviews of the main areas included in the present work.  
In Chapter 1, a review that was written at the beginning of this project with the aim of 
gathering information about new methods for CD diagnosis and for quality control of 
gluten-free foods, is presented. The second review article, presented in Chapter 2, 
describes the state of the art of new analytical trends using screen-printed electrodes 
nanostructured with nanomaterials as electrochemical sensing transducers for clinical 
applications.  
Part II includes Chapter 3 and Chapter 4. The former chapter consists of an article 
dealing with the study of nano-modified screen-printed electrodes for general use as 
electrochemical biosensor transducers. Chapter 4 includes four articles about the 
development and application of electrochemical immunosensors for the detection of the 
selected CD serological biomarkers, using the best transducer surface obtained in the 
studies carried out in Chapter 3. The first article presents the development of an 
electrochemical immunosensor (EI) for the detection of anti-transglutaminase (anti-tTG) 
autoantibodies; the second article presents the study of an EI for the detection anti-gliadin 
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antibodies (AGA). In the third paper, a nanostructured dual-screen-printed electrode was 
employed for the multiplexed determination of both anti-tTG and AGA antibodies. Finally, 
the last presented work (corresponding to a manuscript still in preparation) describes an 
EI for the detection of deamidated gliadin peptides (DGP). 
At the end of the dissertation the Final considerations are presented. This 
designation was chosen since partial conclusions have been presented in the different 
chapters. This final chapter gives an overview of the entire work, highlighting successes 
and limitations as well as a future outlook.  
GENERAL INTRODUCTION 
 5 
 
GENERAL INTRODUCTION 
 
Celiac disease  
Celiac disease (CD) is a life-long inflammatory autoimmune condition of the 
gastrointestinal tract affecting genetically susceptible individuals (Shaoul et al., 2007), and 
the only treatment available is a strict gluten-free diet (Hill et al., 2006). It is estimated 
that celiac disease affects celiac disease affects primarily the European ancestry, being an 
important public health issue. However, CD is still greatly underdiagnosed.  
The humoral response is triggered by the ingestion of gluten proteins found in gluten-
containing foods such as wheat, rye and barley (Briani et al., 2008). The gluten proteins 
can be classified according to their solubility: the alcohol-insoluble fractions, the 
glutenins; and the alcohol-soluble fractions, designed as prolamins due to their high 
content of the amino acids proline and glutamine. Prolamins are called gliadins in wheat, 
hordeins in barley, secalins in rye and avenins in oats (Hill et al., 2006). Gliadins are the 
main gluten proteins involved in the pathophysiology of CD, triggering the immune 
system for the production of antibodies. 
The pathogenesis of celiac disease involves a complex interplay between 
environmental, genetic, and immunologic factors, involving both adaptive and innate 
immune system. After the ingestion of gluten, gliadin (or similar peptides), resistant to 
digestive enzymes, cross the epithelial barrier reaching the cytosol where are deamidated 
by transglutaminase enzymes, creating epitopes with increased immunostimulatory 
potential. Then, deamidated gliadin peptides (DGP) are presented, in association with the 
human leucocyte antigens (HLA) DQ2 or DQ8 of antigen presenting cells, to CD4+ T cell. 
The expression of pro-inflammatory cytokines by activated T cells promotes the release of 
matrix metalloproteinases that are responsible for epithelial cell damage and tissue 
remodeling. The response to gluten also involves the innate immune system, because 
epithelial cells secrete interleukin (IL)-15 and express nonclassic major histocompatibility 
complex (MHC) class I molecules in response to gluten exposure. This in turn activates 
CD8+ cytotoxic T cells expressing the natural killer receptors, which can target and 
destroy epithelial cells that carry the stress-induced molecule (Briani et al., 2008; 
Holtmeier et al., 2006). 
A 33 amino acid gliadin peptide, a highly specific substrate for deamidation by tissue 
transglutaminase and capable of stimulating all gliadin specific T cell lines in a very 
vigorous manner, as well as being resistant to the breakdown of endogenous proteases and 
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peptidases, has been identified by the group of Shan et al. (2002). In Figure 1 an 
illustration of the mechanism underlying CD pathogenesis is presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 1. Hypothetical scheme for digestion of dietary gluten in celiac disease patients. (adapted 
from  Mowat 2003). 
 
Currently, the diagnosis of celiac disease requires a small intestinal (jejunal) biopsy. In 
case of a positive result, clinical improvement is based on a gluten-free diet. Valuable 
immunological assays have been developed for the non-invasive diagnosis of CD, which 
are useful to prevent the underdiagnosis of CD and avoiding jejunal biopsies (Bahia et al., 
2001). The most widely used methodology for CD clinical diagnosis is an enzyme-linked 
immunosorbent assay (ELISA). Serological tests, based on highly specific antibody-
antigen interactions, are fundamental to identify gluten intolerance and have also been 
employed in monitoring the response to a gluten-free diet (Kaukinen et al., 2007). 
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Measurement of serum antigliadin antibodies (AGA) was ﬁrst used as a diagnostic tool 
and, then, as a means of assessing continued inﬂammation of the small intestine, allowing 
the monitoring of the patients’ compliance with a gluten-free diet, which is the only 
treatment available so far. However, in recent years, there is a tendency to no longer 
recommend AGA tests for routine diagnosis because the immunoglobulin A (IgA) isotype 
antibodies toward tissue transglutaminase (anti-tTG), identified as the CD autoantigen, 
are generally acknowledged as the first choice test (Kaukinen et al., 2007, Dahlbom et al., 
2005). According to Rostom et al. (2006), anti-tTG IgA antibody tests have sensitivities 
higher than 90% and specificities higher than 95%. In contrast, AGA IgA tests have a 
sensitivity of about 80% and a specificity ranging from 80 to 90% (Shuppan 2000; Hill et 
al., 2005) However, some patients are IgA deficient, which jeopardizes the pathology’s 
detection by serological tests. In these cases, the determination of AGA IgG and anti-tTG 
IgG has been suggested as an alternative (Dahlbom et al., 2005).  
In 2004, Schwertz et al. (2004) showed that the detection of antibodies against DGP 
could be valuable for the diagnosis of celiac disease. Particulary, IgG anti-DGP antibodies 
are more sensitive and more specific for CD than AGA IgG (Volta et al., 2008) and their 
performance is at least as good as that of IgA AGA (Sugai et al., 2006, Niveloni et al., 
2007, Volta et al., 2008). The new test displayed a higher diagnostic accuracy than AGA 
antibody tests and, although less sensitive than tTG antibodies, showed a significantly 
higher specificity than tTG antibody tests (Volta et al., 2008). The combined use of tTG 
and DGP antibodies seems to be a very useful tool for celiac disease diagnosis. Moreover, 
antibodies toward DGP can be helpful in disease follow-up (Volta et al., 2008).  
It is important to note that despite the poor sensitivity and specificity of native gliadin 
antibody tests in comparison with the tests for the deamidated peptide or even tTG 
antibodies; commercial ELISA kits for AGA antibody detection are still commercialized by 
several companies (e.g. Phadia, Biosystems, Zedira, etc…). There is no discussion about 
tTG being the main autoantigen in CD, however, due to the lack of higher standardization 
of the reference methods for the different immunoassays, the development of a tool that 
allows a more complete serological screen of CD still was not yet accomplished and is of 
the utmost importance.  
Due to the many recent development in the electrochemical biosensors field, this 
decentralized analytical tool can be an excellent alternative option to perform CD clinical 
diagnosis.  
In Chapter 1 of this dissertation a Review about the state of the art regarding the 
conventional and recent alternative methods for celiac disease diagnosis, as well as gluten-
free food control, is presented. 
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Electrochemical biosensors 
Nowadays, the (bio)analytical field assists to a continuing demand for faster and 
simpler analytical methods for the determination of relevant analytes in the fields of 
clinical, environmental and food analysis. Therefore,  biosensors have become interesting 
analytical devices that offer new possibilities within (bio)analysis.  
A biosensor (Figure 2) can be defined as a self-contained integrated device that is 
capable of providing specific quantitative or semi-quantitative analytical information 
(using a biological recognition element (biochemical receptor) which is retained in direct 
spatial contact with a transduction system (Thévenot et al., 2001, Farré et al., 2009). Once 
the interaction of the biochemical receptor with the analyte is converted into a signal 
detectable by the transduction system, the signal is send to a readout or display by 
appropriate electrical equipment (Farré et al., 2009, Thévenot et al., 2001, Justino et al., 
2010). Biosensors can be classified according to their biorecognition principle used for 
sensing (e.g. enzymes, nucleic acids, antibody or whole cells) and according to the 
transduction element employed (e.g., electrochemical, optical, piezoelectrical or thermal). 
Most of the biosensors described in the literature are electrochemical (Farré et al., 2009; 
Justino et al., 2010).  
 
 
Figure 2. Squeme of a biosensor design. 
 
Biorecognition
element
TransducerSample
Electrical
signal
Principle of Biosensors
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Electrochemical Immunosensors 
The development of immune-based assays for the detection and quantification of 
antibody-antigen interactions continues to be a subject of intensive research and 
development efforts. Therefore, within the electrochemical biosensors, electrochemical 
immunosensors (EIs) are in many cases the best option for point-of-care (POC) 
diagnostics because they provide specific and sensitive detection. EIs are affinity ligand-
based solid-state biosensor devices in which the immunochemical reaction is coupled to 
an electrochemical transducer. The fundamental basis of all immunosensors is the 
specificity of the molecular recognition of antigens by antibodies to form a stable complex, 
which is similar to the immunoassay methodology (Luppa et al., 2001, Farré et al., 2009, 
Tudorache and Bala 2007).  
Immuno-based assays that rely on antibody–antigen interactions provide a promising 
means of analysis owing to their specificity1 and sensitivity1 (Zhang et al., 2008). High 
specificity is achieved by the molecular recognition of target analytes (usually the 
antigens) by antibodies to form a stable complex on the surface of an immunosensor 
(Killard et al., 1995). On the other hand, the sensitivity depends on several factors 
including the use of high affinity analyte-specific antibody(ies), their orientation after 
immobilization on the immunosensor surface, and the detection system used to measure 
the analytical signal (Killard et al., 1995). 
Antibodies are a family of glycoproteins known as immunoglobulins (Ig). There are 
five distinct classes of glycoproteins (IgA, IgG, IgM, IgD, and IgE) with IgG being the most 
abundant class (approximately 70%) and the most often used in immunoanalytical 
techniques. Antibodies are usually represented as a Y-shaped molecule (Figure 2) based 
upon two distinct types of polypeptide chains that differ according to their molecular 
weight. There is a smaller chain, which is the “light” chain, with a mass of approximately 
25 kDa and a larger chain with a mass of approximately 50 kDa, known as the “heavy” 
chain. In each Ig molecule, there are two light and two heavy chains which are held 
together by disulfide bonds. Both heavy and light chains are divided into constant (C) and 
variable (V) domains based on their amino acid sequence variability. The light chains have 
                                                           
1 In the field of biosensors, the concept of specificity is in straight correlation with the selectivity, which is the 
ability of the sensor device to detect, in an unequivocal way, the analyte of interest, and sensitivity appears in 
terms of detection limits. In terms of qualitative diagnosis in medical sciences, sensitivity and selectivity are 
based on the fact that the results of tests performed with a diagnostic tool, can be positives (a: trues; b: false 
positives) or negatives (c: false negatives; d: trues). In this context, sensitivity is defined as the ratio between 
the number of true positive tests (a) and their sum, and the number of false negative tests (c), as: (a / (a + c)). 
And selectivity is defined as the ratio between the number of true negative tests (d) and their sum, and the 
number of false positive tests (b), as: (d/ (d+b)) (Aguilera-Herrador et al., 2010). 
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a single variable domain (VL) and a single constant domain (CL). In comparison, a heavy 
chain consists of a single variable domain (VH) and three constant domains (CH1, CH2, 
CH3). In general, the antibody molecule may be divided into two main fragments, the 
non-antigen binding fragment (designate as Fc) and the antigen-binding fragment 
(F(ab´)2), as can be observed in Figure 3. The variable domains in both chain types are the 
most important regions with regard to the antibody–antigen binding interaction. The 
specificity of an antibody towards the binding site (or epitope) of its antigen is a function 
of its amino acid sequence. Within the VL and VH domains, there are three distinct 
subregions of high sequence variability, known as hypervariable regions. There are three 
on each light chain and three on each heavy chain, forming six hypervariable loops known 
as complementarity determining regions, which constitute the antigen binding site. It is 
the diversity in this region that allows the production of high-affinity antibodies against 
almost any antigen (Cass 1990). 
Antibodies can be divided in polyclonal antibodies and monoclonal antibodies. A 
polyclonal antiserum will contain many different antibody molecules with varying 
affinities and specificities. In contrary, monoclonal antibodies are produced by a single 
clone of antibody-producing cells and therefore all molecules from the clone have the 
same specificity and affinity (Cass 1990).The intermolecular forces which contribute to the 
stabilization of the antibody-antigen complex are the same as those involved in the 
stabilization of the configuration of proteins and other macromolecules (Cass 1990). It is 
estimated that 108 antibody specificities can be produced from this one basic molecular 
structure, and an individual antibody will usually recognize only one antigen, although 
there are possible cross-reactivities (Zhang et al., 2008). 
Therefore, EIs present high selectivity and sensitivity which allows early detection of 
many diseases. Furthermore, EIs are also cost-effective. In the EI sensing strategy, most 
antibodies and antigens are intrinsically unable to act as redox partners, therefore an 
appropriate label is often conjugated to a particular component of the immunocomplex to 
promote an electrochemical reaction. The produced electrochemical signal is then 
quantitatively related to the amount of analyte present in a sample solution and is 
recorded with the use of bench or portable instruments which are usually capable of 
applying different electrochemical techniques such as voltammetry, amperometry, 
potentiometry, impedance spectroscopy, and conductimetry (Farré et al., 2009, Justino et 
al., 2010, Ricci et al., 2012). 
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Figure 3. Schematic representation of the “Y”-shaped structure of an antibody (Zhang et al. 
2008). 
 
 
The enzyme linked immunosorbent assay (ELISA) is the accepted method for the 
detection of any molecule suitable for antibody targeting. The use of electrochemical 
transducers for the development of immunosensors has important advantages compared 
with ELISA, which make them interesting alternatives to the conventional immunoassays 
(Ricci et al., 2012). The employment of small sample volumes, the possibility of real-time 
analysis due to the direct translation of the electrical signal into the readout signal, and 
the achievement of low detection limits are some of the advantageous features of EIs. 
Moreover, there is a continuous effort on the miniaturization of the instrumentation. All 
these characteristics make EIs attractive tools for immunosensing development. 
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Immobilization procedures in solid phase bioassays 
Electrochemical immunosensors are usually obtained through the immobilization of a 
recognition element (i.e. antigen or antibody) on the electrode surface (Ricci et al. 2012). 
The manner in which the recognition element is immobilized on the solid phase is a 
critical aspect in the immunosensor’s architecture and requires special consideration. 
Immobilization of the biological materials onto the transducer surface is the key step for 
the successful fabrication of biosensors. Biomolecules have been immobilized by 
adsorption, covalent attachment, entrapment, cross-linking, and affinity binding 
(Albareda-Sirvent et al., 2000; Tudorache and Bala 2007; Zhang et al., 2008; Sassolas et 
al., 2012). The chosen immobilization method should provide an orientation of the 
recognition element with minimal steric hindrance in order to guarantee a favourable 
interaction between the analyte and the binding sites (i.e. the paratopes or epitopes, for an 
antibody or an antigen, respectively). 
Adsorption 
Adsorption is a rapid and simple procedure for the immobilization of antigens and 
antibodies onto a solid phase, especially for disposable biosensors. Physical adsorption 
based on van der Waals attractions and electrostatic and hydrophobic interactions 
between biomolecule and solid surface, is the most often used method because of its 
simplicity. For this reason, physical adsorption is frequently used as a preliminary test 
before undertaking further improvement or designing more complex biosensors. The most 
important drawback of this technique is that the forces between biomolecule and support 
are weak and cannot be controlled easily. As a consequence, the biological component can 
be leached during the assay, depending on experimental conditions such as pH, ionic 
strength, temperature, and solvent (Albareda-Sirvent et al., 2000). 
Covalent attachment 
Covalent immobilization of the biological recognition component on the solid 
electrode surface can be achieved through direct attachment or by use of, for example, the 
self-assembled monolayer (SAM) procedure. In the direct attachment on gold surfaces, 
thiol groups of biomolecules can form covalent bonds with the transducer's surface. The 
activation of solid carbon surfaces has also been described for the covalent immobilization 
of biomolecules. In this case, the covalent coupling of biomolecules can be achieved 
between the carboxyl groups of a support and the amino function of the biomolecule, or 
reversely, employing a support modified with amino groups for the binding of carboxyl-
GENERAL INTRODUCTION 
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terminated molecules (Sassolas et al. 2012). In the SAM process the electrode surface 
should be made of gold or should be coated with a gold layer. Then, by use of sulfur-
containing compounds (thiols, sulfides, and disulfides) a monomolecular layer can be 
formed on the gold surface by simple immersion of the electrode in the sulfur-containing 
solution. Active groups (–COOH, –NH2, –OH) on the surface of the monolayer are then 
reacted with the biomolecule of interest, leading to covalent bonding. SAMs haves 
important characteristics which are necessary for the immobilization procedure, such as 
stability, reproducibility, and uniformity of the monolayer (Tudorache and Bala 2007).  
Entrapment  
The immobilization of the biocomponent by entrapment within a suitable matrix, 
which is then deposited on the electrode support, can improve its stability. Immobilization 
in matrices such as gels, polymers, pastes, or inks can also be as simple as physical 
adsorption. The biological material is usually mixed and well homogenized with the 
supporting material and then applied on the electrode’s surface as an additional 
membrane that must be dried or polymerized. The matrices used include gelatins, 
polyurethanes, poly(vinyl alcohol), carbon paste, and carbon ink. The principal advantage 
of this technique is its compatibility with mass fabrication techniques. 
Electropolymerisation is a special example of the entrapment technique in which the 
biological molecule is homogenized in a monomer matrix and is then deposited on the 
transducer surface as a polymeric film produced by electropolymerisation (Tudorache and 
Bala 2007). 
Cross linking 
Immobilization by intra- or intermolecular cross-linking has also been used to coat 
electrode surfaces with specific biomolecules. The method is based on the formation of 
three-dimensional links between the biological material and bi- or multifunctional 
reagents. The resulting modified biological material is completely insoluble in water and 
can be adsorbed on a solid surface (Tudorache and Bala 2007, Albareda-Sirvent et al., 
2000).  
Affinity  
Speciﬁc afﬁnity interactions for biomolecule immobilization have been widely used in 
immunoassay systems in recent years. The (strept)avidin–biotin interaction is the most 
employed (Weber et al.,  1989). Usually it involves biotinylating the capture element and 
coating a solid phase with either avidin or streptavidin. The dissociation constants of 
biotin–avidin and biotin–streptavidin interactions are of the order of 10-15 mol L-1 and are 
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some of the largest free energies of association observed for non-covalent interactions 
(Gitlin et al., 1987). The complexes also withstand high temperatures, pH variations, and 
are resistant to dissociation when exposed to chemicals such as detergents and protein 
denaturants (Jones and Kurzban 1985). Another used afﬁnity-based immobilization 
technique for the immobilisation of antibodies in immunoassay systems involves a 
bacterial antibody-binding protein. The two most common of which are Protein A and 
Protein G. These proteins bind speciﬁcally to antibodies through their non-antigenic (Fc) 
regions, which allow the antigen binding sites of the immobilized antibody to be oriented 
away from the solid phase and be available to bind the target analyte. As these proteins 
interact directly with the Fc region of antibodies, there is no need for antibody 
biotinylation.  
 
Immunosensor formats 
Most of the developed immunosensors are based either on a competitive or non-
competitive assay, when applied to the detection of low and high molecular weight 
molecules, respectively (Ricci et al., 2007; Zhang et al., 2008). In a competitive 
immunoassay, sample analyte and labelled analyte compete for a limited number of 
antibody-binding sites. In electrochemical immunoassays, an enzyme label or an 
electroactive label is commonly used. The signal produced by the bound labelled analyte is 
usually inversely proportional to the amount of sample analyte. When immobilised 
antibodies react with the free antigens in competition with labelled antigens  (Figure 4A) 
or, reversely, when immobilised antigens compete with free antigens for labelled free 
antibodies  (Figure 4B), the immunoassay format is a defined as direct competitive. But 
when a secondary antibody is used as label after binding with the Fc region of the primary 
antibody, the format is denoted as indirect competitive immunoassay (Figure 4C) (Ricci et 
al.,  2007;  Ricci et al., 2012). 
In a non-competitive immunoassay (also known as a two-site “sandwich” 
immunoassay), the sample analyte is captured by an excess of a capture antibody, 
separating it from the bulk sample (Figure 4D). After the interaction between immobilised 
antibodies and free antigens, an excess of secondary labelled antibodies, directed toward a 
second binding site of the antigen, is added. These labeled antibodies will only bind to the 
existing capture antibody–analyte complex. In an ideal non-competitive immunoassay, no 
signal would be produced in the absence of analyte because there are no appropriate 
binding sites available for the secondary labelled antibody. However, in practice, this is 
not the case due to non-specific interactions between the secondary antibody and other 
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components of the immunoassay. Therefore, it is always desirable to use a blocking agent 
to reduce these non-speciﬁc interactions. (Ricci et al., 2007; Zhang et al., 2008). 
The ideal format to perform an immunoassay should be as simple as possible. Thus, a 
label-free direct competitive format, as shown in figure 4A, would be the ideal. However, 
besides simplicity other aspects, such as selectivity and sensitivity, have to be considered. 
Therefore, in some cases it is important to use a non-competitive assay with two 
antibodies, one of them monoclonal (usually the capture element), that react with the 
same antigen to ensure the selectivity of the assay.  
 
 
Figure 4. Schematic representation of different immunoassays formats. (adapted from Ricci et al. 
2007). 
A
D
C
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Cyclic voltammetry as a tool for development of electrochemical 
immunosensors 
In electrochemical analysis involving voltammetry, a three-electrode cell configuration 
is used and is constituted of a working electrode (i.e. the electrode at which the reaction of 
interest occurs); a reference electrode (to maintain/ control the potential of the working 
electrode), and a counter or auxiliary electrode to carry the cell current (Cass 1990; Wang 
2000). When the potential of the working electrode is maintained or shifted to a value 
where the oxidation or the reduction of species in solution occurs, a current flows between 
the solution and the electrode. With an appropriate control of the experimental 
conditions, the intensity of this current can be related to the analyte concentration and the 
applied potential can provide information about the identity of the species. Since the 
intensity of the measured current results from the oxidation (anodic current) or reduction 
(cathodic current) of chemical species in solution, voltammetric techniques can only be 
applied to electroactive species or non-electroactive species that are previously converted 
into electroactive species or coupled to faradaic processes.  
The current resulting from an electrochemical reaction is called faradaic current, 
because it obeys Faraday's law (i.e. the reaction of one mole of electroactive substance 
involves a charge change of 96,487 coulombs). In non-faradaic processes no charge 
transfer occurs across the interface between the solution and the electrode. However, 
there are changes in the structure of this interface that may cause a transient flow of 
external currents. These two processes occur simultaneously, so the total current is the 
sum of the faradaic current and the non-faradaic (background) current. Thus, the most 
recent voltammetric techniques aim to minimize the contribution of non-faradaic 
processes in order to improve the signal to noise ratio (Wang 2000). 
Cyclic voltammetry (CV) is a voltammetric technique widely used to generate the 
signal in EIs devices. CV involves sweeping the potential between two limits, E1 and E2, at 
a fixed scan rate. Once potential E2 is reached the scan direction is reversed whilst 
maintaining the same scan rate (Figure 5 and 6). CV is a useful technique for the study of 
electrochemical characteristics and also for examining more complex electrochemical 
systems such as enzyme-coupled reactions. Bearing in mind that enzymes are common 
labels for immunoassays (e.g., alkaline phosphastase has been used extensively as label in 
immunoassays, including EIs) the employment of CV as detection technique is a good 
option to understand the mechanism of electron transfer at the electrode surface. 
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Figure 5. Potential-time excitation signal in a cyclic voltammetric experiment (Wang 
2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Typical cyclic voltammogram for a reversible O + ne- ↔ R redox process (Wang 2000). 
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Alkaline phosphatase as electrochemical enzymatic label 
Alkaline phosphatase (AP) (orthophosphoric monoester phosphohydrolase) is widely 
used as enzyme label in immunoassays. AP has a molecular weight in the range of 80 kDa 
and exibiths optimum activity at alkaline pH values. Magnesium is also considered 
essential for maximum AP enzymatic activity. AP's role as lable in immunoassays is largely 
exploited because AP is easily conjugated to haptens, antibodies, and other proteins, and 
is the most active of all alkaline phosphatases; moreover it presents a high turnover 
number and  broad substrate specificity (Fernández-Sánchez et al., 1998, Preechaworapun 
et al., 2008).  
In EIs, AP is used to generate electroactive organic products, most of which can be 
detected and quantified. Electrochemical detectors are generally sensitive and rapid for 
the analysis of the product of the enzyme hydrolysis of an AP substrate. Several AP 
substrates, useful for electroanalysis, have been studied for the use in immunoassays, such 
as: catechol monophosphate (Szydlowska 2006), 3-indoyl phosphate (IP) (Martinez-
Montequin et al., 2000; Diaz-Gonzalez et al., 2002; Fanjul-Bolado et al., 2004;  Diaz-
Gonzalez et al,. 2005), hydroquinone diphosphate (HQDP) (Wilson and Rauh 2004), 4-
nitrophenol phosphate (NPP) (Rosen and Rishpon 1989; Kim and Kwak 2005; Fanjul-
Bolado et al., 2006), p-aminophenyl phosphate (APP) (Rosen and Rishpon 1989; Hart et 
al., 1997; Pemberton et al., 1999; Gyurcsanvi et al., 2002; Moore et al., 2003; Dong et al., 
2006; Kwon et al., 2006), 1-naphthyl phosphate (NTP) (Pemberton et al., 1999; Chikae et 
al., 2007), phenyl phosphate (PheP) (Rosen and Rishpon 1989; Hart et al., 1997; Wilson 
and Rauh 2004; Sun et al., 2006), and 2-phospho-l-ascorbic acid (AAP) (Kokado et al., 
2000; Gyurcsanyi et al,. 2002; Moore et al., 2003). During the enzymatic process, these 
substrates are converted to the electroactive species catechol, indigo carmine (IC), 
hydroquinone (HQ), 4-nitrophenol (NP), 4-aminophenol (AP), 1-naphthol (NT), phenol 
(Phe), and l-ascorbic acid (AA), respectively. 
A new method in which AP catalyzes the deposition of metallic silver was developed by 
Fanjul-Bolado et al., (2007). In this method 3-indoxyl phosphate/silver (3-IP/Ag+) is used 
as the AP electrochemical substrate. 3-IP is basically constituted by an indolic ring 
substituted in position 3 by a phosphate group. In the presence of AP this substrate is 
hydrolyzed in position 3, giving an indoxyl intermediate. This indoxyl intermediate will 
oxidize, producing indigo blue, and reduce silver ions present in solution into a metallic 
deposit. Therefore, metallic silver is co-deposited with indigo blue. The deposited silver is 
electrochemically stripped into solution and the resulting current intensity is measured by 
anodic stripping voltammetry. The described mechanism is illustrated in Figure 7. 
Metallic silver will be deposited where the enzymatic AP label is attached, which is 
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especially important to avoid cross-contamination and to ensure that the measured signal 
correspondes to the immune-labelled reaction. 
 
 
 
 
 
 
 
Figure 7. Mechanism of alkaline phosphatase-catalyzed silver deposition for electrochemical 
detection (adapted from Fanjul-Bolado et al., 2007). 
 
 
Screen-printed electrodes 
A wide variety of electrodes have been used as support to fabricate biosensor devices, 
including carbon paste electrodes (Fernández-Sánchez et al., 2000), glassy carbon 
electrodes (Dai et al., 2003), and gold electrodes (Ouerghi et al., 2001). Recently, several 
biosensor devices have been developed on screen-printed electrodes (Hernández-Santos et 
al., 2004; Díaz-González et al., 2005; Singh et al., 2005). The screen-printing 
microfabrication technology is nowadays well established for the production of thick-film 
electrochemical transducers (Tudorache and Bala 2007). This technology allows the mass 
production of reproducible, inexpensive, customized and mechanically robust solid-strip 
electrodes. Moreover, typical disadvantages of conventional electrodes such as memory-
effects due to difficult, time-consuming and sometimes inefficient cleaning steps can be 
surpassed with these disposable SPEs. Another important feature that these electrodes 
exhibit is related to the miniaturisation of the corresponding device, along with their ease 
of handling and manipulation. Several SPE configurations based on different materials 
can be constructed. The process of production and design of SPEs consists of sequential 
layer-by-layer deposition of an ink onto an insulating support or substrate, which will 
define the geometry of the sensors (Bilitewski et al., 1992; Albareda-Sirvent et al., 2000; 
Mooring et al., 2005, Tudorache and Bala 2007). The substrates are commonly made of 
Metalloenzymatic detection
AP
Ag+ Ag0
Voltammetric detection
3-IP
Indigo blue
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alumina, ceramics, PVC, gold, iron, etc. and the conducting path of the electrode consists 
of carbon ink/paste, or platinum, gold, or other metal pastes. SPEs can also consist of two 
(working and reference) or three electrodes (working, reference and auxiliary), designated 
first-generation or secondary generation, respectively (Bilitewski et al., 1992; Albareda-
Sirvent et al., 2000; Mooring et al., 2005; Tudorache and Bala 2007). 
The sensing element is the analyte-specific part of biosensors. The capture element can 
be immobilized onto the surface of the working electrode, employing the previously 
referred immobilization strategies. (Timur et al., 2004; Domínguez-Renedo et al., 2007; 
Tudorache and Bala 2007; Alonso-Lomillo et al., 2009; Sassolas et al., 2012) Therefore, 
SPE-based biosensors seem well suited to complement, or replace, standard analytical 
methods in fields such as clinical diagnostics, environmental analysis, and food quality 
control. Indeed, easy-to-use self-testing glucose strips, based on screen-printed enzyme 
electrodes, coupled to pocket-size amperometric meters, have dominated the $5 
billion/year diabetes monitoring market over the past two decades (Newman and Turner 
2005). The current research in the field of biosensors has revealed that SPEs are perfect 
candidates to construct  more sensitive, reproducible and low–cost biosensors for routine 
analysis (Alonso-Lomillo et al., 2010). Figure 8 shows the design of a typical SPE and the 
corresponding dimensions. 
 
 
 
 
 
 
 
 
Figure 8. Example of screen-printed electrodes. 
 
Nanomaterial-based electrochemical transducers  
The SPE's surface, besides playing an important role as transducer, also works as the 
sensing phase. Therefore, new strategies are being explored to better amplify the 
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transduction of biological events in a sensitive way. The nanostructuration of electrode 
surfaces with carbon-based nanomaterials and gold nanoparticles provides outstanding 
properties for the solid sensing platform.  
Since their discovery in the early 1990s, attributed to Iijima (Iijima 1991), the 
application of carbon nanotubes (CNTs) has been growing in different areas of research. 
CNTs are formed by one (single-walled carbon nanotubes, SWCNTs) or multiple 
cylindrical layers of graphene sheets (multi-walled carbon nanotubes, MWCNTs) 
(Fernández-Abedul and Costa-García 2008; Agüí et al., 2008). These CNTs have 
diameters ranging from fractions of nm to several centimeters cm, with both their ends 
normally capped by fullerene-like structures. (Trojanowicz 2006). CNTs present large 
length-to-diameter aspect ratios which provide high surface-to-volume ratios and the 
ability to promote electron transfer in electrochemical reactions, making them excellent 
nanomaterials for sensing applications (Agüí et al., 2008). One important aspect to 
consider when working with CNTs is their insolubility both in polar and non polar solvents 
as a consequence of their hydrophobic walls. Therefore, to obtain stable dispersions it is 
necessary to modify their surface with, for example, surfactants or biopolymers or to 
functionalize their structure in acidic or basic media. For example, the oxidation of CNTs 
in acidic medium is a simple and widely employed method to generate functional groups 
and, at the same time, to eliminate impurities. Obtaining a homogeneous CNT dispersion 
is very important for the subsequent nanostructuration of electrode surfaces. 
Another carbon-based material that started to capture researcher’s attention at the 
same time were carbon nanofibers (CNFs) (Rodriguez 1993). CNFs are cylindrical 
nanostructures with graphene layers arranged as stacked cones, cups or plates (Rodriguez 
1993). They have lengths in the order of µm, while their diameter varies between some 
tens to several hundred nm (Wang and Lin 2008). The use of CNFs for biosensor 
development has grown in recent years because of their adequate physical and chemical 
properties (e.g., conductivity, surface area, inherent and induced chemical functionalities, 
and biocompatibility) (Wang and Lin 2008). 
Despite the fabrication method, the initially obtained CNFs had the same 
disadvantages of low solubility and impurities as CNTs. The methods used to overcome 
these problems are the same as described for the CNTs, i.e. the generation of functional 
groups on their surfaces using acidic media. However, it is noted that the CNFs are more 
susceptible to undergo structural changes due to thermal treatments (Kuvshinov et al., 
2009) and the oxidation of their surfaces. Therefore CNFs present higher solubilities than 
CNTs, which facilitates their dispersion in aqueous media. 
CNTs and CNFs share the same basic composition (graphene) and appearance with 
diameters of 3-100 nm and lenghts of up to mm (Jong 2000). Moreover, both structures 
I. STATE OF THE ART 
22  
 
can be obtained through chemical vapor deposition. The process consists essentially of 
thermal decomposition of a carbonaceous gas (such as acetylene, ethylene, methane) due 
to the reaction at high temperatures with other gases (ammonia, nitrogen, hydrogen) in 
the presence of a metal catalyst. The nanomaterials are deposited on the metal substrate 
in a random or, in certain conditions, an orderly manner. The major drawback of this 
method is the great number of structural defects of the resulting carbon nanomaterials. 
Since they have similar formation and growth mechanisms, the type of nanostructure 
obtained depends therefore on the experimental conditions employed (Jong 2000; 
Chuang et al,. 2008; Kuvshinov et al., 2009). 
As was referred before, chemical, electrochemical, and thermal treatments are applied 
to generate functional groups on the CNT/CNF surfaces which can allow covalent binding 
of biomolecules. Moreover, covalent binding of biomolecules employing cross-linking 
agents or affinity binding through the biotin-(avidin/streptavidin) interaction can also be 
employed (Wang and Lin 2008) to augment the CNTs and the CNFs ability to adsorb 
protein material. Physical adsorpion of biomolecules onto the carbon nanomaterial's 
surface or direct entrapment in carbon ink or paste are also options for biomolecule 
immobilisation. Figure 9 shows typical representative schemes of the described carbon 
nanomaterials.  
 
 
Figure 9. 3D schemes of (A) SWCNT, (B) MWCNT, and (C) CNFs . 
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In addition to carbon nanomaterials, metal nanoparticles have become extremely 
suitable for creating new sensing assays. Gold nanoparticles (NPAus) are of great promise 
for the construction of bioelectroanalytical devices because of their unique properties, 
which allows the improvement of the biocompatibility of the solid sensing phase (Yáñez-
Sedeño et al., 2005; Suprun et al,. 2010). Moreover, gold nanoparticles present a high 
surface-to-volume ratio, a high surface energy, the ability to decrease the distance between 
proteins and the transducer surface and the ability to act as an electron-conducting 
pathway between prosthetic groups and the electrode surface, which may facilitate 
electron transfer between redox proteins and the electrode surface (Yáñez-Sedeño et al., 
2005; Liu et al., 2003).  
Among the conventional methods for the preparation of gold nanoparticles based on 
the reduction of Au(III) compounds, the most popular has been the reduction of 
tetrachloroauric acid (HAuCl4) with citrates in water. This method was introduced in 1951 
by Turkevitch et al. (1951), and gives rise to gold nanoparticles of approximately 20 nm in 
diameter. The method was subsequently improved by other researchers in order to control 
the diameter of the nanoparticles (Frens 1973). Other methods are based on the reduction 
of the gold species (HAuCl4) with sodium borohydride (NaBH4) in sodium citrate (Raj et 
al., 2003) or by applying microwave-radiation (Xu 2008). The use of the photochemical 
reduction of the tetrachloroaurate anion (AuCl4-) makes a controlled particle size possible 
(Dong and Zhou 2007). 
Gold nanoparticle-modified electrode surfaces can be prepared by covalent binding of 
gold nanoparticles with functional groups of self-assembled monolayers (SAMs); thiols or 
dithiols in case of gold electrodes, or with amino groups; by entrapment, or 
electropolymerization, of colloidal gold into the electrode by mixing the gold with the 
other components in the composite electrode matrix or by direct deposition of 
nanoparticles onto the electrode surface (Yáñez-Sedeño et al., 2005). Immobilization 
through affinity using the (strept)avidin–biotin interaction is also a possibility, for 
example by modifying the electrode surface with biotin and the NPAus with avidin or 
streptavidin. Electrochemical deposition of NPAus has recently been reported as the 
method of choice for simple, low-cost nanostructuring and nanopatterning of electrode 
surfaces (Figure 10). Electrochemical deposition methods allow a fast, simple, efficient 
and reproducible modification of the electrode surface with gold nanoparticles. 
Furthermore, these methods are applicable to any type of electrode. 
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Figure 10.  Schematic representation of the electrodeposition process of nanoparticles on the 
electrode surface and their use for analytical purposes. 
 
One of the new trends is the use of hybrid materials, formed between carbon and gold 
nanomaterials, as last generation transducers for the development of biosensors. Carbon 
and metal-based nanomaterials have exceptional properties that once conjugated in 
hybrid surfaces lead to a synergic effect on each material property, presenting collective 
characteristics that are drastically different from the individual components (Gu et al. 
2009). 
The use of nanomaterials relies on the principle that some materials whose structural 
dimensions are in the nanometer scale are capable of presenting very different properties 
than the same material with larger dimensions. 
The role of nanomaterials, as interface between biological recognition events and 
electronic signal transduction, can lead to exiting opportunities in the construction of 
novel biosensor devices. The ease of modification is one of the features that make SPE 
excellent candidates to be applied as nanostructured electrodic transducer surfaces. 
In Chapter 2, a revision on the state of the art of the use of electrochemical biosensors 
based on nanostructured screen-printed electrodes for clinical applications can be found. 
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Main goals 
Attending to the specificity of immunological reactions with the advantages of 
electrochemical techniques, the main goal this dissertation was the development, 
manufacturing and optimization of the best transducer surface to obtain sensitive, 
reproducible, robust and low-cost electrochemical immunosensors for routine analyses of 
CD clinical serological diagnosis. 
In order to achieve the proposed immunosensing strategy several development and 
integration steps were addressed: 
 
 Development, characterization, optimization, and reproducible production of 
nanostructured SPCEs in order to provide an adequate transducer surface for the 
sensor devices. The nanostructuration of the SPCEs with multiwalled carbon 
nanotubes (MWCNTs), CNFs, NPAus, and hybrids of MWCNTs/NPAus and 
CNFs/NPAus was explored.  
 
 Evaluation of the biofunctionality of the developed transducers through their 
ability to adsorb protein material on their surface using direct adsorption of the 
streptavidin/biotin system. The biofunctionality was evaluated and optimized 
using alkaline phosphatase and 3-indoxyl phosphate/silver (3-IP/Ag+) to produce 
a product (metallic silver) which is detectable by anodic stripping voltammetry. 
 
 Development and optimization of individual electrochemical immunosensors for 
the determination of CD serological markers (AGA and anti-tTG autoantibodies, 
and DGP). 
 
 Construction of a multiplexed EI for the simultaneous determination of AGA and 
anti-tTG autoantibodies, integrating the individually optimized sensors in the 
design of the multiplexed sensor. 
 
 Validation of the developed methods by comparing the obtained results with the 
results obtained by the established methods for CD serological diagnosis (i.e. 
ELISA). 
 
 Application of the developed and optimized immunosensors for quantification of 
the serological CD markers in human serum samples. 
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Abstract 
Celiac disease (CD) is an autoimmune enteropathy, characterized by an inappropriate 
T-cell-mediated immune response to the ingestion of certain dietary cereal proteins in 
genetically susceptible individuals. This disorder presents environmental, genetic, and 
immunological components. CD presents a prevalence of up to 1% in populations of 
European ancestry, yet a high percentage of cases remain underdiagnosed. The diagnosis 
and treatment should be made early since untreated disease causes growth retardation 
and atypical symptoms, like infertility or neurological disorders. The diagnostic criteria for 
CD, which requires endoscopy with small bowel biopsy, have been changing over the last 
few decades, especially due to the advent of serological tests with higher sensitivity and 
specificity. The use of serological markers can be very useful to rule out clinical suspicious 
cases and also to help monitor the patients, after adherence to a gluten-free diet. Since the 
current treatment consists of a life-long glutenfree diet, which leads to significant clinical 
and histological improvement, the standardization of an assay to assess in an unequivocal 
way gluten in gluten-free foodstuff is of major importance. 
 
Keywords: Celiac disease. Autoimmune. Transglutaminase. Gliadin.  
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Abbreviations 
AGA anti-gliadin antibodies 
CD celiac disease 
EIs electrochemical immunosensores 
EMA endomysial antibodies 
ELISA enzyme-linked immunosorbent assay 
Ig immunoglobulin 
ROC receiver operating characteristics 
tTG tissue transglutaminase 
 
 
Introduction 
Celiac disease (CD) is a disorder of the small intestine caused by an inappropriate 
immune response to wheat gluten and similar proteins of barley and rye in genetically 
susceptible individuals. CD can be also referred as celiac sprue, nontropical sprue, gluten-
sensitive enteropathy or idiopathic steatorrhea [1]. The classic presentation, with 
malabsorption, was first described by Samuel Gee in 1888 [2], but the relation between 
the disease and wheat was not reported until the late 1940s by Willem Karel Dicke, who 
observed that the ingestion of certain cereal grains was harmful to children with celiac 
disease [2, 3]; later, John W Pauley described the associated histologic changes in the 
intestine [4].  
CD is found mainly in Caucasians, occurring in 1 per 130-300 individuals in the 
western European population [5-7]. Although CD is one of the most common immune-
mediated disorders, still remains a considerable prevalence of undetected cases [8].  
It is more appropriate to consider CD as a multisystem disorder, rather than mainly 
gastrointestinal. A considerable number of conditions are associated to CD namely 
osteoporosis, malignancy and infertility. It is also associated with other autoimmune 
disorders, such as dermatitis herpetiforms, type 1 diabetes or autoimmune thyroiditis, and 
also with neurological and genetic disorders [4, 9-12]. 
 
Clinical presentation 
Celiac disease can be diagnosed at any age;  however, it presents most commonly in 
early childhood (between 9 and 24 months) or in the third or fourth decade of life [13-16]. 
As occurs in other autoimmune disorders, CD is more common in females than in males at 
a ratio of 3 to 1 [17]. 
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Although, it is a disorder that primarily affects the small bowel, the symptoms can 
range from classical gastrointestinal symptoms, such as diarrhea and abdominal 
distension, which are more common in infants and young children, to non-specific 
gastrointestinal symptoms and extra-intestinal manifestations, typical of older age groups; 
moreover, some patients are asymptomatic [8, 18]. The concept of the “celiac iceberg” has 
been used to emphasize the clinical variability of celiac disease and that many cases are 
still undiagnosed [10].  
The clinical presentation of CD is, therefore, very heterogeneous, ranging from an 
asymptomatic or silent stage to a clinically overt or symptomatic form [19]. The 
asymptomatic forms are characterized by extraintestinal symptoms, but with typical 
histological changes and positive serology. The classical or symptomatic form presents 
typical gastrointestinal symptoms, histological changes and positive serology. 
The term “latent" CD characterizes the subjects with genetic predisposition to develop 
CD. They do not have a flat mucosa, despite a gluten-containing diet, but probably will 
develop clinically overt CD later in life [20-22].This patients usually present increased 
intraepithelial lymphocytes (IELs) and positive serology for endomysial antibodies (EMA) 
and tissue transglutaminase (tTG) antibodies with HLA-DQ2 or DQ8 predisposing 
genotype [23-25]. 
Finally, the term “refractory” CD refers to patients who do not respond to a gluten-free 
diet or who previously responded but later became non-responsive, presenting severe 
villous atrophy despite maintenance of a strict gluten-free diet [26]. 
The severity of symptoms is not necessarily proportional to the severity of the mucosal 
lesions. In fact, currently, there are more subjects with asymptomatic or mild celiac 
disease than with the classical symptoms of severe malabsorption [3, 21].  
 
Genetics and pathogenesis 
The disease is genetically determined, affecting 10% of first degree relatives and 75% of 
the monozygotic twins being both affected. The human leucocyte antigen HLA-DQ2 is 
presented in 90-95% of CD patients and the remaining 5-10% of patients is HLA-DQ8 
positive [18]. Although the possession of the HLA proteins is necessary, it is not sufficient 
for CD development, since about 30% of the healthy population possesses them [27-29].  
Gluten is a complex mixture of wheat storage proteins that can be alcohol-soluble, 
fractions, the gliadins, and alcohol-insoluble fractions, the glutenins [28]. Based on their 
differential N-terminal sequence, size and electrophoresis mobility [30] gliadins are 
subdivided into α, β, γ, and ω-gliadins. Glutenins consist of low molecular weight (LMW) 
and high molecular weight (HMW) glutenins [31].  
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Gliadins are also called prolamins due to their high content in the aminoacids proline 
and glutamine. It is generally accepted that prolamins are the major triggering factors in 
CD [32]. Gliadins have analogous proteins that are present in barley (hordeins), rye 
(secalins) and oats (avenins). Recent studies failed to identify the toxic aminoacid 
sequence in oats [33] being considered toxic in only a minority of patients with CD [18].  
The mechanism underlying CD pathogenis can be explained by the ingestion of the 
alcohol-soluble protein components of wheat, barley, and rye. These gluten peptides are 
resistant to digestion by gastric and pancreatic enzymes due to their high content in 
proline, reaching the epitelial cell membrane and passing into the cytosol [34]. The 
deamidation of these proline-rich gluten peptides is mediated by tTG enzyme [35] creating 
epitopes with increased immunostimulatory potential. The deamidated epitope are then 
presented, in association with the human leucocyte antigens DQ2 and DQ8 of antigen 
presenting cells, to CD4+ T cells expressing α/β T-cell receptor [36]. These T cells become 
activated and express proinflamatory cytokines [37] that, in turn, promote the release of 
matrix metalloproteinases which cause epithelial cell damage leading to the development 
of the flat mucosa, typical of CD [37]. The resulting tissue injury leads to further release of 
tTG [29]. 
The in-vitro study by Lu Shan and colleagues [38] reported a highly stable 33-mer 
peptide, rich in proline and glutamine, which has been isolated from gliadin and is 
thought to contain the toxic sequence. This 33 amino acid peptide has been reported to 
have immunodominant characteristics, being resistant to degradation by all gastric, 
pancreatic and intestinal brush border membrane proteases in the human intestine, and is 
readily available for T-cell recognition and activation. 
 
Diagnostic and management 
The diagnosis of CD is complicated by the diversity of clinical manifestations that are 
related to the age at onset and symptomatology.  
 
Biopsy  
Diagnostic criteria for CD in both children and adults are still based on the guidelines 
proposed in 1990 by the European Society for Paediatric Gastroenterology and Nutrition 
(ESPGAN) [39]. Small bowel biopsy has been the standard diagnostic test for CD during 
the last 30 years. The biopsy is performed during an upper endoscopy and should only 
take place during a normal gluten-containing diet, when villous atrophy and crypt 
hyperplasia can be detected. Multiple samples are taken from the second or third part of 
the duodenum. Inadequate sampling and patchy villous atrophy can lead to an incorrect 
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diagnosis. Moreover, it should also be considered that isolated marked villous flattening 
and IELs can be found in other diseases [40].  
Recently, there has been an increase in atypical forms of CD, including cases without 
significant gastrointestinal symptoms, and cases presenting symptoms and complications 
of CD before the development of villous atrophy [41-42].  
 
Biological markers 
Recent guidelines from the ESPGAN [39], and the North American Society for 
Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) [43] have suggested 
an algorithm for diagnosis (Fig. 1), in which the serological tests appear as the first test to 
clear clinical suspicion of celiac disease in patients presenting characteristic symptoms or 
in those who belong to a risk group. These patients at risk are those with celiac disease 
associated disorders, as endocrine, neurological, liver, genetic and autoimmune diseases; 
first- and second-degree relatives of celiac patients are also at risk. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Proposed approach for the evaluation of patients with suspected celiac disease [39, 43]. 
Patients with IgA deficiency
Suspicious of celiac disease 
(on a gluten containing diet)
IgA class tTG and/or EMA serological tests
Negative results : low probability of CDPositive results: high probability of CD 
Remaining clinical suspcious
Small bowel biopsy
Confirmed the characteristic histological features of CD
Start a  gluten-free diet
Test for IgG antibodies
Clinical and/or histological improvement, confirms the diagnosis of CD
Positive results
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Antibody tests cannot replace histological studies of bowel biopsies; however they are 
very important as a screening tool, for early detection of CD cases [1]. Serological tests can 
also be employed in the follow-up and management of CD. Indeed, according to the 
ESPGAN criteria, when the diagnosis of CD is established by clinical, analytical and 
histologic studies, repeated endoscopy with duodenal biopsy is not necessary if the 
patient's condition improves after introducing a gluten-free diet; the results of repeated 
endoscopy could be rather confusing, since normalization of the histology may take up to 
8 years [44].  
The serologic tests use highly specific antibody-antigen interactions and are 
fundamental to identify the gluten intolerance and to monitor the response of the CD 
patients to a gluten-free diet [45]. There are two types of serologic tests. One detects the 
antibodies against the antigen gliadin (i.e. anti-gliadin antibodies (AGA)), in which the 
immunoglobulin A (IgA) isotype is considered to be the most specific [46], and the other, 
the autoantibody test, which detects antibodies to IgA tissue transglutaminase (IgA-tTG 
antibodies) and IgA endomysial antibodies (IgA-EMA) [18], that are usually present in 
serum during the active phase of CD [47]. However, some patients are IgA deficient, and, 
therefore, in that case, the detection of the pathology by the serological tests is 
jeopardized. Selective IgA deficiency affects about 2-5% of patients diagnosed with CD 
[48]. In these cases, the determination of the IgG class of antibodies against gliadin (IgG-
AGA), endomysium (IgG-EMA) and tTG (IgG-tTG antibodies) has been suggested as an 
alternative [47]. 
Since their description in 1958, AGA have been used as the serological markers for CD 
[28]. Both IgA and IgG AGA are present in the sera of patients with CD, although they lack 
of specificity, as gliadin may cross the normal gut mucosa, being present in 5-10% of 
healthy population. 
Endomysium is a connective tissue protein found in the collagenous matrix of human 
and monkey tissue [3]. EMA association with CD was first described in 1984 [49] and its 
detection rapidly became the serological test of choice, due to its specificity of almost 
100%.  The use of human umbilical cord as subtract has been proposed as a valid 
alternative to the monkey esophagus [50-51]. 
Tissue transglutaminase (tTG) is a calcium-dependent enzyme expressed both intra- 
and extracellulary, and is implicated in physiologic processes like extracellular matrix 
(ECM) formation, cell adhesion and apoptosis [53]. tTG serves as a cross-linker of 
different ECM proteins, resulting in the formation of an ε-(γ-glutamyl)-lysin bond. Gliadin 
is the preferred substrate for tTG [3]. It was suggested that it has the ability to crosslink 
itself to gluten leading to antibody formation [54]. In 1997 tTG was identified as the auto-
antigen recognized by the EMA [55] and was identified as the main autoantigen in CD.  
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Sensitivity and specificity of serological markers 
The most sensitive and specific serologic markers of celiac disease are the EMA and 
the tTG IgA antibodies [48]. While two different types of tests are used for detect these 
autoantibodies, they detect antibodies to the same antigen, the tTG [56]. IgA anti-tTG 
antibody and IgA anti-EMA tests have sensitivities higher than 90% and specificities 
higher than 95%, and, therefore, the serological tests to detect those antibodies are 
recommended for initial screening [57].  In contrast, IgA AGA has a sensitivity of about 
80% and a specificity ranging from 80-90%. For routine diagnosis, the determination of 
gliadin antibodies in serum is no longer recommended, since they are less sensitive and 
specific than EmA and tTG antibody tests [43, 58].  
IgG anti-EMA and anti-tTG antibodies, in spite of having a specificity rounding 95%, 
present poor sensitivities (around 40%) and for this reason these antibodies have been 
used less frequently as serological markers [57]. However, because IgA deficiency has an 
increased prevalence among celiac patients [29], care should be taken in interpreting the 
results of IgA antibody tests. In the case of IgA deficiency, measurement of IgG anti-
EMA/tTG and IgG anti-gliadin antibodies should be performed. Positive results for IgA 
anti-EMA/tTG antibodies, or IgG anti-EMA/tTG antibodies and AGA in the case of IgA 
deficiency should be followed by intestinal biopsy. A biopsy might also be recommended 
in cases of negative serology, when there is a high clinical suspicion. 
In positive serological cases, followed by a negative biopsy, it is important to consider 
HLA typing, since the absence of both HLA-DQ2 and/or HLA-DQ8 alleles has a very high 
negative predictive value, helping to rule out the disease in cases of equivocal biopsy 
results [3, 4, 56].  
It is established that the most widely used methodology for CD clinical serological 
diagnostic purposes is an enzyme-linked immunosorbent assay (ELISA). Several high 
quality commercial kits are available to detect IgA antibodies to tTG antibodies, which 
appear to have equivalent diagnostic sensitivity and specificity to EMA IgA. The 
advantages of tTG testing is that the ELISA test, eliminates the disadvantages associated 
with the use of EMA, namely the higher cost, time-consuming protocol which is unsuitable 
for testing large numbers of samples, the use of monkey oesophagus (or human umbilical 
cord) and the subjective interpretation of the immunofluorescence analysis [15]. Several 
studies have compared the analytical and clinical utility of commercially anti-
transglutaminase ELISAs assays [59-73], and found that the use of tTG as antigen for CD 
diagnosis presents an adequate sensitivity and specificity. Therefore, major efforts have 
been concentrated on developing a tTG-based ELISA, using either the commercially 
available guinea pig tTG or human recombinant tTG. 
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The first generation assays for tTG antibodies detection used guinea pig liver tTG as 
the antigen. Second generation kits using purified human tTG or human recombinant tTG 
(H-tTG) were developed and introduced in routine practice. Several studies compared the 
first and second generation kits and concluded that the human antigens improve assay 
sensitivity and selectivity [63, 74-76]. A third generation of kits using tTG-gliadin peptide 
complexes as the antigen, has also been proposed, however it seems to have no advantage 
over human recombinant antigen kits, specially regarding specificity [77, 78].  
Several second-generation assays are commercially available, and were introduced in 
routine practice of clinical laboratories. These assays use either recombinant human tTG 
or purified H-tTG as antigen. 
Van Meensel [79] and colleagues evaluated 10 different commercially available 
second-generation IgA anti-tTG ELISA kits, and showed that most of these assays 
presented excellent performance, with good linear ranges. According to the optimal 
receiver operating characteristics (ROC) curve cut-off employed, the sensitivity values 
ranged from 91% to 97% and the specificity ranged between 96% and 100%. Since the 
areas under the ROC curve did not differ significantly, the results of the kits could be 
compared; however, there is some variability between these immunosorbent assays which 
needs to be solved in order to reach higher homogeneity. 
 
Gluten-free food control 
Two guidelines concerning the management of CD were recently published: 
“Recommendations of NASPGHAN” [43] and “National Institutes of Health (NIH) 
Consensus Development Conference Statement on Celiac Disease” [80]. 
After a positive diagnosis for CD, the only treatment available, so far, is a lifelong strict 
adherence to a gluten free diet, which will permit the recovery of the intestinal mucosa 
[18]. However, a diet completely free of gluten would be difficult, if not impossible, to 
maintain. Gluten is a common component in the human diet, and its exclusion presents a 
big challenge for celiac disease patients.  Gluten plays a key role in determining the unique 
baking quality of wheat by conferring water absorption capacity, cohesivity, viscosity and 
elasticity to dough [81]. After sugar, it is perhaps the second most widespread food 
component in Western civilization [82]. Since about 10% of gluten seems to be made up of 
potentially toxic gliadin peptides [83] it is extremely important to evaluate the purity of 
gluten-free products, in order to ensure a safe diet for celiac patients. To certify gluten-free 
products, the use of highly sensitive assays is mandatory. The European Union, World 
Health Organization and Codex Alimentarius require reliable measurement of the wheat 
prolamins, gliadins, rather than all wheat-derived proteins [84]. There is still no general 
agreement on the analytical method to measure gluten in ingredients and food products 
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[85], although the official limits described in the Codex Draft Revise Standard (2000) are 
20 ppm for foodstuffs naturally gluten-free and 200 ppm for foodstuffs rendered gluten-
free [86]. Nevertheless, to measure gluten traces in food, immunochemical methods are 
usually chosen to determine gliadins [87-92]. Besides the quality control of gluten-
containing products, it is important to assess gluten in foodstuff that can be contaminated 
with native or heated proteins from wheat, barley and rye.  
In the recent years several analytical possibilities for the detection of the wheat protein 
component gliadin in food products have been exploited, such as the polymerase chain 
reaction (PCR) technology, mass spectrometry or high-performance liquid 
chromatography (HPLC). PCR allows the amplification of a specific DNA fragment, 
flanked by two oligonucleotides that act as primers in the amplification reaction carried 
out by DNA polymerase. The amplified product is visualized by staining with a fluorescent 
dye or by Southern blotting after a gel electrophoresis. The amplification of gluten-specific 
DNA fragments by PCR has been reported [93, 94]. Normally, PCR results are only 
qualitative, however, by incorporating internal standards, the results provide 
semiquantitative measurements. Employing real-time PCR (rt-PCR) highly accurate 
quantitative results can be obtained. A quantitative competitive PCR system has been 
constructed, evaluated and compared to ELISA, obtaining a good correlation of the results 
between the two methods [95]. In this study a wheat-, barley- and rye-specific 
WBR11/WBR13 primer pair was used. These primers were also used in a quantitative 
competitive PCR system to detect gluten traces in flours and ‘‘gluten-free’’ bakery products 
[96]. Piknova and colleagues achieved detection limits of 200 mg/kg of wheat in flour 
using real-time PCR [97]. Henterich and colleagues performed a rt-iPCR (real-time 
immuno-polymerase chain reaction (iPCR)) for the detection of the cereal protein gluten, 
gliadin. Using iPCR a detection limit of 16 mg gliadin/100 g food was achieved [98].  
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry allows the detection of large proteins from highly complex protein mixtures 
such as those present in gluten prolamins [99]. The high resolution and sensitivity of this 
technique allows the elucidation of protonated molecular masses of most of the gliadin, 
hordein, secalin and avenin components. Méndez and colleagues [100] concluded that the 
analysis of gliadin-containing foods by this technique allows the immediate identification 
of the characteristic gliadin mass pattern, consequently permitting easy identification of 
gliadins in such samples with a detection sensitivity of 50-100 ng total protein loaded. In 
another study the first non-immunological alternative to quantify gluten gliadins in food 
samples was presented [101]. The procedure allowed the microquantification of gluten in 
processed and unprocessed gluten-containing food samples below toxic levels for CD 
patients, with a linear response in the 0.4 - 10 mg per 100 g range and a detection 
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sensitivity similar to that of ELISA systems. A new protocol for determining small 
amounts of gliadins in foods that contain relatively large amounts of other prolamin 
proteins from maize and/or rice was also described [102]. This strategy combines a two-
step procedure of extraction (60% aqueous ethanol followed by 1 M acetic acid) with 
subsequent MALDI-TOF analysis to corroborate the presence of these ethanol-soluble 
wheat prolamin fraction. HPLC allows the separation and qualitative and quantitative 
determination of compounds with analytical interest. A widely used HPLC technique is the 
reversed phase high performance liquid chromatography (RP-HPLC). In reversed phase 
system, stationary phase is slightly polar or non-polar, while mobile phase has stronger 
polarity. A RP-HPLC system has already been described for the separation and 
quantitative determination of wheat prolamins in food [103,104]. Also a flow cytometry 
(FCM) method for to the quantitative determination of picogram levels of gliadin was 
developed [105]. FCM is a high-throughput technique that is able to analyse a large 
numbers of cells individually using light-scattering and fluorescence measurements [106]. 
In the work of Capparrelli and colleagues, rat antibodies against a 16-residue peptide of 
gliadin, common to the α, β, γ, and ω-gliadins, were used. A detection limit under 10 
pg/ml was achieved.  
Despite the efforts in developing new analytical strategies for gluten control in 
foodstuffs, the most used method of measurement of gliadin still relies on the ELISA-like 
techniques. Thus, two commercial immunoassays are currently available to assess gluten 
content of gluten-free foods. The association of Analytical Communities endorses the 
method originally developed by Skerritt and Hill [93], the sandwich ω-gliadin ELISA, 
which uses a monoclonal antibody to the heat-stable ω-gliadin fraction. Since  the ω-
gliadin fraction  is not denatured when heated for cooking or processing, this assay can be 
used to assess gluten content of foods containing both native and heated protein. One 
major drawback of this assay is that measurements of this subfraction with the 
extrapolation to total gliadin have theoretical errors of -44 to +80% [94]. Moreover it is 
unable to accurately detect and quantify barley prolamins and cannot accurately quantify 
hydrolyzed gluten [109]. 
The other test is the R5 ELISA [110] that has been proposed as the standard method 
for gluten analysis in gluten-free foods by the Codex Committee on Methods of Analysis 
and Sampling [111], promoted by the Codex Committee on Nutrition and Foods for special 
dietary uses [112]. This test uses the R5 monoclonal antibody directed to the potentially 
celiac toxic epitope QQPFP (glutamine-glutamine-proline-phenylalaline-proline) present 
in wheat, rye and barley prolamins. This immunoassay is able to quantify native and 
heated gluten although it seems to over estimate barley hordein [113] and to be unable to 
accurately quantify hydrolyzed gluten [109]. 
CELIAC DISEASE: FROM GLUTEN TO DIAGNOSIS 
 
 47 
 
New strategies for celiac disease diagnosis and gluten-free food analytical 
control  
Currently, biosensor development is widespread in many fields and a considerable 
effort is being focused on the development of even more rapid, sensitive, high sample 
throughput and, specially, on-site analytical strategies that can be applied in point-of-care 
analysis. Two kinds of sensors are found in the bibliography: optical and electrochemical. 
 
Optical biosensors 
De Stefano and colleagues [114] proposed the development of a porous silicon-based 
(PSi) optical biosensor for the detection of trace amounts of gliadin using a recombinant 
glutamine-binding protein (GlnBP) from Escherichia coli as a molecular probe. The 
solutions containing the molecular probe and the analyte, peptic-tryptic (PT)-gliadin, were 
directly spotted on the sensor surface. GlnBP was covalently linked to the surface of the 
PSi surface via a functionalization process.The proposed optical protein microsensor with 
a PSi-based transducer sensor allows a sensitive, fast and easy readable optical response; 
moreover it is able to work under reducing conditions, which solves some problems 
related to prolamin extraction. The results showed that about 45% of the spotted proteins 
have selectively bound the respective peptide. A fiber-optic biosensor for the detection of 
anti-gliadin antibodies was also developed [115].The biosensor has been developed by 
coating a tapered optical fiber by immobilization of gliadin using the electrostatic self-
assembled (ESA) method which allows the construction of nanometric scale recognition 
surfaces on the fiber optic, allowing a real time monitorization of the sensor behavior. 
Gliadin antigens were successfully immobilized onto the surfaces of tapered optical fibers 
using the ESA method which has been proved to be an efficient immobilization strategy. 
The biosensors were tested using antibodies conjugated with and without peroxidase. A 
high sensitivity sensor was obtained, with fast response times as compared with standard 
ELISA tests. 
 
Electrochemical immunosensors 
Yet, the most commonly used biosensor strategy relies on electrochemical sensors. New 
electrochemical immunosensors (EIs), which employ cost-effective, user-friendly and 
highly sensitive analytical transduction devices, have appeared as new exciting 
alternatives to the conventional immunochemical tests which are based on indirect 
detection compromising real-time analysis. EIs are a self-contained integrated device that 
is capable of providing specific quantitative or semi-quantitative analytical information 
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using an immobilized immunological recognition element (for detecting a target analyte 
by structural complementarity) and an electrochemical based-transducer which converts 
the biological interaction into a measurable signal [116]. 
Recently, two EIs for the detection of celiac disease toxic gliadin in foodstuffs were 
reported. Nassef and colleagues [117] developed an electrochemical immunosensing 
strategy for the detection of toxic gliadin using an antibody, coined CDC5, which was 
raised against the putative immunodominant celiac disease toxic epitope of α-gliadin, 56-
75. For anchoring the captured antibody, two different surfaces, based on a gold electrode 
modified with acidic self-assembled monolayers (SAMs), were proposed. A good 
performance regarding sensitivity, specificity and reproducibility was obtained. When 
applied to real sample analysis an excellent performance correlation was achieved when 
compared with ELISA as well as considerable decrease in the time to perform the assay. In 
order to improve sensitivity, the use of antibody fragments instead of whole antibodies 
was also exploited. A new electrochemical immunosensor based on the spontaneous 
adsorption of antigliadin Fab fragments (CDC5-Fab) on gold surfaces was developed [118]. 
CDC5-Fab forms a stable monolayer on gold after 15 min and presents a 2 months long-
term stability, when stored at 4ºC with more than 90% of antigen recognition ability. By 
using amperometry to evaluate the ability of Fab modified electrodes to detect gliadin a 
limit of detection of 3.29 ng/mL was achieved. This Fab immunosensor has shown to be 
highly sensitive, rapid, simple and to have a short assay time. 
Regarding clinical diagnosis of CD using EIs, some advances are also being achieved. 
Balkenhohl and Lisdat developed impedimetric immunosensors for the detection of 
antibodies directed against gliadin [119] and for the detection of autoantibodies against 
transglutaminase [120] in human serum. The immunosensors were based on the 
immobilization of gliadin and transglutaminase onto disposable screen-printed gold 
electrodes which were covered with a polyelectrolyte layer of poly (sodium-4-
styrensulfonic acid). Although the results suggest a lower precision, as compared to 
ELISAs, an acceptable sensitivity was achieved, which makes the developed sensors 
reliable and promising methodologies for the analysis of anti-transglutaminase and anti-
gliadins antibodies in human serum. On the other hand, Pividori and colleagues proposed 
an amperometric electrochemical immunosensor based on the physical adsorption of tTG 
from guinea pig liver on graphite–epoxy composite (GEC) electrodes [121]. For 10 positive 
and 10 negative processed serum samples a sensitivity of 70% and a specificity of 100% 
were achieved, as compared with the commercial ELISA method. The developed sensor 
appears as a promising alternative to the conventional ELISA assays, as it is a simple, low 
cost and point-of-care analytical method. The authors also proposed the evaluation of the 
benefits of transfer the developed methodology to disposable screen-printed electrodes. 
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Although the immunosensor technology seems promising, some limitations still 
remain, such as long-term stability, surface effects, and interferences resulting from 
complex sample matrices.  
 
Conclusions 
The knowledge of celiac disease has grown in the last two decades and there has been a 
sharp increase in the number of newly diagnosed individuals. The different clinical 
presentations of CD can complicate the diagnosis and, therefore, delay the treatment of 
the disease. The advances in the efficacy of serological antibody testing potentiate the 
possibility of future accurate screening programmes in the community, working as a first-
line method to clarify clinically suspicious cases in an underdiagnosed stage and also to 
manage the follow-up of this multifactorial disease. 
Patients with a low to moderate probability of presenting the disease should be 
submitted to blood studies rather than to small bowel biopsy. Several commercially 
available enzyme-linked immunoasorbent assay kits can be employed in CD screening. 
Among them, those using the serological markers IgA anti-tTG antibodies present the 
highest diagnostic accuracy. Although the overall diagnostic performance of the tests is 
good and similar for the different assays, greater standardization is required. 
After a positive diagnosis, the implementation of a gluten-free diet is the only 
treatment available for CD. Two immunological methods for gluten food analysis are 
commercially available, and both use monoclonal antibodies toward gluten proteins. 
Further studies are necessary to develop an analytical method that can discriminate and 
quantify the celiac-toxic polypeptides in food ingredients and processed foods. 
At the moment, ELISA assays are the recommended approach to the diagnosis of CD. 
Regarding gluten assessment in food products, ELISA R5 was provisionally endorsed by 
Codex Alimentarius, although there is not a standard methodology that receives universal 
agreement. There are several problems regarding the pretreatment of the food products 
which starts immediately with the extraction process. 
The need for a standardized methodology to perform an unequivocal clinical diagnosis 
of CD as well as to determine quantitatively the gluten content in food products with the 
gluten-free label still remains. 
 
Future perspectives 
Possible areas of future study may be directed toward new immunosensing strategies 
that combine the high specificity of traditional immunochemical methods with 
miniaturized systems that allow development of a point-of-care test for CD clinical 
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diagnosis and gluten-free food quality control. Nevertheless, the reference methods need 
to present better international agreements, in order to achieve a higher standardization 
for the different immunoassays. 
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Abstract 
Point-of-care testing is used to rapidly provide reliable results in an easy manner, and is 
therefore one of the current tendencies in research and development in analytical 
chemistry. Biosensors are excellent alternatives to perform decentralized analytical 
operations. Among the different transducers of these sensors, electrochemical transducers 
stand out due to their attractive features such as high sensitivity and selectivity, rapid 
response and low cost. The development of disposable screen-printed electrodes was an 
important contribution to the electrochemical biosensor (EB) field due to their electrical 
properties and small size, which allows the reduction of the electrochemical 
instrumentation down to small pocket-size devices, making them applicable for both 
personal and professional use. In recent years, the integration of nanomaterials on the 
electrode surface has been gaining relevance since it improves the transducer's sensing 
platform, promoting aspects such as the increase of the electroactive area, the improval of 
the electron transfer, the enhancement of biocompatibility, and the maintenance of the 
biological element's activity. This review presents an overview of the progress in the field 
of EBs that are based on nanostructured screen-printed electrode transducer surfaces and 
their application in clinical analysis.  
 
Keywords:  
Electrochemical Biosensors. Screen-printed electrodes. Nanomaterials. Point-of-care 
testing. 
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Abbreviations   
AChE   Acetylcholinesterase 
AgNPs    Silver nanoparticles 
ASV   Anodic stripping voltammetry 
AuNPs Gold nanoparticles 
BRAC1   Breast cancer 1 
BSA   Bovine serum albumin  
CA   Cancer antigen 
CEA   Carcinoembryonic antigen 
CF   Cystic fibrosis 
ChOx   Cholesterol oxidase 
ChE   Cholesterol esterase 
CNF   Carbon nanofiber 
CNP   Carbon nanoparticle 
CnT I   Cardiac troponin I 
CNT   Carbon nanotube 
CV   Cyclic voltammetry 
DPV   Differential pulse voltammetry 
EB   Electrochemical biosensors 
EIS   Impedance spectroscopy  
Fe3O4 NPs  Iron oxide 
GOx Glucose oxidase 
GRF  Graphene 
hCG  Human chorionic gonadotropin  
IL-6  Interleukin-6  
MWCNTS Multiwalled carbon nanotubes 
PfHRP-2 Plasmodium falciparum histidine-rich protein 2 
POC Point-of-care 
PSA Prostate specific antigen  
QDs Quantum dots 
RIgG Rabitt imunoglobulin G  
SAMs   Self-assembled monolayers 
Si   Silica nanoparticles 
SPE   Screen-printed electrodes 
SWCNTs    Single-walled carbon nanotubes 
SWV   Square wave voltammetry   
tTG   Tissue transglutaminase  
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1. Introduction 
Nowadays, an evolution of analytical (bio)chemistry towards simpler, faster and in situ 
analytical performances is observed. Since the 1990s, patient self-testing has grown in 
popularity and there are commercially available test kits for pregnancy, blood pressure, 
drugs of abuse, blood glucose, cholesterol, among others [1]. The need to save time and 
money, gaining, simultaneously, in efficacy, implies the decentralization of analytical 
operations to a point-of-care (POC) system platforms [2, 3]. Warsinke [1] proposed an 
algorithm to simplify the process of clinical testing through POC tests (Fig. 1). 
Moreover, POC testing can also be very useful in resource-limited settings [4]. For this 
purpose, electrochemical biosensors (EBs) are becoming exiting alternatives to the 
centralized clinical setting diagnostic techniques. EBs present advantages such as short 
analysis times, low assay costs and real-time measurements. With regard to quality and 
cost, EBs can be a better option than standard analytical methods. For the design of an EB, 
before the immobilisation of the capture element onto the electrode surface, the choice of 
the base electrode is a crucial step [5]. A wide variety of electrode materials have been 
used as transducers to fabricate EBs, including platinum [6], gold [7, 8, 9], and distinct 
forms of carbon [10], such as carbon paste [11], glassy carbon [12, 13], carbon ﬁber [14], 
epoxy graphite [15], and graphene [16]. Recently, several EBs have been developed on 
disposable and small-size screen-printed electrodes (SPEs) [17,18]. Bearing in mind that 
the achievement of high sensitivity requires innovative approaches that couple different 
amplification platforms [19], the modification of transducer surfaces with carbon, metal, 
and gold nanoparticles is being subject of intense investigation. One of the new trends is 
the use of hybrid nanomaterials as last generation transducers for the development of 
electrochemical biosensors. This article intends to give a wide perspective of advances in 
the last years regarding the employment of nanostructured screen-printed electrodes as 
transducer surfaces in the construction of electrochemical biosensors for clinical 
diagnosis.  
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Figure 1. Proposed algorithm of the process of clinical testing using central laboratory versus 
decentralized POC testing (from [1]). 
 
2. Screen-printing technology 
The main disadvantage of EBs based on conventional electrodes, such as carbon paste 
and glassy carbon, among others, is the regeneration of their surfaces. To overcome this 
problem, in recent years the application of disposable SPEs has been gaining special 
attention for use as electrochemical transducers [20]. The screen-printing technology, 
adapted from the microelectronics industry, offers high-volume production of extremely 
inexpensive, and yet, highly reproducible and reliable single-use sensors; a technique 
which holds great promise for on-site monitoring [17]. There are many commercial 
sources of SPEs in different configurations (e.g. Pine Research Instrumentation, 
http://www.pineinst.com/echem; PalmSens Electrochemical Sensor Interface, 
http://www.palmsens.com; BioSens Technology, http://www.rusens.ru; DropSens, 
www.dropsens.com) [18]. These disposable robust solid strip electrodes have successfully 
been employed in the development of analytical methodologies that respond to the 
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growing need to perform rapid in situ analyses [17]. Other important features of these 
electrodes are related to the miniaturisation of the measuring device, their ease of 
handling, and their manipulation in a disposable manner. The construction of SPEs 
includes a series of basic stages, namely: selection of the screen, selection and preparation 
of the inks, selection of the substrate, and the printing, drying and curing steps [17]. Like 
this, several SPE configurations based on different materials can be made. In summary, 
the design and production process of SPEs consists in sequential layer-by-layer deposition 
of an ink onto an insulating support or substrate, which will define the geometry of the 
sensors [21, 22, 23]. The substrate is commonly composed of alumina, ceramics, PVC, 
gold, iron, etc and the conducting path of the electrode are made of carbon ink/paste, or 
platinum, gold or other metal pastes. SPEs can also contain two (working and reference) 
or three electrodes (working, reference and auxiliary), designated  first-generation and 
secondary generation SPEs, respectively. The sensing element is the analyte-specific part 
of the biosensors. Enzymes, microorganisms, antibodies, nucleic acids and receptors have 
commonly been employed in the construction of screen-printed biosensors. They can be 
immobilized onto the surface of the working electrode, employing a variety of 
immobilization strategies [18, 24, 25, 26]. The electrochemical instrumentation used with 
SPE biosensors has been reduced to small pocket-size devices which make them applicable 
for both personal and professional use. Thus, SPE-based biosensors seem well suited to 
complement, or replace, standard analytical methods in fields such as environmental 
analysis, food quality control and clinical diagnostics. In fact, SPEs have progressively 
been incorporated in routine analysis in the clinical and environmental field. The 
possibility of working with customized SPEs that can be produced because of their 
versatility of design is another interesting characteristic since it allows multiplex 
detection. The electrode mask can have multiple working electrodes, and therefore 
different analytes of interest can be determined. This is especially important for multiple 
analyses, saving time and money. In critical clinical situations this type of analysis has an 
even higher importance because it can discard different pathologies and conduct the 
patient to the correct treatment.  
 
3. Nanomaterial-based electrochemical transducers  
The emergence of nanotechnology is opening new horizons for the application of 
nanomaterials in biosensors and bioassays. These nanomaterials are of considerable 
interest due to their unique physical and chemical properties, which offer excellent 
prospects for chemical and biological sensing. Nanotechnology has therefore been applied 
to improve the performance of biosensors and in recent years great attention has been 
I.STATE OF THE ART 
 
68  
 
given to nanostructured materials of different chemical composition, produced as 
nanoparticles, nanowires or nanotubes [27]. Bearing in mind that the electrode surface 
simultaneously works as the support for the immobilization of the recognition element 
and as the sensing surface, SPEs are being modified with different nanomaterials in order 
to improve their electrochemical behavior [28, 29, 30]. The modification of the electrode 
surface with nanomaterials provides an additional sensing platform that minimizes 
problems which may occur during the biosensor's construction, such as: the poisoning of 
the electrode surface due to non-speciﬁc adsorption, irreproducibility due the washing 
steps, and incorrect orientation of the capture element's/analyte's free-binding sites. 
Different strategies were developed for efficient deposition of nanomaterials and 
nanoparticles onto solid phase transducers as well as for the immobilization of the 
biological elements on their surfaces. The manner in which the nanomaterials or the 
recognition element are immobilized on the solid phase is a critical aspect in the 
biosensor's architecture and requires special consideration. The most widely used 
strategies are: physical adsorption, covalent binding, entrapment (including 
electropolymerisation), cross-linking and affinity binding [18, 22, 26, 31]. Electrochemical 
deposition approaches are often reported as methods of choice for the simple low-cost 
nanostructuring and nanopatterning of electrode surfaces. 
The chosen method should provide an excellent patterning and immobilization of the 
chosen nanomaterial on the electrode surface as well as a good orientation of the 
recognition element with minimal steric hindrance to interact favorably with the analyte.  
 
 
 
4. Clinical applications of screen-printed-based transducers surfaces 
modified with nanomaterials 
In clinical analysis, SPEs present added advantages. Among them, the employment of 
small sample volumes and the possibility of developing disposable biosensors due to their 
low cost can be cited. Besides avoiding the tedious and time-consuming electrode surface 
cleaning steps, SPEs enable the use of low reaction volumes because of their reduced 
dimensions, which reduces reagent consumption. Moreover, the decrease in the diffusion 
distances for the analytes to reach their surface-bound receptor partners allows shorter 
incubation periods and, thus, faster assays [32]. Enzymatic sensors, genosensors and 
immunosensors can be manufactured by modifying screen-printed electrode surfaces with 
nano-scale materials. 
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4.1. Carbon nanomaterial-based biosensing  
Carbon materials such as graphene (GRF), carbon nanotubes (CNTs), and carbon 
nanofibers (CNFs) [10, 27, 33, 34] are widely exploited for the construction of 
electrochemical transducers. GRF is a flat monolayer of carbon atoms tightly packed into a 
two-dimensional (2D) honeycomb lattice, and is a basic building block for graphite 
materials of all other dimensions. It can be wrapped up into 0D fullerenes, rolled into 1D 
nanotubes or stacked into 3D graphite [35]. GRF fascinated many researchers as it 
provides a large detection area, biocompatibility, and unique electronic properties such as 
ultra-high mobility and an ambipolar field-effect with much lower synthesis costs [35].  
CNTs consist of a graphite sheet rolled up into a nanoscale-tube, with a diameter of 1–
2 nm in case of single-wall carbon nanotubes (SWCNTs), or can be concentric, closed 
graphite tubules with diameters of 2–50 nm and an interlayer distance approximately 
0.34 nm, which are multi-walled CNTs (MWCNTs) [10, 27, 34].  
CNFs are cylindrical nanostructures with graphene layers arranged as stacked cones, 
cups or plates [36]. They have lengths in the order of µm, while their diameter varies 
between some tens to several hundred nm [34].  
Fullerene (C60) is another carbon-based material that is characterized by having 
multiple redox states in a wide range of potentials and being stable in many redox forms 
[37], therefore it has been reported that it plays an important role in electron transfer. 
Fullerene consists of a spherical molecule that has a truncated icosahedron shape that 
resembles a cage-like fused-ring structure.  
These carbon nanomaterials present excellent electrochemical properties and their 
application as sensing phases contributes to the increase of the electroactive area and the 
electron transfer rate. However, carbon-based materials lack bioreactivity and therefore 
some methods have been employed to solve this limitation. For instance, chemical, 
electrochemical, and thermal treatments are applied to generate functional groups on the 
material's surface which allows covalent binding of biomolecules. Moreover, covalent 
binding of biomolecules employing cross-linking agents or affinity binding through the 
biotin-avidin/streptavidin interaction can also be employed [34]. Fisioadsorption of 
biomolecules onto the carbon nanomaterial's surface or direct entrapment in carbon ink 
are also options.  
Several studies regarding the use of SPEs modified with carbon-based materials, either 
CNTs or graphene, have been reported. Recently, a novel screen-printed electrode, based 
on low-cost vegetable parchment technology, was developed and employed graphene 
nanosheets as the sensing phase for the determination of prostate specific antigen (PSA) 
in human serum samples [38]. In this study, amine-modified graphene oxide (GRF-NH2) 
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was physically adsorbed on the electrode surface providing an excellent coating platform 
for the immobilization of the capture antibodies through glutaraldehyde cross-linking.  
Using linear sweep voltammetry the proposed "sandwich-type" immunoassay showed a 
wide linear concentration range (over 6 orders of magnitude) with a minimum value of 2 
pg mL-1. In Fig. 2 a squeme of the described immunosensor is presented. A genosensor for 
the impedimetric detection of DNA polymorphism correlated to cystic fibrosis was 
proposed by Bonanni et al. [39]. In this case, screen-printed carbon electrodes (SPCE) 
containing carboxyl functionalized MWCNTs were used for the covalent immobilization of 
an amino-modified oligonucleotide probe, complementary to the cystic fibrosis (CF) 
mutant gene. A non-complementary DNA sequence and a three-mismatch sequence 
corresponding to the wild DNA gene (present in healthy people) were used as negative 
controls. The developed protocol allowed the very sensitive detection of the triple base 
deletion in a label-free CF-related DNA sequence, achieving a limit of detection (LOD) of 
around 100 pM. 
In table 1 a summary of other carbon nanomaterial-based SPE transducers is 
presented. Sensors for the detection of PSA [38], IgG immunoglobulins [40, 44], human 
chronic gonadotropin [41], anti-carcinoembryonic antigen (CEA) [42, 43], thrombin [47, 
49] and to assay DNA hybridization [45, 46, 48, 50] were developed. Several enzymatic 
sensors were also reported [51, 52, 53].  
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Figure 2. Schematic representation of the immunosensing strategy followed by Yan et al. to 
dectect PSA using a disposable graphene nanosheets-modified SPE (from [38]). 
 
 
 
I I.STATE OF THE ART 
 
72  
 
Table 1. Analytical characteristics of clinical biosensors based on SPE modified with carbon nanomaterials as transducer surface 
Screen-printed 
electrode 
Nanomaterial Nanomaterial 
immobilization procedure 
Recognition  element Recognition element 
immobilization technique 
Analyte Analysed sample Electrochemical 
technique 
Limit of detection REF* 
 
IMMUNOSENSORS 
Graphite MWCNTs Entrapment  Anti‐RIgG antibodies Phase inversion RIgG ‐ Amperometry 1.66 µg ml‐1 40 
Graphite MWCNTs Entrapment Anti‐hCG antibodies Phase inversion 
 
hCG ‐ Amperometry 14.6 mIU mL‐1 41 
Graphite CNP 
 
Entrapment Anti‐CEA antibodies Covalente attachment CEA Urine ASV 32 pg mL‐1 40 
Graphite MWCNT 
 
Entrapment Anti‐CEA antibodies  Covalence attachment CEA Saliva and serum SWV 1×10−12 g mL−1 43 
Carbon Graphene  Fisioadsorption Anti‐PSA antibody Cross‐linking PSA Serum samples CV 0.46 pg mL‐1 38 
Graphite CNTs Entrapment Anti‐ human IgG Fisioadsorption Human IgG Human serum 
samples 
DPV 0.06 pg mL‐1 44 
 
GENOSENSORS 
Carbon Fullerene (C60) Entrapment E. coli 16S rDNA probe Fisioadsorption E. coli 16S rDNA target ‐ DPV ‐ 45 
Graphite MWCNTs 
 
Fisioadsorption DNA probe Fisioadsorption DNA target ‐ EIS 22 fmol 46 
Carbon MWCNTs Fisioadsorption Oligonucleotide probe 
complementary to the 
CF mutant gene 
Covalence attachment 
 
CF mutant gene ‐ EIS 100 pM 39 
Carbon MWCNTs Fisioadsorption Thrombin aptamer Covalence attachment Human alpha thrombin Human serum spiked 
with human alpha 
thrombin 
EIS 105 pM 47 
Graphite SWCNTs Fisioadsorption (BRCA1) DNA probe Fisioadsorption (BRCA1) DNA target ‐ DPV 378.52 nM 48 
Graphite Graphene Fisiadsorption Thrombin aptamer Fisiasorption Thrombin ‐ EIS ‐ 49 
Graphite MWCNTs 
 
Fisiadsorption DNA aptamer Covalence attachment Lysozyme ‐ EIS 12.09 lg ml‐1 50 
 
ENZYMATIC SENSORS 
Carbon MWCNTs Fisioadsorption Lactate dehydrogenase Cross‐linking Lactate Blood samples Amperometry 7.5×10−6 mol L‐1 51 
Rhodium–
graphite 
MWCNTs Fisioadsorption CytochromeP450scc 
(CYP11A1) 
Fisioadsorption Cholesterol ‐ Amperometry ‐ 52 
Carbon MWCNTs Cross‐linking Tyrosinase Fisioadsorption Methimazole Pharmaceuticals CV 0.056 µM 53 
 
ASV (Anodic stripping voltammetry); BRCA1 (breast cancer 1); CEA (carcinoembryonic antigen); CF (Cystic fibrosis); CNP (carbon nanoparticle); CV (Cycliv voltammetry); Differential pulse voltammetry (DPV);  GRF (graphene); hCG (human chorionic 
gonadotropin);  Eis (impedance spectroscopy); MWCNTS (multiwalled carbon nanotubes); PSA (prostate specific antigen); RIgG (rabitt imunoglobulin G ); SWCNTS (singlewalled carbon nanotubes); SWV (Square wave voltammetry).  
*References.
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4.2. Metal nanomaterial-based biosensing  
Besides carbon nanomaterials, noble metal nanoparticles (NPs) are receiving a high 
share of attention since they allow the immobilization of biomolecules, retaining their 
biological activity, and the formation of an efficient conducting interface with 
electrocatalytic properties [54]. Chemical and physical methods have been employed to 
synthesize noble metal NPs in order to obtain a good level of homogeneity and to provide 
fine control over size, shape and surface properties, to better take advantage of their 
unique physicochemical properties for biosensing [55]. Metal nanoparticles are also 
widely used as labels, however this review focuses on their role in transducer surface 
modification. 
Gold is the most commonly employed metal in the construction of electrochemical 
biosensors. As electrode material, gold is not as good as carbon but its chemical reactivity 
still remains. An especially interesting reaction occurs between gold and thiols (RSH) and 
disulphides (RSSR’). In this reaction the homolytic rupture of S-H or S-S bonds implies 
the formation of self-assembled monolayers (SAMs). Depending on the thiols or 
disulphides, gold can be modified simply for possessing different functionalities, making it 
possible to achieve a high degree of surface functionality. This extends the possibilities for 
making other modifications by means of common chemical reactions. Moreover, cysteine 
and cystine residues from proteic material allow direct chemisorption to gold surfaces. 
This is of tremendous interest in the construction of biosensors. Due to the spontaneity of 
these reactions, the trend in system development is directed towards the increase in the 
number of interactions between gold and proteic material. Therefore, apart from the 
chemical reactivity, the gold surface's structure is very important. The use of continuous 
gold surfaces has the inconvenience of promoting a high number of interactions, which 
can imply a less selective orientation as well as drastic changes in the structure of the 
chemisorped proteic material. As a consequence, the biological activity of the recognition 
element can be altered and, in turn, the efficacy of the immunosensors is low. A solution to 
this problem is the utilization of gold nanostructures because they possess the same 
chemical reactivity but are more biocompatible [9, 56]. Therefore, gold NPs (NPAus) 
provide stable and high surface-to-volume ratio surfaces for the immobilization of 
biomolecules while retaining their biological activity. Due to their high surface energy, 
their ability to decrease the distance between proteins and metal particles, and their ability 
to act as an electron-conducting pathway between prosthetic groups and the electrode 
surface, may facilitate electron transfer between redox proteins and the electrode surface 
[9]. Moreover they are cost-effective and easy to prepare. Gold nanoparticle-modified 
electrode surfaces can be prepared in three ways: (a) binding of NPAus with functional 
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groups of self-assembled monolayers (SAMs); (b) direct deposition of NPAus on the bulk 
electrode surface; (c) incorporating colloidal gold into the electrode by mixing the gold 
with the other components in the composite electrode matrix [9]. Silver NPs (NPAgs) have 
recently become one of the most popular materials to fabricate sensors for the detection of 
a variety of compounds as they are capable of facilitating the electron transfer of some 
biological molecules [54]. Synthesis of metallic NPAgs through reduction of silver ions 
with different reagents [33], UV or electron beam irradiation [33], or electrochemical 
methods [35–40] are some of the methods described in the literature. The electrochemical 
deposition of silver onto solid surfaces is probably the easiest and fastest option. 
Wei Wu et al. [57] developed a novel transducer surface based on a nanosilver-doped 
DNA polyion complex membrane (PIC).This was achieved by the modification of a screen-
printed carbon electrode (SPCE) using Nafion-entraped double-stranded DNA molecules. 
The double-stranded DNA provides a three-dimensional network that adsorbs the silver 
ions, providing a facile pathway for the formation of NPAgs through the reduction of the 
silver ions using NaBH4. CEA antibodies bind to the surface of the NPAgs through their 
amino acids that form complexes with the metal. The developed immunosensor was used 
to analyze CEA in 50 real samples and the results were in good agreement with the results 
provided by a commercial enzyme-linked immunosorbent assay (ELISA). The authors 
concluded that the PIC membrane enhanced the sensitivity of the assay. 
Moreno et al. [58] proposed the immobilization of oligonucleotide-functionalized gold 
nanoparticle probes (affinity modules) by electrodeposition on arrayed screen-printed 
gold electrodes (Fig. 3). The final hybridization reaction of complementary 
oligonucleotides and PCR products was carried out with amperometric detection using 
horseradish peroxidase (HRP) as an enzymatic reaction. The authors pointed out that the 
proposed hybridization strategy can be applied to many other kinds of molecules such as 
aptamers, enzymes or antibodies. Chikae et al. [59] exploited saccharide–protein 
interactions in order to detect Alzheimer's amyloid-beta (Aβ) peptides. An SPE modified 
with (electrodeposited) NPAus coated with an acetylenyl-terminated SAM was used as the 
sensing phase. The saccharide immobilized in the SAM monolayer captured Aβ peptides 
and the oxidation peak current response of the tyrosine (Tyr) residue of Aβ was detected 
by differential pulse voltammetry.  
Although NPAus are the most frequently reported metal nanoparticles for surface 
enhancement, Fe3O4 [69, 72] nanoparticles were also reported as biocompatible metal 
nanomaterials for modification of SPEs.  
In table 2 other biosensors for clinical applications based on gold nanostructured [60, 
61, 62, 64, 65, 66, 67, 68] and silver [57, 70, 71] nanoparticles, using SPEs as transducer 
surfaces are presented. 
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Figure 3. Illustration of a proof of concept for the selective immobilization of affinity modules of 
olignucelotides functionalized with gold nanoparticles on SPEs, as proposed by [58]. 
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Table 2. Analytical characteristics of clinical biosensors based on SPE modified with metal nanoparticles as transducer surface 
Screen-printed 
electrode 
Nanomaterial Nanomaterial 
immobilization procedure 
Capture element Capture element 
immobilization 
technique 
Analyte Analysed sample Electrochemical 
technique 
Limit of detection REF* 
 
IMMUNOSENSORS 
Graphite Colloidal gold Entrapment 
 
IL‐6 antibody Entrapment IL‐6 ‐ DPV/ EIS 1.0 ng L−1  60 
Carbon AuNPs Electrochemical deposition PSA 8A6 antibody 
PSA 5G6 antibody 
Fisioadsorption fPSA and tPSA Cell cultures of 
prostate tumor cells 
CV 1 ng mL‐1 61 
Carbon AuNPs Entrapment Anti‐myoglobin Fisioadsorption Myoglobin Human plasma CV 10 ng ml‐1 62 
Carbon AgNPs Chemical reduction Anti‐CEA Fisioadsorption CEA Serum samples DPV 10 pgmL−1  57 
Carbon Colloidal gold Electrochemical deposition Anti‐CnT I antibodies Fisioadsorption CnT I ‐ EIS 0.2 ng mL−1 63 
 
GENOSENSORS 
Carbon AuNPS Electrochemical deposition Sars DNA probe Streptavidin/Biotin Sars DNA target ‐ CV 2.5 pmol L‐1 64 
Graphite AuNPs Entrapment  Thrombin aptamer Covalence attachment  Thrombin ‐ Cv/ SWV 10‐9 M 65 
Gold AuNPs Electrochemical deposition DNA probe Electrodeposition of 
affinity modules 
DNA target ‐ Amperometry ‐ 58 
Carbon AuNPs Electrochemical deposition Four pneumoniae 
probes 
Affinity (streptavidin–
biotin interaction) 
Four pneumoniae 
targets 
‐ CV 3‐8 pM 66 
Gold AuNPs Electrochemical deposition of affinity 
modules 
LiKMP‐11 aptamer Electrodeposition LiKMP‐11 ‐ Amperometry 0.025 mg mL‐1  67 
Carbon NPAus ‐ RT‐specific peptide Cross link HIV‐1 RT Human serum SWV 0.8 pg mL−1 60 
Graphite Fe3O4 NPs Entrapment 
 
DNA probe Covalence attachment 
though SAMs 
HIV‐1 sequences 
tare7get 
‐ EIS/ SWV 50 pM 69 
 
ENZYMATIC SENSORS 
Carbon AgNPs Electrochemical deposition ‐ ‐ Lamotrigine ‐ DPV 3.72×10−7 M 70 
Carbon AuNPs Electrochemical deposition Saccharide Covalence attachment  Amyloid‐beta peptide ‐ DPV ‐ 59 
Carbon AgNPs Entrapment GOx Entrapment Blood glucose Rabbit serum Amperometry ‐ 71 
Carbon Fe3O4 NPs Entrapment ChOx; ChE ‐ Cholesterol ‐ Chronoamperometry ‐ 72 
ASV (Anodic stripping voltammetry); AgNPs (silver nanoparticles); AuNPs (gold nanoparticles) CnT I (cardiac troponin I); CEA (carcinoembryonic antigen); CF (Cystic fibrosis); CV (Cyclic Voltammetry); Differential pulse voltammetry (DPV); GOx (Glucose 
Oxidase); hCG (human chorionic gonadotropin); EIS (Impedance spectroscopy); Interleukin-6 (IL-6); MWCNTS (multiwalled carbon nanotubes); PSA (prostate specific antigen); RT (reverse transcriptase); SARS (Severe Acute Respiratory Syndrome); SAMs (self-
assembled monolayers); SWV (Square wave voltammetry).   
*References.
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4.3. Hybrid nanomaterial-based biosensing  
The use of hybrid materials as last generation transducers is generating great 
expectative for their introduction in the development of electrochemical transducers for 
biosensors. This hybrid conjugation can consist of carbon and gold nanoparticles or of a 
bimetallic system. Like was referred before, carbon nanomaterials have exceptional 
electrochemical characteristics but lack some reactivity. This problem can be surpassed by 
combining them with metal-based nanomaterials [73, 74]. Hybrid surfaces lead to a 
synergic effect on each material property presenting collective characteristics that are 
drastically different from the individual components [75]. Thus, screen-printed electrodes 
have been modified with different hybrid nanomaterial conjugates. However, despite good 
characteristics such as sensitivity and reproducibility of these nanohybrid modified 
screen-printed electrodes, their use is still reduced.  
Recently, a disposable amperometric biosensor (Fig. 4) was developed for the 
detection of Plasmodium falciparum histidine-rich protein 2 (PfHRP-2) in the sera of 
humans with P. falciparum malaria [76]. For this purpose, disposable SPEs were modiﬁed 
with MWCNTs and NPAus. Bare SPEs, MWCNT-modiﬁed SPEs, and NPAu- and 
MWCNT-modiﬁed SPEs (Nano-Au/MWCNT/SPEs) for the amperometric detection of 
PfHRP-2 were compared, and Nano-Au/MWCNT/SPEs yielded the highest 
immunosensing performance among the tested electrodes, with a detection limit of 8 
ng/ml. The sensor was compared with a commercial ELISA kit and showed to be more 
sensitive and speciﬁc. These kind of cost-effective and portable diagnosis methods assume 
even more importance in regions with severe economic limitations. An electrochemical 
transducer surface nanostructured with a hybrid conjugation of carbon nanotubes and 
gold nanoparticles for the simultaneous detection of IgA and IgG anti-transglutaminase 
(tTG) and anti-gliadin antibodies was recently reported by our team [77]. The respective 
antigens (i.e. tTG and gliadin) were successfully  immobilized on  a  nanohybrid  screen-
printed  carbon  electrode  surface  and  10  different  human  sera  were assayed. A good 
correlation between the results and the results from a commercial  ELISA  kit was 
obtained, indicating  that  the  dual-electrochemical  immunosensor is  a  trustful  
analytical  screening  tool.  
Table 3 summarizes the principal analytical characteristics of recently developed 
biosensors based on hybrid-SPE surfaces. 
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Figure 4. Schematic representation of the fabrication and the assay procedure of the 
immunosensor based on nano-hybrid modified SPE for PfHRP-2 antigen (red diamonds) detection. 
BSA, bovine serum albumin (adapted from [76]). 
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5. Conclusions and Future Prospects  
The use of thick-film technology for the production of screen-printed electrodes seems 
to be one of the most promising methods for the development of electrochemical 
biosensors. Advantages such as miniaturization, mass production, customization, 
portability and low cost stand out with these electrodes, placing SPEs as the ultimate and 
versatile electrodic surface for analytical sensing operations. The advent of interesting 
nanomaterials allows the modification of SPE surfaces which improves electrochemical 
and biochemical features of the sensing platform. Disposable, sensitive, specific and fast 
nanostructured-based SPE surfaces are gaining special attention in the clinical analysis 
field. The relevance of EBs for clinical diagnosis will increase even more as the necessity to 
save money raises as well as the growing need for decentralized clinical applications. 
Moreover, the greatest impact of EBs will be felt at point-of-care testing locations without 
laboratory support, either regarding electric equipment or concerning sampling 
procedure. Nonetheless, relevant and not yet totally controlled aspects such as the storage 
and stability of biological materials immobilized onto the electrode surface has to be 
improved. The philosophy of rapid in-situ tests requires patient-friendly sampling 
techniques. The employment of small volumes of blood or other matrices (e.g. saliva, 
sweat, tears, etc.) are good alternatives. The continuous miniaturization of this technology 
into reliable, robust and easy-to-use instrumentation is a key to the success of the use of 
EBs in point-of-care testing.  
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Table 3. Analytical characteristics of clinical biosensors based on SPE modified with hybrid nanomaterials as transducer surface 
Screen-printed 
electrode 
Nanomaterial Nanomaterial 
immobilization procedure 
Capture element Capture element 
immobilization 
technique 
Analyte Analysed sample Electrochemical 
technique 
Limit of detection REF* 
 
IMMUNOSENSORS 
 
Carbon MWCNTs 
NPAUs 
Fisioadsorption 
Electrochemical deposition 
Anti‐ 
PfHRP‐2 antibody 
Fisioadsorption PfHRP‐2 Human serum Amperometry 8 ng ml‐1 76 
Carbon MWCNTs 
AuNPs 
Entrapment 
Entrapment 
Anti‐ AChE antibody SAM AChE Human red blood 
cells 
CV 
SWV 
0.05 nM. 78 
Carbon MWCNTs 
AUNPs 
Fisioadsorption 
Electrochemical deposition 
tTG Fisioadsorption Anti‐tTG Human serum CV 
 
n/a 79 
Carbon MWCNTs 
NPAUs 
Fisioadsorption 
Electrochemical deposition 
Gliadin Fisioadsorption Anti‐gliaidin IgA 
Anti‐gliadin IgG 
Human serum CV 9.1 U mL−1 
9.0 U mL−1 
80 
C arbon MWCNTs 
AUNPs 
Fisioadsorption 
Electrochemical deposition 
tTG 
Gliadin 
Fisioadsorption Anti‐tTG IgA 
Anti‐tTG IgG 
Anti‐gliadin IgA 
Anti‐gliadin IgG 
Human serum CV 2.45 U mL−1 
2.95 U mL−1 
3.16 U mL−1 
2.82 U mL−1 
 
77 
Carbon Graphene 
AuNPs 
Fisioadsorption 
Electrochemical deposition 
Anti‐CA CA 153 
Anti‐CA 125 
Anti‐CEA 
Fisioadsorption CA 153 
CA125 
CEA 
Serum samples ASV 1.5 x 10‐3 UmL‐1 
3.5 x 10‐4 UmL‐1 
1.2 x 10‐3 UmL‐1 
81 
Graphite MWCNTS 
Colloidal gold, 
Entrapment with Ricin antigen Fisioadsorption Ricin antibody Serum samples Amperometry 2.1 ng mL_1 82 
Carbon MWCNTs 
Graphene 
AuNPs 
Entrapment 
Fisioadsorption 
Fisioadsorption 
RaHIgG Fisioadsorption H IgG Serum samples DPV 44 pg/mL 83 
 
GENOSENSORS 
 
Gold QDs/Si Fisioadsorption Thrombin aptamers Fisioadsorption Thrombin Human blood serum DPV 0.1ngmL_1 84 
 
AChE (Acetylcholinesterase); ASV (Anodic stripping voltammetry); AuNPs (gold nanoparticles); CA (cancer antigen); QDs/Si (quantum dots/ silica nanoparticles); CEA (carcinoembryonic antigen); CV (Cyclic Voltammetry); DPV (Differential pulse voltammetry); 
NPAus (gold nanoparticles); MWCNTS (multiwalled carbon nanotubes); PfHRP-2 (Plasmodium falciparum histidine-rich protein 2); PSA (prostate specific antigen); SAMs (self-assembled monolayers); SWV (Square wave voltammetry); tTG (tissue 
transglutaminase)   
*References. 
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Abstract 
A nanohybrid electrochemical transducer surface was developed using carbon and gold 
nanomaterials. The strategy relayed on casting multiwalled carbon nanotubes or carbon 
nanofibers onto a screen-printed carbon electrode surface, followed by in situ generation 
of gold nanoparticles by electrochemical deposition of ionic gold, in a reproducible 
manner. These transducers, so fabricated, were characterized using both electrochemical 
and microscopic techniques. Biofunctionality was evaluated using the streptavidin-biotin 
interaction system as the biological reaction model. These platforms allow to achieve low 
detection limits (in the order of pmoles), are reproducible and stable at least for a month 
after their preparation, being a perfect candidate to be used as transducer of different 
sensor devices. 
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1. Introduction 
Amplified transduction of biological events remains a major challenge to electrical 
bioassays [1]. The development of electrochemical transducers that make use of electrode 
surfaces modification with nanomaterials became an exciting area of development for 
modern analytical science. The use of nanomaterials extend the potentialities of those 
electrodes surfaces improving their original electrochemical properties providing a low-
background current, high signal to noise ratio and fast electron transfer [2].  
Carbon nanotubes (CNTs) and carbon nanofibers (CNFs) based electrochemical 
biosensors have been used in the development of new designs of electrochemical 
biosensors which have found widespread use in several analytical applications [3–10]. 
Most applications of these materials rely on the modification of the working electrodes [8]. 
An application involving carboxylated-multiwalled carbon nanotubes (MWCNTs) 
dissolved in a DMF:water mixture used to modify commercially available screen-printed 
electrodes (SPEs), with considerable advantages regarding the conventional SPEs, was 
also reported [11]. Carbon-nanostructures exhibit a unique combination of excellent 
mechanical, electrical and electrochemical properties, such as large length-to-diameter 
aspect ratios, good electrical conductivity and a wide potential range. However, these 
present some lack of reactivity which can eventually lead to a decrease in protein 
adsorption. To overcome this disadvantage the transducers surface can be simultaneously 
modified with gold nanoparticles (NPAus) which have high surface energies and are 
therefore quite reactive [12]. Several studies employing NPAus in electrochemical 
applications such as bioassays, biosensor, chemical sensor and electrocatalysis have also 
been reported [13–15]. There is a variety of methods for depositing NPAus onto different 
substrates [16–18]. For instance, Martínez-Paredes and colleagues [19] proposed an 
electrochemical method to generate gold nanostructured screen-printed carbon 
electrodes. The developed electrochemical surface was applied to the detection of lead 
underpotential deposition and to the construction of geno- [20] and immunosensors [21]. 
NPAus works as an excellent adsorbent support, solving carbon limitations and enhancing 
biocompatibility [14]. 
The achievement of high sensitivity requires innovative approaches that couple 
different amplifications platforms [22]. Hence, the metal nanoparticle/carbon 
nanostructure hybrid system allows a synergic effect on each material property since the 
hybrid system may have collective characteristics that are drastically different from 
individual component [23]. The physical deposition of gold on bulk carbon substrates is 
an attractive method for the preparation of nanostructured electrodes and some 
applications were already published [1, 24-27].  
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To study the advantages of the transducer surface nanostructuration, the interface 
between protein and the nanomaterials can be accomplished using the classic 
streptavidin-biotin system. Streptavidin coated-surfaces have been widely applied to solid-
phase assays, mainly immune ones, due to the extraordinary properties of streptavidin-
biotin interaction [28]. Streptavidin-biotin technology relies on the extremely tight and 
specific affinity between these two molecules associated with the exceptional stability of 
these proteins [29-30]. 
In this work we studied different methodologies for modify the screen-printed carbon 
electrodes (SPCEs) in a reproducible manner in order to obtain the best nanohybrid 
transducer surface. As far as we are concerned, there are no previous reports of SPCEs 
modification with nanohybrid materials and their application as electrochemical 
transducer surface. 
Several nanostructured-based electrochemical transducers were studied. SPCEs 
surface was modified with carboxylated multiwalled carbon nanotubes (MWCNTs) or 
carboxyl-funcionalized carbon nanofibres (CNFs) and, moreover, with an hybrid 
conjugation of these carbon nanomaterials with gold nanoparticles (NPAus). The results 
of the modification were evaluated using the biological streptavidin-biotin complex. The 
transducer performance was optimized by effective blocking of non-specific binding (NSB) 
of the labels using bovine serum albumin (BSA) and casein. Alkaline phosphatase (AP) 
worked as the enzymatic label and a mixture of 3-indoxyl phosphate with silver ions (3-IP-
Ag+) as the substract. The analytical signal obtained resulted from the anodic redissolution 
by cyclic voltammetry of metallic silver generated enzymatically. The electrochemical 
behavior of these modified electrodes was carefully evaluated assessing aspects as 
detection limits, sensitivity, reproducibility, stability and biocompatibility. 
Chronocoulometry and scanning electron microscopy (SEM) were also employed in the 
characterization of the hybrid surface. 
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2. Experimental 
2.1. Apparatus and electrodes 
Voltammetric experiments were performed with an Autolab PGSTAT 12 (Eco Chemie, 
The Netherlands) potentiostat/galvanostat interfaced to an AMD K-6 266MHz computer 
system and controlled by Autolab GPES 4.8 (software version for Windows 98). All the 
measurements were carried out at room temperature. 
Single-use screen-printed carbon electrodes (SPCEs) were purchased from DropSens 
(Oviedo, Spain). The DropSens electrodes incorporate a conventional three-electrode 
configuration, printed on ceramic substrates (3.4-1.0 cm). Both working (disk-shaped 4 
mm diameter) and counter electrodes are made of carbon inks, whereas pseudoreference 
electrode and electric contacts are made of silver. An insulating layer was printed over the 
electrode system, leaving uncovered the electric contacts and a working area which 
constitutes the reservoir of the electrochemical cell, with an actual volume of 50 µL. The 
SPEs were easily connected to the potentiostat through a specific DropSens connector 
(Spain, ref. DSC).  
A JEOL JSM-6100 scanning electron microscope (20 kV, Japan) was used to 
characterize the working electrodes. A pHmeter MicropH2001 (Crison Instruments S.A., 
Spain) and an ultrasonic bath Ultrasons (J.P. Selecta, Spain) were also employed. 
 
2.2. Reagents and solutions 
Tris(hydroxymethyl)aminomethane (Tris), magnesium nitrate, bovine serum albumin 
fraction V (BSA), β-Casein from bovine milk (casein), streptavidin (molecular weight, 66 
000), biotin conjugated to alkaline phosphatase (B-AP; dimer, four units of B per 
molecule of AP, molecular weight, 160 000), were purchased from Sigma (Madrid, Spain). 
Standard gold (III) tetrachloro complex (AuCl4−), silver nitrate, hydrochloric acid fuming 
37% and nitric acid (HN03) were obtained from Merck (Germany). Biosynth (Switzerland) 
supplied 3-indoxyl phosphate disodium salt (3-IP). Ultrapure water obtained with a Milli-
RO 3 plus/Milli-Q plus 185 purification system from Millipore Ibérica S.A. (Madrid, 
Spain) was used throughout this work. Carboxyl modified multiwalled carbon nanotubes 
(MWCNTs) were purchased from Nanocyl (ref. 3151) and carboxyl modified carbon 
nanofibers (CNFs) were kindly provided by the company “Grupo Antolín” (Valencia, 
Spain). 
Working solutions of streptavidin were made in 0.1 M Tris-HNO3 pH 7.2 buffer (buffer 
1).  Working solutions of B-AP were prepared in 0.1 M Tris-HNO3 pH 7.2 containing 2 mM 
Mg(NO3)2 (buffer 2). A mixture solution of 1.0 mM 3-IP and 0.4 mM silver nitrate were 
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prepared daily in 0.1 M Tris-HNO3 pH 9.8 and 20 mM Mg(NO3)2  (buffer 3) and stored in 
opaque tubes at 4 °C. BSA and casein lyophilized powder was reconstituted in buffer 1. 
The MWCNTs solutions were prepared by dilution with a mixture of DMF:water (1:1) as it 
was reported in a previous work [11]. CNFs solutions were made in water. The solutions 
were prepared in water using an ultrasonic bath for 30 minutes. Gold tetrachloroaurate 
dilutions were prepared in 0.1 M HCl. 
All chemicals employed were of analytical reagent grade. 
 
2.3. Analytical Procedure 
2.3.1. Screen-printed Carbon Electrodes (SPCEs) Nanostructuration with Carbon 
Nanomaterials 
The modification of the SPCEs was carried out by depositing 4µL or 10 µL of the 
MWCNTs or CNFs dispersion, respectively, on the working electrode surface. The solution 
was left to dry at room temperature until its absolute evaporation. Finally, modified SPCEs 
were carefully washed with water and dry at room temperature. 
2.3.2. Generation of the Hybrid Surface between Carbon Nanomaterials and Gold 
Nanoparticles (NPAus) 
Gold nanostructures were generated in situ over SPCE-MWCNTs and SPCE-CNFs 
(SPCE-MWCNT-NPAus and SPCE-CNF-NPAus, respectively) applying a constant current 
intensity for a certain period of time in an acidic solution of AuCl4-. After that, and in the 
same medium, a potential of + 0.1 V was applied during 2 minutes, in order to desorb 
hydrogen. Finally, the gold nanostructures were generously rinsed with water. 
2.3.3. Evaluation of the Nanostructured SPCEs using the Streptavidin-Biotin Reaction 
A drop of 10 µL of streptavidin solution with an adequate concentration was placed on 
the pretreated surface of the SPCE and left there for a fixed time at adequate temperature. 
Then, the electrode was washed with buffer 1 to remove the excess of protein. Free surface 
sites were blocked with an adequate concentration of BSA or casein by placing a drop of 
40 µL solution for 30 min. Thus, after another washing step with buffer 2, an aliquot of 40 
µL of B-AP (1x10-10 M) was dropped on the streptavidin modified electrode for an hour 
reaction. After a washing step with buffer 3, the enzymatic reaction was carried out 
dropping an aliquot of 40 µL of a mixture of 1.0 mM 3-IP and 0.4 mM silver nitrate 
solutions. The redissolution peak of the silver deposited on the electrode surface was 
recorded when anodic stripping scan was carried out from + 0.03 V to + 0.4 V in the case 
of the electrodes modified with the carbon nanostructures; and from – 0.002 V to + 0.4 V 
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in the case of the presence of gold nanoparticles, at scan rate of 50 mV/s using cyclic 
voltammetry. 
 
2.3.4. Characterization of the hybrid surface 
The hybrid system between the carbon nanomaterials and the gold nanoparticles was 
characterized by scanning electron miscroscopy (SEM) and chronocoulometry. With this 
purpose, oxidation of gold were carried out by holding the electrode at a potential of + 
0.85 V in a 0.1 M hydrochloric acid medium recording the current vs. time curve. The area 
under the curve was used to relate the amount of transfer charge with the mass of gold 
involved in the process using the Faraday equation [19]. 
 
3. Results and discussion  
3.1. Optimization of the SPCEs coating process with the CNFs and 
MWCNTs 
Five concentrations, between 0.025 mg mL-1 and 0.5 mg mL-1, of functionalized CNFs 
were studied using the procedure explained in section 2.3.1.  Electrochemical detection of 
the redissoluted peak of silver was performed as described in section 2.3.3.  
Figure 1a shows the results of the dependence of  ip with the different concentration of the 
CNFs modified SPCEs. It can be observed that as CNFs concentration increases, the 
analytical signal also increases until the value of 0.25 mg ml-1 since there is an increment 
of the superficial area available for the adsorption of streptavidin. The surface reaches the 
saturation for a concentration of 0.25 mg ml-1. For 0.5 mg mL-1 a slightly decrease seems 
to take place. The modification of the electrode surface with carbon nanomaterials 
improves aspects such as the electroactive area and heterogeneous rate constants for the 
electron transfer. Although, the excessive modification of the electrode surface can 
produce an increment of this mesoporous film thickness, producing higher capacitances 
[11].The best relation between the faradaic and capacitive intensities was achieved for 0.25 
mg mL-1. No significant background signals were detected for all the studied 
concentrations. Cyclic voltammograms recorded for the concentration of 0.25 mg ml-1, 
regarding analytical and background signals, were presented in Figure 1b. 
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Fig. 1. a) Dependence between ip and the concentration of CNFs solution in water.  Streptavidin 
concentration, 10-7 M; B-AP concentration, 5.0 x 10-10 M; 3-IP concentration, 1.0 mM; silver ion 
concentration, 0.4 mM; BSA 1% ; analytical signal (black bars) and background signal (grey bars). 
Data are given as average ± SD (n = 3). b) Cyclic voltammograms of B-AP 5.0x10-10 M at a SPCE-
modiﬁed with 0.25 mg ml-1 solution of CNFs. Analytical signal (solid line) and the background 
signal (dashed line). Other experimental conditions as in Figure 1a. 
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SPCEs working electrodes were modified with MWCNTs dispersed in DMF:water (1:1) 
with a concentration of 0.1 mg mL-1 as it was reported in a previous work [11]. These 
authors showed that the amount of MWCNTs employed not only improves electrodic 
surface features as the rate constants for the electron transfer and the electroactive area 
but also have a raising effect the double-layer capacitance. For the optimized value of 0.1 
mg mL-1 this analytical disadvantage was minimized without compromising the analytical 
signal. 
The optimization of the blocking solution is a key step for the development of any 
transducer surface. In this way, different blocking agents, casein and BSA at 1%, 2% and 
3% of concentrations were studied. Moreover, streptavidin concentration was other 
optimized parameter. Streptavidin works as primary coating being used to immobilize 
biotin, which is associated with alkaline phosphatase (B-AP). An alkaline phosphatase 
concentration of 5.0x10-10 M was used through the optimization procedure. The response 
of the electrode surfaces to the two studied parameters was evaluated. The obtained 
results demonstrate that casein 3% was the most efficient blocking solution for SPCEs 
(data not show). BSA didn’t avoid NSB, being the reproducibility jeopardized (data not 
show). Regarding blocking solution optimization for the modified electrodes, BSA 
revealed to be the most efficient in avoiding protein unspecific adsorption. Moreover, the 
fact of being more ease of handling and less expensive then casein, are also positives 
aspects of using BSA as the blocking solution. The obtained results suggest that BSA 1% 
was highly effective in minimizing NSB. Regarding streptavidin concentration, the value of 
10-7 M showed to be the unanimous choice for the screen-printed surfaces considered, 
being established as the optimum concentration level ensuring sensitivity. This behavior 
was due to the full recover of the porous surface at the refereed value, since streptavidin 
was left on the surfaces to dryness. Figure 2 shows the effect of different concentrations of 
streptavidin on the analytical response of all the transducer, except for SPCE-NPAus 
format which streptavidin concentrations was optimized in a previous work [31]. 
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Fig. 2. Effect of the different concentrations of streptavidin (10-8 M; 10-7 M; 10-6 M; 10-5 M) on the 
ip. B-AP concentration, 5.0 x 10-10 M; 3-IP concentration, 1.0 mM; silver ion concentration, 0.4 
mM; casein 3% (SPCEs) BSA 1% (SPCEs modified electrodes). Data are given as average ± SD (n = 
3). 
 
3.2. Electrochemical generation of gold nanostructures on the carbon-
modified electrode surface 
Gold nanoparticles were electrochemically deposited onto the surface of SPCEs 
previously modified with carbon nanotubes or carbon nanofibers in optimized conditions. 
Gold nanoparticles have been formed from AuCl4- of different concentrations prepared in 
0.1 M HCl by applying a constant current intensity for a period of time. Three gold 
concentrations (0.1 mM AuCl4-, 0.5 mM AuCl4-, 1 mM AuCl4-), 3 current intensities (-5 µA, 
-10 µA, -100 µA) and 3 deposition times (60 s, 120 s and 300 s) were studied using the 
procedure described in section 2.3.2.. 
Figure 3 shows the results obtained for the gold concentration of 1 mM with the 
transducer previously modified with MWCNTs. In all cases it can be observed that the 
analytical signal obtained is similar for all times assayed. Regarding the three current 
intensities applied (-5, -10, -100 µA) there is no considerably difference from -5 to -10 µA 
since the slightly enhancement of the current can be justified with the standard deviation. 
As was reported in a previous work from Martínez-Paredes and colleagues [19] the 
formation of gold nanoparticles is influenced by the current intensity that is applied, the 
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time of gold deposition and gold concentration. Namely, the particle diameter seems to be 
indirectly proportional with time deposition and reduction intensity. For large deposition 
times occurs a shift in potential towards more negative potentials (-0.70 V) during gold 
electrodeposition. In the acid medium the generation of hydrogen occurred at this 
potential improving the nucleation of gold on the electrode surface in a detriment of 
growth of nanoparticles.  The bar diagrams in Figure 3 shows that current decreases when 
increases the time for electrodeposition. For a 60 s deposition time the best analytical 
signal was achieved applying a constant current intensity of -100 µA. However, the results 
revealed that for these experimental conditions (-100 µA) there was a considerable 
standard deviation. Instead, a current intensity value of -5 µA was chosen for further 
studies. These results were also observed for the other gold concentrations in study (data 
not show). In order to achieve the best relation between sensitivity and reproducibility the 
concentration of 0.1 mM of AuCl4- was selected (Figure 4). For the hybrid transducer 
surface between CNFs and NPAus was verified a similar behavior (data not show), 
therefore the selected values for the studied parameters were the same. 
So, in both hybrid system, whether had carbon nanotubes or carbon nanofibers, the 
results indicate that the best compromise between sensitivity and reproducibility was 
achieved for a 0.1 mM AuCl4- electrodeposited at -5 µA during 60 seconds. In Figure 5 
SEM images of the hybrid electrodic surfaces were shown. The mean diameter of the gold 
nanoparticles formed on the working electrodes of carbon nanostructured SPCEs was 
predicted from these SEM images and 92 ± 15 nm was the value obtained. For this 
situation, the amount of gold deposited over the SPCE, determined by chronocoulometry, 
was of 76 ± 2 ng. 
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Fig. 3. Effect of the current intensity and deposition time of gold on the analytical signal. B-AP 
concentration, 1.0 x 10-10 M ; 3-IP concentration, 1.0 mM; silver ion concentration, 0.4 mM; BSA 
1%.  SPCE-MWCNTs (0.1 mg mL-1 MWCNTs) and AuCl4- (1.0 mM).  
 
 
0
20
40
60
80
100
120
140
160
180
0.1 0.5 1
i p
 / µ
A
Current / -µA
 
Fig. 4. Comparison of the effect of three gold concentrations on the analytical signal for the same 
deposition time (60 s) and current intensity (-5 µA). Rest of experimental conditions as in Figure 3. 
Data are given as average ± SD (n = 3). 
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Fig. 5. SEM images of the working electrode of the optimized nanostructured screen-printed carbon 
electrodes.  SPCE-MWCNT-NPAus (A); SPCE-CNF-NPAus (B). Gold electrodeposition at -5 µA for 
60 s. Gold concentration: 0.1 mM. (amplification factor: 10 x 103). 
 
3.3. Comparison of different transducer platforms 
In order to study the effect of the transducers surfaces on the analytical signal six 
different transducers (SPCEs, SPCE-NPAus, SPCE-CNFs, SPCE-MWCNTs, SPCE-CNF-
NPAus, SPCE-MWCNT-NPAus) were evaluated and compared using the streptavidin-
biotin reaction as model analyte. Figure 6 gives the results obtained.  
The electroactive surface area (A) of each transducer was also calculated (Table 1). The 
A of modiﬁed SPEs was calculated using the Randle–Sevcik equation for a reversible 
electrochemical process under diffusive control (Ta =25 ◦C) (Equation 1): 
 
(1)                                  ip = 2.69 × 105 AD1/2n3/2 v1/2 C                              
where n is the number of electrons involved in the redox reaction, A is the electroactive 
area of the electrode (cm2), D is the diffusion coefﬁcient of the molecule in solution, C is 
the concentration of the analyte molecule in the solution (mol cm−3) and v is the scan rate 
(Vs−1). The A was calculated from the cyclic voltammograms for 1.0×10−3 M ferricyanide in 
HClO4 0.1M solution (D= 7.77×10−6 cm2 s−1 [32]). The geometric area of a SPCEs is 12.56 
mm2. 
The data present in Figure 6 shows that the nanostructured surfaces present better 
analytical signals comparing with the nonnanostructured SPCEs. It was also observed that 
the SPCE-NPAus allows to obtain similar sensitivity as that obtained with SPCE-
MWCNTs. However in the case of SPCE-CNFs the analytical signal was lower, probably 
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due to the fact that CNFs are less functionalized than MWCNTs. The hybrids 
nanostructuration improved considerably the analytical signal respect to the other 
surfaces. In the case of the hybrid surfaces, the SPCE-MWCNT-NPAus are better in terms 
of sensitivity then SPCE-CNF-NPAus. However, the data provided in Figure 6 are not 
supported by the electroactive areas obtained. When we compare the electrodes modified 
with CNTs and CNFs, the last ones present a higher A. The same situation is observed 
regarding the hybrids with CNTs and CNFs. Nevertheless, the data obtained in Figure 6 
indicates that CNTs are more effective in adsorbing streptavidin. Moreover, the A of the 
transducer SPCE-NPAus is the smallest. Although they are also the best transducers 
regarding the analytical response, standing out the hybrid surfaces. This is maybe due to 
the fact that NPAus improves the adsorption processes, besides provide a stable surface 
for the immobilization of biomolecules retaining their biological activities. The obtained 
results indicate that the electroactive area available is not directly related with the 
efficiency for the adsorption of the protein material, instead the nature of the transducer 
surface is the factor that determines the analytical response. For the same concentration of 
streptavidin (1.0x10-7 M) the hybrid surfaces present high adsorption efficacy. The hybrid 
structures formed by NPAus and carbon nanomaterials seem to present positive synergic 
features resulting collective in a more interesting analytical tool than when they appear 
individually.   
i p
/ µµ µµ
A
 
Fig. 6. Effect of the different transducers on the analytical signal for a B-AP concentration of 1.0 x 
10-10 M. [Streptavidin] = 10-7 M. Other experimental conditions as in Figure 2. Data are given as 
average ± SD (n = 3). 
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Table 1. Electroactive areas (mm2) data of the studied transducers. Data are given as average ± SD (n = 3). 
SPCES SPCE-NPAuS SPCE-CNTS SPCE-CNFs SPCE-CNT-NPAus SPCE-CNF-NPAus 
8.73 ± 0.07                            8.28 ± 0.09                      9.92 ± 0.14 11.3 ± 0.33 10.10 ± 0.02 12.2 ± 0.16 
 
3.4. Alkaline phosphatase calibration plot 
Using the optimum conditions described previously, calibration plots of B-AP were 
obtained for all transducers. Table 2 lists the characteristics of the calibration plots 
obtained for each transducer. The reported limit of detection (LOD) and quantification 
(LOQ) were calculated from the calibration plots using the equations: LOD=3s/m and 
LOQ=10s/m (where s is the standard deviation of the intercept and m is the slope of the 
calibration plot) [32]. To evaluate the reproductibility of the electrode response, analysis 
of B-AP at three concentrations on the calibration plot was studied by three replicate 
measurements in three different days. The obtained LOD for the SPCEs showed small 
variations (from 1.1 to 5.1×10−11 M) regarding the electrodes nanostructured with the 
carbon nanostructures and NPAus. The hybrid transducers showed a better overall 
analytical performance, standing out their lowest LOD in the order of 10-12 M. The wider 
linear ranges (10−12 to 10−10 M) and lower LOD (6.1×10−12 M) were found for the hybrid 
SPCE-MWCNT-NPAus. This transducer also presented the highest slope.  
 
 
3.5. Long-term stability  
To study the transducer stability four series of several SPCE-MWCNT-NPAus and 
SPCE-CNF-NPAus were prepared and stored at 4ºC and at room temperature. In order to 
evaluate the stability of those single-use electrodes the transducers were tested following 
the procedure described in Section 2.3.3.. The voltammetric measurements were made on 
the same day of preparation and past 7, 15 and 30 days. The results, present in Figure 7, 
did not show any appreciable change among the analytical signal. 
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Fig. 7. Stability of the hybrid transducers for a month. (A) SPCE-MWCNT-NPAus and (B) SPCE-
CNF-NPAus stored at 4ºC (1) and room temperature (2). Other  experimental conditions as in 
figure 3. Data are given as average ± SD (n = 3). 
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Table 2. Analytical data from the calibration graphs obtained with different nanostructured surfaces in the determination of alkaline 
phosphatase. 
 Regression equation 
(ip (A); CB-AP (mol L-1) 
n* Linear range (mol L-1) Correlation 
 coeficient 
LOD (mol L-1) LOQ (mol L-1) Reproductibility 
(RSD%)** 
SPCEs ip = (14.19 ± 0.39) x10
4 C B-AP + 
(1.04 ± 0.24) x10−6 
4 2.5 x10−11 – 1.0x10−10 0.996 1.1x10−11 3.74x10−11 13.4 (0.01) 
7.70 (0.05) 
25.3 (0.075) 
 
SPCE-NPAus ip  = (41.03 ± 1.38) x10
4 C B-AP + 
(3.9 ± 0.79) x10−6 
5 1.0 x10−11 –9.0x10−11 0.993 1.3 x10−11 4.3 x10−11 0.40 (0.03) 
1.40 (0.05) 
2.00 (0.07) 
 
SPCEs-CNFs ip  = (18.01 ± 0.27) x10
4 C B-AP + 
(1.09 ± 0.14) x10−5 
4 5.0 x10−11 –1.0x10−9 0.999 5.1x10−11 1.7x10−10 1.70 (0.075) 
1.20 (0.10) 
12.0 (0.50) 
 
SPCEs-
MWCNTs 
ip  = (39.98 ± 0.89) x10
4 C B-AP + 
(6.64 ± 1.35) x10−6 
5 1.0 x10−11 – 2.5x10−10 0.998 2.3x10−11 7.6x10−11 23.6 (0.05) 
13.4 (0.10) 
7.20 (0.15) 
 
SPCE-CNF-
NPAus 
ip = (83.08 ± 9.4) x10
4C B-AP – 
(4.17 ± 0.41) x10−6 
5 5.0 x10−12 –7.5x10−11 0.999 3.3x10-12 1.1x10−11 7.60 (0.01) 
6.90 (0.035) 
0.90 (0.05) 
 
SPCE-
MWCNT-
NPAus 
ip = (92.65 ± 1.0) x10
4C B-AP – 
(3.36 ± 0.85) x10−6 
10 5.0 x10−12 –1.2x10−10 0.999 6.1x10−12 2.0x10−11 15.8 (0.01) 
6.80 (0.05) 
1.80 (0.10) 
* Number of points;** Between the parentheses are shown the concentrations (nmol L-1)  
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4. Conclusions 
Sensitive transducer surfaces were compared in terms of their analytical potential 
using the high affinity streptavidin-biotin interaction as biological reaction model. The 
optimized transducers were studied regarding sensitivity, reproducibility, biocompatibility 
and stability. The best results were achieved with the hybrid conjugation between carbon 
nanomaterials, especially carbon nanotubes, and gold nanoparticles. The developed 
hybrid surfaces can work as excellent platforms for a wide range of electrochemical 
biosensor devices, moreover, once modified with streptavidin offers an at least 30 days 
stable surface, perfect to use on solid-phase assays with biotinylated molecules. 
 
 
Acknowledgments 
This work has been supported by the Spanish project BIO2009-11286 and by a PhD 
grant (SFRH/BD/46351/2008) attributed to Marta Maria Pereira da Silva Neves by 
Fundação para a Ciência e Tecnologia (FCT) and Fundo Social Europeu (FSE).  
 
 
 
 
 
 
 
 
 
 
 
 
II.RESEARCH AND DEVELOPMENT 
 
106  
 
References 
1. R. Cui, H. Huang, Z. Yin, D. Gao, J. Zhu, Biosens.  Bioelectr. 2008, 23, 1666. 
2. G. Liu, Y. Lin, Talanta 2007, 74, 308. 
3. J. Wang, Y. Lin, Trends Analyt. Chem. 2008, 27, 619. 
4. V. Vamvakaki, M. Fouskaki, N. Chaniotakis, Anal. Lett.  2007, 40, 2271.     
5. J.S. Huang, Y. Liu , T. Y. You, Anal. Meth. 2010, 2, 202. 
6. A. Arvinte, F. Valentini, A. Radoi, F. Arduini, E. Tamburri, L. Rotariu, G. Palleschi, 
C. Bala, Electroanalysis 2007, 19, 1455. 
7. X. LU, J. Zhou, W. Lu, Q. Liu, J. Li, Biosens. Bioelectr. 2008, 23, 1236. 
8. M. T. Fernández-Abedul, A. Costa-García, Anal. Bioanal. Chem. 2008, 390, 293. 
9. L. Aguí, P. Yáñez-Sedeño, J. M. Pingarrón, Anal. Chim. Acta. 2008, 622, 11. 
10. K. Balasubramanian, M. Burghard, Anal. Bioanal. Chem. 2006, 385, 452. 
11. P. Fanjul-Bolado, P. Queipo, P. J. Lamas-Ardisana, A. Costa-García, Talanta  
2007, 74, 427. 
12. X. L. Luo, A. Morrin, A. J. Killard, M. R. Smyth. Electroanalysis 2006,  18, 319-
326. 
13. P. Yáñez-Sedeño, J. M. Pingarrón, Anal. Bioanal. Chem. 2005, 382, 884. 
14. S. Guo, E. Wang, Anal. Chim. Acta. 2007, 598, 181. 
15. A. Merkoci. FEBS Journal 2007, 274, 310. 
16. D. L. Feldheim, A.F. Colby Jr., Metal Nanoparticles-Synthesis, Characterization 
and Applications [M], Marcel Dekker, New York, 2002. 
17. G. Schmid, M. Bäumle, M. Geerkens, I. Heim, C. Osemann, T. Sawitowski, Chem. 
Soc. Rev. 1999, 28, 179. 
18. M.C. Daniel, D. Astruc, Chem. Rev. 2004, 104, 293. 
19. G. Martínez-Paredes, M. B. González-García; A. Costa-García, Electrochem. Acta. 
  2009, 54, 4801. 
20. G. Martínez-Paredes, M. B. González-García, A. Costa-García, Electroanalysis, 
2009, 21,379. 
21. V. Escamilla-Gómez, D. Hernández-Santos, M. B. González-García, J. M. 
Pingarrón-Carrazón, A. Costa-García, Biosens. Bioelectron. 2009, 24, 2678. 
22. L. Wang, Small, 2005, 1, 1036. 
23. Y. Gu, X. Hou, H. Hu, B. Yu(F), L. Wang, F. Zhou. Mat. Chem. and Phys. 2009, 
116, 284. 
24. T. I. Abdullin, O. V. Bondar, I. I. Nikitina, E. R. Bulatov, M. V. Morozov, A. Kh. 
Hilmutdinov, M. Kh. Salakhov, M. Çulha, Bioelectrochem. 2009, 77 37. 
25. J. Lin, C. He, L. Zhang, S. Zhang, Anal. Biochem. 2009, 384, 130. 
 HYBRID TRANSDUCER SURFACES 
 107 
 
26. N. Alexeyeva, J. Kozlova, V. Sammelselg, P. Ritslaid, H. Ma¨ndar, K. Tammeveski. 
Appl. Surface. Science. 2010, 256, 3040. 
27. X. Hu, S. Dong,  J of Mat Chem, 2008, 18, 1279. 
28. J. Ylikotila, L. Välimaa, H. Takalo, K. Pettersson. Colloids and Surfaces B: 
Biointerfaces, 2009, 70, 271. 
29. O. H. Laitinen, V. P. Hytönen, H. R. Nordlund, M. S. Kulomaa. Cell. Mol. Life Sci. 
2006, 63, 2992.     
30. L. S. Cassandra, S. M. Jaqueline, H. N. Giang, Top Curr Chem, 2006, 261, 63. 
31. G. Martínez-Paredes,  M. B. González-García, A. Costa García, Sens Actual B: 
Chem, 2010, 149, 329. 
32. R. S. Nicholson, Anal Chem 1965, 37, 1351. 
33. J. C. Miller, J. N. Miller, Statistics for Analytical Chemistry 4th ed, Ellis Horwood, 
New York, 1993. 
 
 
 ! 109!
!
 
Chapter 4 
Screening for celiac disease serological 
markers 
 
Celiac disease detection using a transglutaminase electrochemical immunosensor 
fabricated on nanohybrid screen-printed carbon electrodes  
M.M.P.S. Neves, M.B. González-García, H.P.A. Nouws, A. Costa-García 
Biosensors and Bioelectronics, 2012, 31 (1), 95–100 
 
Voltammetric immunosensor for the diagnosis of celiac disease based on the 
quantification of anti-gliadin antibodies  
M.M.P.S. Neves, M.B. González-García, A. Santos-Silva, A. Costa-García 
Sensors and Actuators B, 2012, 163 (1), 253–259 
 
Multiplexed Electrochemical Immunosensor for Detection of Celiac Disease 
Serological Markers 
M.M.P.S. Neves, M.B. González-García, C. Delerue-Matos, A. Costa-García 
Sensors and Actuators B, 2012 (in press) 
 
Detection of antibodies against deamidated gliadin in human serum samples 
 
 SCREENING FOR ANTI- TISSUE TRANSGLUTAMINASE ANTIBODIES 
 111 
 
Celiac disease detection using a transglutaminase electrochemical 
immunosensor fabricated on nanohybrid screen-printed carbon 
electrodes 
 
Marta M. P. S. Nevesa,b,c, M. B. González-Garcíac, H. P. A. Nouwsa A. Costa-Garcíac 
aREQUIMTE,Instituto Superior de Engenharia do Porto, Dr. Bernardino de Almeida 431, 
4200-072 Porto, Portugal 
bFaculdade de Farmácia da Universidade do Porto,Rua Aníbal Cunha 164,4099-030 Porto, 
Portugal 
cDepartamento de Química Física y Analítica, Universidad de Oviedo, C/. Julián 
Clavería 8, 33006 Oviedo, Spain 
 
Abstract 
Celiac disease is a gluten-induced autoimmune enteropathy characterized by the 
presence of tissue tranglutaminase (tTG) autoantibodies. A disposable electrochemical 
immunosensor (EI) for the detection of IgA and IgG type anti-tTG autoantibodies in real 
patient’s samples is presented. Screen-printed carbon electrodes (SPCE) nanostructurized 
with carbon nanotubes and gold nanoparticles were used as the transducer surface. This 
transducer exhibits the excellent characteristics of carbon-metal nanoparticle hybrid 
conjugation and led to the amplification of the immunological interaction. The 
immunosensing strategy consisted of the immobilization of tTG on the nanostructured 
electrode surface followed by the electrochemical detection of the autoantibodies present 
in the samples using an alkaline phosphatase (AP) labelled anti-Human IgA or IgG 
antibody. The analytical signal was based on the anodic redissolution of enzymatically 
generated silver by cyclic voltammetry. The results obtained were corroborated with a 
commercial ELISA kit indicating that the electrochemical immunosensor is a trustful 
analytical screening tool. 
 
 
Keywords: Electrochemical immunosensors. Transglutaminase. Celiac disease. Screen-
printed electrodes. Carbon nanotubes. Gold nanoparticles.  
II.RESEARCH AND DEVELOPMENT 
 
112  
 
1. Introduction 
Celiac disease (CD) is a gluten-sensitive enteropathy triggered by dietary gluten in 
genetically susceptible individuals. CD has a strong association with human leucocyte 
antigen HLA-DQ2 and HLA-DQ8. Although the presence of these HLA proteins is 
necessary for developing celiac disease, it is not enough since about 30% of the healthy 
population possess them (McGough and Cummings, 2005). CD patients normally 
experience a massive immune reaction that leads to the production of autoantibodies and 
to the destruction of the small-intestinal mucosal morphology and intestinal dysfunction 
(Lindfors et al., 2009). Over time there has been a substantial increase in background 
prevalence of the disease, affecting around 1% of most populations (Lohi et al., 2007; 
Rubio-Tapia and Murray, 2010). 
The diagnostic criteria for CD, which require endoscopy with small bowel biopsy, have 
been changing over the last few decades, especially due to the advent of serological tests 
with higher sensitivity and specificity for the measurement of these antibodies (Neves et 
al., 2010). Serologic testing has impacted the rate of diagnosis as well as the 
understanding of the epidemiology of this autoimmune condition (Rubio-Tapia and 
Murray, 2010). Current diagnostic routines include serology in combination with the 
histological examination of at least one biopsy that demonstrates mucosal villous atrophy 
while the patient consumes gluten containing food. When a decline of CD-related 
autoantibodies and the remission of the symptoms are observed when the patient is on a 
gluten-free diet, the second biopsy may not be needed (Hill et al., 2005). Therefore, 
serological tests, without surrogating the histological exam, have been used as a front-line 
strategy for screening candidates for the need of a duodenal biopsy (Sugai et al., 2010), 
avoiding such unnecessary invasive exams. Moreover many patients have little or no 
gastrointestinal symptoms while presenting extraintestinal syntomatology (Briani et al., 
2008; Lindfors et al., 2009). Another important aspect to consider in a serological 
diagnosis is the selective IgA deficiency of the patient. If an individual presents a negative 
serological test but exhibits suggestive symptoms, the possibility of IgA deficiency should 
be considered and an IgG test must be performed. The identification of tissue 
transglutaminase (tTG) as the antigen against which the autoantibodies are directed, has 
led to a greater understanding of the pathogenesis of CD and to the development of 
improved serological tests (Alaedini and Green, 2005; Hill and McMillan, 2006; 
Armstrong et al., 2011). The common methodology for CD clinical serological diagnostic 
purposes is an enzyme-linked immunosorbent assay (ELISA). ELISA tests that measure 
the antibodies directed against tTG have high diagnostic sensitivity and specificity for the 
detection of CD. In an ELISA, antibodies are detected after several incubation, washing 
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and separation steps. An alternative to these high-cost and laborious assays could be 
electrochemical immunosensors (EIs). EIs combine the specificity inherent to antigen–
antibody interactions with the high sensitivity of electrochemical transduction (Alonso-
Lomillo et al., 2010), offering new exciting alternatives to the conventional 
immunochemical tests which are based on indirect detection, compromising real-time 
analysis. 
There are few publications concerning the development of EIs to aid the diagnosis of 
CD. As far as we are concerned, regarding the use of EIs for the detection of 
autoantibodies directed against tTG, only 3 studies are published. An impedimetric 
immunosensor for the detection of antibodies against transglutaminase in human serum 
was presented by Balkenhohl and Lisdat (2007). The immunosensor was based on the 
immobilization of transglutaminase onto disposable screen-printed gold electrodes which 
were modified with a polyelectrolyte layer of poly(sodium 4- styrenesulfonic acid). Using 
impedance spectroscopy a qualitative analysis was carried out. According to the authors, 
an acceptable sensitivity was achieved but the results suggest a lower precision than 
ELISA. In a second study (Pividori et al., 2009) an amperometric electrochemical 
immunosensor based on the physical adsorption of tTG from guinea pig liver onto 
graphite–epoxy composite (GEC) electrodes was proposed. For 10 positive and 10 negative 
processed serum samples a sensitivity of 70% and a specificity of 100% were achieved 
when compared with the commercial ELISA method. Only a qualitative study was 
performed and no correlation between the analytical signal and the amount of antibodies 
present in the samples was established. More recently, an electrochemical immunosensor 
for the detection of human anti-tissue transglutaminase IgA and IgG antibodies in real 
samples by the covalent attachment of tTG to gold electrodes by the use of self-assembled 
monolayers of a group carboxylic-terminated bipodal alkanethiol was developed (Dulay et 
al., 2011). The results obtained with the immunosensor showed a good correlation with 
those obtained using a commercial ELISA. 
Baring in mind that one of the big challenges of analytical chemistry is the 
development of accurate and sensitive methods that allow rapid in situ analyses, a 
disposable electrochemical immunosensor for CD clinical evaluation through the detection 
of antibodies to tTG in human serum is proposed. The electrochemical transducer surface 
consists of a screen-printed carbon electrode (SPCE) modified with multiwalled carbon 
nanotubes (MWCNTs) and gold nanoparticles (NPAus). Carbon nanostructure/metal 
nanoparticle hybrids have been widely exploited in the last years for electrochemical 
sensing applications since the conjugation of each material enhances their individual 
properties (Agüí et al., 2008).  Therefore the immunosensing strategy consisted on the 
immobilization, by physical adsorption, of human tTG on a screen-printed carbon 
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electrode modified with carbon nanotubes and gold nanoparticles. The nanomaterials are 
used as an efficient amplification interface between the biorecognition process and the 
electrochemical transduction event. After the reaction with the patient’s serum a 
secondary enzyme-labelled antibody is used to obtain electrochemical detection using 3-
indoxyl phosphate and silver ions. The results indicate that the proposed immunosensor 
can be competitive with the standard methodology. 
 
2. Materials and methods 
2.1.       Instrumentation 
Voltammetric experiments were performed with an Autolab PGSTAT 12 (Eco Chemie, 
The Netherlands) potentiostat/galvanostat interfaced to an AMD K-6 266 MHz computer 
system and controlled by Autolab GPES 4.8 (software version for Windows 98). All the 
measurements were carried out at room temperature. Disposable screen-printed carbon 
electrodes (SPCEs) were purchased from DropSens (Spain). These electrodes incorporate 
a conventional three-electrode configuration, printed on ceramic substrates (3.4x1.0 cm). 
Both the working- (disk-shaped 4 mm diameter) and counter electrodes are made of 
carbon inks, whereas the pseudoreference electrode and the electric contacts are made of 
silver. A ring-shaped layer printed around the working electrode constitutes the reservoir 
(50 µL) of the electrochemical cell. The SPCEs were easily connected to the potentiostat 
through a specific DropSens connector (Spain).  
2.2. Chemicals and immunochemicals 
Tris(hydroxymethyl)aminomethane (Tris), magnesium nitrate, bovine serum albumin 
fraction V (BSA), were purchased from Sigma (Spain). Carboxyl modified multiwalled 
carbon nanotubes (MWCNTs) were purchased from Nanocyl (Belgium). Standard gold 
tetrachloroaurate (AuCl4-), silver nitrate, hydrochloric acid (37%) and nitric acid (HNO3) 
were obtained from Merck (Germany). Biosynth (Switzerland) supplied the 3-indoxyl 
phosphate disodium salt (3-IP). Human tissue transglutaminase (recombinantly produced 
in insect cells) was purchased from Zedira (Germany). Goat anti-human IgG (Fc specific) 
conjugated with alkaline phosphatase (anti-H-IgG-AP) was purchased from Sigma (Spain) 
and goat anti-human IgA (alpha chain specific) labelled with alkaline phosphatase (anti-
H-IgA-AP) was provided by Invitrogen (Spain). The validation of the developed procedure 
was performed with anonymous sera samples analysed by Varelisa Celikey and Varelisa 
Celikey IgG ELISA kits supplied by Phadia (Germany). Each kit contained six standard 
serum samples (0, 3, 7, 16, 40, 100 U mL-1) and a positive and a negative control. The kit’s 
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manufacturers propose a range of values with clinical significance for the analysis of the 
samples: an equivocal result lays between 5 and 8 U mL-1 in the case of IgA detection and 
between 7 and 10 U mL-1 for IgG determination. Below and above these values the samples 
are classified as negative or positive, respectively, for CD. Ultrapure water obtained with a 
Millipore Direct-QTM purification system from Millipore Ibérica S.A. (Spain) was used 
throughout this work. All chemicals employed were of analytical reagent grade. 
Working solutions of tTG were prepared in a 0.1 M Tris-HNO3 pH 7.2 buffer. Working 
solutions of the secondary alkaline phosphatase labelled antibodies were prepared in 0.1 
M Tris-HNO3 pH 7.2 containing 2 mM Mg(NO3)2. A solution containing 1.0 mM 3-IP and 
0.4 mM silver nitrate was prepared daily in 0.1 M Tris-HNO3 pH 9.8 and 20 mM 
Mg(NO3)2 and stored in opaque tubes at 4ºC.  The MWCNTs solutions were prepared by 
dilution of the concentrated solution with a mixture of DMF:water (1:1). The gold 
tetrachloroaurate solution was prepared in 0.1 M HCl. 
2.3. Electrode nanostructuration 
The modification of the screen-printed electrodes with nanohybrid structures was 
previously studied in our group (Neves et al., 2011). Single-use SPCEs were modified with 
4 µL of a 0.1 mg mL-1 MWCNTs dispersion and the solution was left to dry at room 
temperature until its complete evaporation. Then, the MWCNTs-modified electrode was 
carefully washed with water and dried at room temperature. The coating process was 
followed by in situ electrochemical deposition of gold nanoparticles (NPAus) by applying a 
constant current intensity of -5 µA for 60 s in an acidic solution of 0.1 mM AuCl4-. The 
resulting SPCE-MWCNT-NPAus were rinsed with water and were ready to use.  
2.4. Immunosensor for the detection of anti-tTG antibodies 
The following procedure (Fig. 1) describes an optimized assay.The SPCE-MWCNT-
NPAus working electrodes were coated with 10 µL  of a 0.1 µg µL-1 tTG solution and left to 
incubate overnight at 4ºC. After the incubation step the electrode was washed with 0.1 M 
Tris-HNO3 pH 7.2 buffer. Free surface sites of the tTG-modiﬁed electrodes were blocked 
with a BSA solution (2% in 0.1 M Tris-HNO3 pH 7.2) during 30 min. The detection of anti-
tTG antibodies was accomplished by incubating the immunosensors with human serum 
samples for 60 min followed by a washing step with a 0.1 M Tris-HNO3 pH 7.2 buffer 
containing 2 mM Mg(NO3)2. Finally, the immunosensor was incubated with an anti-H-
IgA-AP (1:30,000) or an anti-H-IgG-AP (1:50,000) solution for 60 min and washed with a 
0.1M Tris pH 9.8 buffer containing 20mM 2 mM Mg(NO3)2. The enzymatic reaction was 
carried out by dropping a 40 µL  aliquot of a solution containing 1.0 mM 3-IP and 0.4 mM 
silver nitrate on the immunosensor’s surface. The enzymatically deposition of silver 
II.RESEARCH AND DEVELOPMENT 
 
116  
 
catalyzed by alkaline phosphatase (AP) was studied previously and the work was already 
reported (Fanjul-Bolado et al., 2007). For the generation of the analytical signal an 
alkaline phosphatase labelled secondary antibody was employed. AP worked as the 
enzymatic label and a mixture of 3-indoxyl phosphate with silver ions (3-IP/Ag+) as the 
substrate. AP hydrolyzes 3-IP resulting in a indoxyl intermediate that will reduce the silver 
ions presents in solution resulting in metallic silver (Ag0) and indigo blue (I). Thus, the 
silver enzymatically deposited on the electrode surface can be detected through the anodic 
peak of the silver when an anodic stripping scan is carried out. After 20 min of reaction, a 
cyclic voltammogram was recorded from - 0.002 V to + 0.4 V, at scan rate of 50 mV s-1, to 
obtain the electrochemical oxidation current of the enzymatically deposited silver. 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Schematic representation of the immunosensor architecture used in this study. 
 
 
3. Results and discussion 
3.1.  Optimization of the immunosensing strategy  
The working area of the SPCE-MWCNT-NPAus (see Supplementary material) was 
coated with different amounts of tTG. The highest analytical signals and the best 
reproducibility were obtained using 10 µL of a 0.1 µg µL-1 tTG solution when left overnight 
anostructured electrode surface
AP AP
BSA                Tissue transglutaminase                  Anti-tissue transglutaminase IgA and IgG autoantibodies
Alkaline phosphatase (AP) labelled anti-Human IgA or IgG antibody
AP
3-IP/Ag+
I/Ag0
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at 4ºC and avoiding the evaporation to dryness of the solution. Non-specific adsorption 
was effectively blocked with the addition of 40 µL BSA (2%) during 30 min. The sensing 
phase of the immunosensor was then completed. The analytical signals obtained with a 
nanohybrid-modified electrode and a non-nanostructured electrode were compared. Fig. 2 
shows cyclic voltammograms obtained for the detection of anti-tTG IgA antibodies using a 
tTG-modified SPCE as well as a tTG-modified SPCE-MWCNT-NPAus. The obtained 
results indicate that the presence of the nanomaterials improves the faradaic/capacitive 
current ratio. The conjugation of MWCNTs and NPAus has already demonstrated to 
possess important analytical properties for biosensors due to the metal nanoparticles’ 
ability to adsorb proteins without compromising their bioactivity, and the excellent 
electrocatalytical properties of the carbon nanotubes (Agüí et al., 2008; Neves et al., 2011). 
The differences observed in the peaks potential can be explained due to the presence of 
gold nanoparticles on the transducer surface. Gold nanoparticles facilitate the reduction of 
silver and, as a consequence of that, the anodic peak of the silver is shifted toward less 
positive potentials (Hernández-Santos et al., 2000; de la Escosura-Muñiz et al., 2004; Lee 
et al., 2004).  
 
 
 
 
 
 
 
 
 
Fig. 2. Effect of the transducer surface on the analytical signal for the detection of anti-tTG IgA 
autoantibodies using a tTG-modified SPCE (grey line) and a tTG-modified SPCE-MWCNT-NPAus 
(black line). Experimental conditions: tTG 0.1 µg µL-1; BSA 2%; control samples diluted 1:2; anti-H-
IgA-AP 1:30,000;  3-IP, 1.0 mM; Ag+, 0.4 mM. Cyclic voltammetric scans from - 0.002 V to + 0.4 V 
at a scan rate of 50 mV s-1. 
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In Fig. 3 voltammograms are shown for the analysis of a positive and a negative 
sample using a tTG-modified SPCE-MWCNT-NPAus and non-tTG-modified SPCE-
MWCNT-NPAus. The data show that the stripping peak current intensity of silver depends 
on the concentration of the alkaline phosphatase labelled antibodies, which in turn 
depends of the amount of autoantibodies in the analysed samples. Therefore the measured 
analytical signals for a positive and a negative sample analysed with the complete sensing 
platform (electrode with tTG) can be perfectly distinguished, the highest peak 
corresponding to the determination of autoantibodies in the positive sample. When the 
same samples were analysed with an incomplete immunosensing strategy (i.e. electrode 
without antigen) two similar peaks with current intensities of approximately 8 µA were 
obtained. Furthermore, these current values are comparable to those obtained with a 
negative sample assayed using a tTG-modified electrode. These results indicate that these 
peaks correspond to the sensor’s background signal resulting from residual non-specific 
protein binding that occur despite of the effective surface blocking and are due to the 
presence of several different immunoglobulins and other proteins in the serum samples. 
Moreover, the obtained current difference for a positive sample analysed in the presence 
or absence of tTG on the electrode surface, indicates that the immunological reaction 
between antigen and autoantibodies was successfully performed. 
 
3.2. Reproducibility 
A precision study of the immunosensor’s performance was carried out by evaluating 
the reproducibility of two interday immunosensing assays of positive as well as negative 
human anti-tTG antibodies sera. Three measurements using three separate sensors were 
preformed on each day and the obtained results indicate a good reproducibility of the 
immunosensor, with an average relative standard deviation (RSD) of 9.32 % for the 
negative samples and 2.01% for the positive samples. 
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Fig. 3.  Cyclic voltammograms obtained in the analysis of positive (black lines) and negative (grey 
lines) serum samples with tTG-modifed (solid lines) and non-tTG-modified nanohybrid electrodes 
(dashed lines). Experimental conditions: tTG 0.1 µg µL-1; BSA 2%; serum samples diluted 1:200; 
anti-H-IgA-AP 1:30,000; 3-IP 1.0 mM; Ag+ 0.4 mM. Cyclic voltammetric scans from - 0.002 V to + 
0.4 V at a scan rate of 50 mV s-1. 
 
3.3. Evaluation of real patient’s samples  
To be able to classify samples as being positive, negative or ambiguous, a cut-off value 
was defined as the average peak current intensity plus three times the standard deviation 
obtained for 8 negative samples. These values are 7.3 µA and 12 µA for anti-tTG IgA and 
IgG antibodies, respectively. The developed immunosensor was then applied to the 
analysis of 10 different human sera from real patients for the detection of anti-tTG class A 
and G antibodies. The results are presented in Fig. 4 and show that four samples were 
positive for celiac disease (S1–S4), presenting both IgA and IgG anti-tTG antibodies, 
sample 5 was only positive for IgG detection, which indicates that the donor is a celiac 
patient with selective IgA deficiency, and the remaining five samples correspond to 
healthy individuals (S6–S10). 
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Fig. 4. Peak current intensities obtained in the determination of (a) IgA and (b) IgG anti-tTG 
autoantibodies in real patient’s samples using the optimized electrochemical immunosensor. 
Experimental conditions: tTG 0.1 µg µL-1; BSA 2%; serum samples diluted 1:200; anti-H-IgA-AP 
1:30,000 (a) and anti-H-IgA-AP 1:50,000 (b); 3-IP 1.0 mM; Ag+ 0.4 mM (average data ± standard 
deviation are indicated (n=3)).  
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3.4. Calibration plot for the determination of anti-tTG antibodies in human serum 
samples  
SPCE-MWCNT-NPAus modified with tTG were used to establish a relationship 
between the stripping peak current intensity and the concentration of anti-tTG antibodies, 
in arbitrary units, using the calibrators of the commercial ELISA kits. The peak current 
intensities were extrapolated to the calibrator solutions plot to convert the results in 
arbitrary units to be able to compare the results, in quantitative terms, with the results 
obtained using the ELISA. The insets (calibration plots) shown in Fig. 5 present the 
relationship between the peak current intensity and the concentration of anti-tTG 
antibodies present in the assayed calibrators. As can be observed the voltammetric 
response of the sensor is not linear within the entire analysed concentration range. 
Saturation is achieved after 40 U mL-1. Using the optimized conditions linear regression 
equations of ip (µA) = (0.53 ± 0.02) [antibody U mL-1] + (1.66 ± 0.48) (r = 0.994) and ip 
(µA) = 0.47 ± 0.01 [antibody U mL-1] + 1.93 ± 0.03 (r = 0.999) were achieved for the 
determination of anti-tTG IgA and IgG autoantibodies, respectively. Examples of cyclic 
voltammograms obtained within the linear ranges are also shown in Fig. 5.  
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Fig. 5.  Cyclic voltammograms of different calibrator solutions in the linear range. (a) [Anti-tTG 
IgA ] (U mL-1), (b) [anti-tTG IgG ] (U mL-1): 0, 3, 7, 16 and 40. Experimental conditions: tTG 0.1 µg 
µL-1; BSA 2%, serum samples diluted 1:200; anti-H-IgA-AP 1:30,000 (a) and anti-H-IgG-AP 
1:50,000 (b); 3-IP 1.0 mM; Ag+ 0.4 mM. Inset: relationship between ip and antibody concentration 
(U mL-1) (average data ± standard deviation are indicated (n=3)). 
 
3.5.  Comparison of the developed immunosensor with a commercial ELISA 
Data given in Table 1 indicate that the results of a quantitative analyses obtained with 
the electrochemical immunoassay do not perfectly match the ELISA results. However, the 
qualitative results (i.e. positive or negative) match perfectly. Moreover to the clinical 
diagnostic of this autoimmune condition the most significant aspect is the qualitative 
detection of the serological markers. For this reason the results achieved with the 
immunosensor were supported by those obtained with the commercial ELISA assay.  
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Table 1. Comparison of the analyses of anti-tTG antibody concentration in different human sera 
using the developed electrochemical immunosensor and a commercial ELISA. 
 Electrochemical immunosensor  ELISA 
Real patient’s 
sera 
Anti-tTG IgA 
antibodiesa 
Anti-tTG IgG 
antibodiesa 
Anti-tTG IgA 
antibodiesb 
Anti-tTG IgG 
antibodiesb 
S1 52.05 ± 6.22 36.28 ± 0.71 82.96 ± 0.29 35.21 ± 1.00 
S2 53.24 ± 2.32 64.06 ± 2.24 81.95 ± 0.18 87.59 ± 1.14 
S3 58.39 ± 2.91 30.68 ± 0.50 59.91 ± 0.01 53.95 ± 0.36 
S4 31.94 ± 2.99 36.85 ± 2.82 61.75 ± 0.11 91.97 ± 0.65 
S5 2.59 ± 1.32 40.21 ± 2.27 0.030 ± 0.001 35.48 ± 0.39 
S6 3.92 ± 0.72 5.74 ± 2.36 0.086 ± 0.003 0.314 ± 0.001 
S7 0.44 ± 0.91 4.22 ± 3.26 0.088 ± 0.007 0.409 ± 0.014 
S8 1.65 ± 0.58 2.99 ± 2.87 0.030 ± 0.003 0.242 ± 0.007 
S9 1.10 ± 0.84 5.93 ± 1.44 0.035 ± 0.012 0.426 ± 0.001 
S10 3.91 ± 0.24 3.28 ± 0.66 0.100 ± 0.002 0.532 ± 0.050 
 
 
a Concentrations are given in U mL-1 (Average data ± standard deviation are indicated (n=3)) 
b Concentrations are given in U mL-1 (Average data ± standard deviation are indicated (n=2)) 
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4. Conclusions 
Combining the advantages of the strong antibody–antigen interaction with the 
sensitivity of the electrochemical techniques, a new disposable electrochemical 
immunosensor for the detection of gluten-induced celiac disease-specific anti-tissue 
transglutaminase IgA and IgG autoantibodies in real patients’ samples was developed.  
Tissue transglutaminase was successfully immobilized on a nanohybrid (carbon 
nanotube/gold nanoparticle) screen-printed carbon electrode surface and 10 different 
human sera were assayed. The results obtained were corroborated with a commercial 
ELISA kit indicating that the electrochemical immunosensor is a trustful analytical 
screening tool. The proposed miniaturized electrochemical immunoassay can be a good 
alternative to the conventional optical screening assays. Moreover the employment of 
disposable SPCEs as electrochemical transducer surfaces, in detriment of classical solid 
electrodes, avoids some problems as memory effects and tedious cleaning processes. 
SPCE-based biosensors allows to perform a point-of-care diagnostic and as a consequence 
the decentralization of clinical applications. A biosensor developed on a screen-printed 
electrode can be a portable and ready-to-use device, able to be competitive not only with 
traditional methods, but also with other biosensors. 
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Supplementary material 
 
Celiac disease detection using a transglutaminase electrochemical immunosensor 
fabricated on nanohybrid screen-printed carbon electrodes 
 
Fig. S1. Scanning electron microscope (SEM) image of the optimized SPCE-MWCNT-NPAus 
working electrode (amplification factor 3×104). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                   0.5 µm 
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Abstract 
Antibodies against gliadin are used to detect celiac disease (CD) in patients. An 
electrochemical immunosensor for the voltammetric detection of human anti-gliadin 
antibodies (AGA) IgA and AGA IgG in real serum samples is proposed. The transducer 
surface consists of screen-printed carbon electrodes modified with a carbon 
nanotube/gold nanoparticle hybrid system, which provides a very useful surface for the 
amplification of the immunological interactions. The immunosensing strategy is based on 
the immobilization of gliadin, the antigen for the autoantibodies of interest, onto the 
nanostructured surface. The antigen–antibody interaction is recorded using alkaline 
phosphatase labelled anti-human antibodies and a mixture of 3-indoxyl phosphate with 
silver ions (3-IP/Ag+) was used as the substrate. The analytical signal is based on the 
anodic redissolution of the enzymatically generated silver by cyclic voltammetry. The 
electrochemical behaviour of this immunosensor was carefully evaluated assessing aspects 
as sensitivity, non-specific binding and matrix effects, and repeatability and 
reproducibility. The results were supported with a commercial ELISA test. 
Keywords: Electrochemical immunosensors. Gliadin. Celiac disease. Point-of-care 
analysis. Screen-printed electrodes. Nanomaterials. 
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Abreviations 
CD – celiac disease  
EIs – clectrochemical immunosensors 
AGA – human anti-gliadin antibodies  
Anti-H-IgA-AP – anti-human IgA antibodies conjugated with alkaline phosphatase  
Anti-H-IgG-AP – anti-human IgG antibodies conjugated with alkaline phosphatase  
SPCEs – screen-printed carbon electrodes 
MWCNTs – carboxylated multiwalled carbon nanotubes  
NPAus – gold nanoparticles 
 
 1. Introduction 
Celiac disease (CD) is an autoimmune enteropathy characterized by an inappropriate 
T-cell mediated immune response to the ingestion of gluten in genetically susceptible 
individuals [1]. Gluten is a complex mixture of wheat storage proteins that can be 
insoluble in alcohol, the glutenins, or soluble in alcohol, the gliadins. The alcohol-soluble 
fractions have analogous toxic proteins that are present in barley, the hordeins, in rye, the 
secalins, and in oats, the avenins [2]. It is generally accepted that gliadins are the major 
triggering factors in CD [3]. The mechanism underlying CD pathogeneses can be explained 
by the ingestion of these alcohol-soluble proteins. The deamidation of these gluten 
peptides is mediated by tissue transglutaminase (tTG) creating epitopes with increased 
immunostimulatory potential. The deamidated epitopes are then presented, in association 
with the human leucocyte antigens DQ2 and DQ8 of antigen-presenting cells, to CD4+ T 
cells [4]. The humoral autoimmune response leads to an abnormal intestinal mucosa 
characterized by villous atrophy and crypt hyperplasia [4] resulting in malabsorption 
related problems. Common serological changes include the appearance of antibodies 
against gliadin, tTG and endomysium, which are specific indicators of the disease. 
In spite of efforts towards the development of new therapeutic strategies [5] the 
recovery of the intestinal mucosal still requires the total elimination of gluten proteins 
from the patient’s diet. Therefore, an early and accurate diagnosis of CD is extremely 
important to control the gastrointestinal damage and to ensure the patient’s quality of life. 
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Small bowel biopsy has been the gold standard diagnostic test for CD during the last 
30 years. However, the different clinical presentations of this condition can complicate the 
diagnosis and, as a result, delay the treatment [6]. Recent guidelines from the European 
Society of Paediatric Gastroenterology and Nutrition [7] and the North American Society 
for Pediatric Gastroenterology, Hepatology and Nutrition [8] have suggested serological 
tests as the front-line test to clear clinical suspicion of celiac disease in patients presenting 
characteristic symptoms or in those who belong to a risk group. In the case of patients that 
have the symptoms but present negative serological tests, IgA class antibodies deficiency 
should be considered. The determination of the IgG class of antibodies against gliadin, 
tTG and endomysium has been suggested as an alternative [9]. 
The advances in the efficacy of serological antibody testing potentiate the possibility of 
accurate screening programs in the community, serving as a first-line method to clarify 
clinically suspicious cases in an underdiagnosed stage and also to manage the follow-up of 
this multifactorial disease [10]. Currently, enzyme-linked immunosorbent assay (ELISA) 
is the most used methodology for clinical serological CD diagnosis; nonetheless the 
development of more rapid, sensitive, and cost-effective strategies that allow point-of-care 
analysis are required. 
Electrochemical immunosensors (EIs) are speciﬁc, fast, portable and low cost devices 
which offer exciting opportunities for numerous decentralized clinical applications, 
ranging from “alternative-site” screening to  home self- testing [11]. The nature of the 
electrochemical sensor’s surface and the strategies for the antibody or antigen 
immobilization have been one of the major issues in immunosensing development. The 
transduction of the biorecognition events requires innovative approaches that couple 
different sensing platforms. The use of hybrid structures formed by combining carbon and 
metal nanomaterials has demonstrated to improve the electrocatalytic efficiency of many 
electrochemical processes allowing a synergic enhancement of each of the material 
properties [12, 13, 14].  
In the recent years, the electrochemical biosensors field have witnessed a growing 
interest in the development of analytical devices to celiac disease diagnosis. The 
employment of EIs for the detection of specific antibodies for CD was first reported in 
2007 by Balkenhohl and Lisdat [15, 16]. These authors developed an impedimetric 
immunosensor for the detection of antibodies directed against tTG using screen-printed 
gold electrodes modified with a polyelectrolyte layer of poly(sodium 4- styrenesulfonic 
acid) [15]. The same authors also developed a similar immunosensor for the 
determination of anti-gliadin antibodies (AGA), using 3-mercaptopropionic acid to modify 
the screen-printed gold electrode surface [16]. The amount of these autoantibodies present 
in positive and negative serum samples was evaluated. The high charge transfer resistance 
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values obtained by impedance spectroscopic measurements were related to the content of 
antibodies; however only a qualitative analysis was performed. Moreover, an acceptable 
sensitivity was achieved but the results suggest a lower precision, when compared with 
ELISA assays. On the other hand, Pividori et al. proposed an amperometric 
immunosensor based on the physical adsorption of tTG from guinea pig liver onto 
graphite–epoxy composite (GEC) electrodes [17]. For 10 positive and 10 negative 
processed serum samples a sensitivity of 70% and a specificity of 100% were achieved, 
compared with the commercial ELISAs, but this method was also based on a yes/no 
binary qualitative system and no direct correlation between the analytical signal and 
antibody concentration was achieved. Pereira et al. [18] have proposed a microfluidic 
immunosensor coupled with electrochemical detection for AGA IgG quantification. The 
methodology consists of a 30-min assay using a pore glass bed coated with the antigen 
gliadin on a bare gold electrode for the detection of the labelled anti-human IgG. The 
results obtained in this work were comparable with those obtained by commercial ELISA 
kits but the work lacks the detection of IgA-class antibodies and immunoglobulin A (IgA) 
isotype is considered to be the most specific [19]. An electrochemical supramolecular 
platform based on cyclodextrin-modified gold surface electrodes to detect antigliadin 
antibodies in real serum samples was also proposed [20]. In this work an amperometric 
detection of AGA IgA and AGA IgG in samples of CD patients in 3 stages of the disease was 
achieved and the results showed a good correlation with an ELISA assay. Two more EIs 
that provide a qualitative and semi-quantitative estimation of the antibody content in real 
sera were reported. One was developed for the detection of human anti-tTG antibodies 
[21] and the other for the detection of human AGA antibodies [22]. In the construction of 
both sensors, the antigen (i.e. tTG or gliadin) was covalently attached onto self-assembled 
monolayers of a carboxylic-terminated bipodal alkanethiol group which was immobilized 
on gold electrodes. The immunosensors performance was corroborated with a commercial 
ELISA kit and the results were in good agreement with those obtained with the 
conventional methodology. However, in almost every case, surface renewable electrodes 
and conventional electrochemical cells are used and this has serious disadvantages has 
memory effects and necessary cleaning processes. In spite of the good analytical results, 
the employed electrochemical devices do not allow to carry out a continuous analytical 
performance. Moreover, for the decentralization of the diagnostic towards a point-of-care 
analysis, the research was to be directed toward more simple, miniaturized and portable 
devices.  
In our group, we already developed a disposable electrochemical immunosensor for 
the detection of IgA and IgG type anti-tTG autoantibodies in real patient’s samples [23] 
using a screen-printed carbon electrode modified with a carbon nanotube (CNT)/ gold 
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nanoparticle hybrid system as transducer surface. That nanostructured electrodic surface 
was developed in a previous work [24] in order to be applied as a transducer surface in 
several biosensor devices. Due to the growing need to perform rapid “in situ” analyses, 
disposable screen-printed electrodes have been successfully employed in the development 
of several biosensors devices in many fields [25]. Furthermore, hybrid CNT-nanoparticle 
materials are interesting because the combination of the physical and chemical properties 
of the individual components leads to a robust and efficient transducer amplification 
platform [12]. 
 In this work we propose the same single-use hybrid transducer platform [24] for the 
quantification of AGA IgA and AGA IgG in human serum. The antigen and secondary 
labelled antibodies’ concentrations were optimized and non-specific binding was also 
studied. The evaluation of real patient’s samples was performed with the developed 
immunosensor and the results were compared with commercial ELISA kits. 
 
2. Materials and methods 
 
2.1. Instrumentation 
Voltammetric experiments were performed with an Autolab PGSTAT 12 (Eco Chemie, 
The Netherlands) potentiostat/galvanostat interfaced to an AMD K-6 266 MHz computer 
system and controlled by Autolab GPES 4.8 (software version for Windows 98). All the 
measurements were carried out at room temperature. Disposable screen-printed carbon 
electrodes (SPCEs) were purchased from DropSens (Spain). These electrodes incorporate 
a conventional three-electrode cell configuration, printed on ceramic substrates (3.4×1.0 
cm). Both the working- (disk-shaped 4 mm diameter) and the counter electrode are made 
of carbon inks, whereas the pseudo-reference electrode and the electric contacts are made 
of silver. A ring-shaped layer printed around the working electrode constitutes the 
reservoir (50 µL) of the electrochemical cell. The SPCEs were easily connected to the 
potentiostat through a specific DropSens connector (Spain). 
2.2. Reagents and solutions 
Tris(hydroxymethyl)aminomethane (Tris), magnesium nitrate, bovine serum albumin 
fraction V (BSA), β-Casein from bovine milk (casein) were purchased from Sigma (Spain). 
Carboxylated multiwalled carbon nanotubes (MWCNTs) were purchased from Nanocyl 
(Belgium). Standard gold (III) tetrachloro complex (AuCl4-), silver nitrate, hydrochloric 
acid (37%) and nitric acid (HNO3) were obtained from Merck (Germany). Biosynth 
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(Switzerland) supplied the 3-indoxyl phosphate disodium salt (3-IP). Wheat gliadin and 
goat anti-human IgG (Fc specific) conjugated with alkaline phosphatase (anti-H-IgG-AP) 
were purchased from Sigma (Spain) and goat anti-human IgA (alpha chain specific) 
labelled with alkaline phosphatase (anti-H-IgA-AP) was provided by Invitrogen (Spain). 
Positive and negative controls (EliA CCP Positive Control 100 and EliA IgG/IgM/IgA 
Negative Control 100) were acquired from Phadia (Germany). The validation of the 
developed procedure was performed using anonymous sera samples, collected in the 
“Hospital Universitario Central de Asturias” (Spain), which were analyzed by VARELISA 
Gliadin IgA Antibodies and VARELISA Gliadin IgG Antibodies ELISA kits supplied by 
Phadia (Germany). Each kit contained six standard serum samples (0, 3, 7, 16, 40, 100 U 
mL-1) and a positive and a negative control. The kit’s instructions established a cut-off 
range regarding the serological recommended normal values to negative (< 11 U mL-1), 
equivocal (11-17 U mL-1) and positive (> 17 U mL-1) determinations. Ultrapure water 
obtained from a Millipore Direct-QTM purification system from Millipore Ibérica S.A. 
(Spain) was used throughout the work. All chemicals employed were of analytical reagent 
grade. Working solutions of gliadin were prepared in a 0.1 M Tris-HNO3 pH 7.2 buffer 
(buffer 1). Working solutions of secondary alkaline phosphatase labelled antibodies were 
prepared in a 0.1 M Tris-HNO3 pH 7.2 buffer containing 2 mM Mg(NO3)2 (buffer 2). A 
solution containing 1.0 mM 3-IP and 0.4 mM silver nitrate was prepared daily in 0.1 M 
Tris-HNO3 pH 9.8 and 20 mM Mg(NO3)2 (buffer 3) and stored in opaque tubes at 4ºC. 
BSA and casein lyophilized powder were reconstituted in buffer 1. All the dilutions of the 
control samples and real sera samples were performed with buffer 1. The MWCNTs 
working solutions were prepared by dilution of the concentrated solution with a mixture of 
the dimethylformamide(DMF):water (1:1) and gold tetrachloroaurate solutions were 
prepared in 0.1 M HCl as was reported in a previous work [24]. 
 
2.3. SPCEs nanostructuration with MWCNTs and NPAus  
The modification of the SPCEs was carried out using the methodology described 
previously [24]. A 4 µL aliquot of the 0.1 mg mL-1 MWCNTs dispersion was deposited on 
the working electrode’s surface. The solution was left to dry at room temperature until its 
complete evaporation. Then, the modified SPCEs were carefully washed with water and 
dried at room temperature. Gold nanostructures were generated “in situ” over the carbon 
nanotube-modified electrode (SPCE-MWCNT-NPAus) by applying a constant current 
intensity of -5µA for 60 s in an acidic solution of 0.1 mM AuCl4-. Finally, the 
nanostructured electrodes were rinsed with water. 
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2.4. Construction of the immunosensor and electrochemical detection 
The following procedure (Fig. 1) describes an optimized assay:  
 
anostructured electrode surface
AP AP
Blocking agent                               Gliadin Anti-gliadin IgA or IgG antibodies
Alkaline phosphatase (AP) labelled anti-Human IgA or IgG antibody
AP
3-IP/Ag+
I/Ag0
 
 
Fig. 1. Schematic representation of the immunosensor architecture used in this study. 
 
The working area of the SPCE-MWCNT-NPAus was coated with 40 µL of a 1 mg mL-1 
wheat gliadin solution and incubated overnight at 4 ºC. The immobilization of the gliadin 
on the electrode surface was achieved by physical adsorption. After the overnight 
incubation step the electrode was washed with buffer 1. Free surface sites of the gliadin-
modiﬁed SPCE-MWCNT-NPAus were blocked with 40 µL of a casein (2%) or BSA (2%) 
solution during 30 min. After a washing step with buffer 1 the sensing part of the 
immunosensor was completed. The detection of anti-gliadin antibodies was accomplished 
by incubating the immunosensors with 40 µL of serum samples (1:200) for 60 min 
followed by a washing step with buffer 2. Finally, the immunosensor was incubated with 
40 µL of anti-H-IgA-AP (1:25,000) or anti-H-IgG-AP (1:50,000) solutions for 60 min and 
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washed with buffer 3. The enzymatic reaction was carried out by placing a 40 µL aliquot of 
the 1.0 mM 3-IP / 0.4 mM silver nitrate solution on the sensor. AP was used as the 
enzymatic label and a mixture of 3-indoxyl phosphate with silver ions (3-IP/Ag+) as the 
substrate. AP hydrolyzes 3-IP resulting in a indoxyl intermediate that will reduce the silver 
ions presents in solution resulting in metallic silver (Ag0) and indigo blue (I) [26]. After 20 
min, the redissolution peak of the silver enzymatically deposited on the electrode surface 
was recorded using an anodic stripping cyclic voltammetric scan from - 0.002 V to + 0.4 V 
at a scan rate of 50 mV s-1.  
 
2. Results and discussion   
 
3.1. Optimization of the experimental conditions 
Each variable involved in the construction of an immunosensor can influence the 
analytical response; therefore an optimization study was carried out using positive and 
negative control samples. 
The adequate concentration of the antigen was evaluated in order to achieve the best 
relation between sensitivity and reproducibility. The data presented in Fig. 2 reveal that a 
gliadin concentration of 1 mg mL-1 is the most adequate because it presents the best 
compromise between the analytical and the background signals, and was selected for all 
subsequent studies. 
In order to minimize nonspecific adsorption, the effect of different blocking agents was 
studied. In the case of the AGA IgA detection, the best analytical /background signal ratio 
was obtained with casein (2%). In the case of the AGA IgG analysis the free surface sites 
were effectively blocked with BSA (2%). With these blocking agents, matrix effects were 
found to be minimal. The influence of the secondary labelled antibody on the analytical 
signal was also investigated. The best relation between analytical and background signal 
was achieved for a dilution of 1:25,000 in the case of anti-H-IgA-AP (Fig. 3a) and 1:50,000 
for anti-H-IgG-AP (Fig. 3b). These optimized conditions were used throughout the work. 
Fig. 4 shows typical cyclic voltammograms obtained for the detection of AGA IgA (Fig. 4a) 
and AGA-IgG (Fig. 4b) in positive control samples (solid lines) and negative control 
samples (dashed lines) in optimized conditions.  
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Fig. 2 Evaluation of the effect of the antigen concentration on the analytical signal using positive 
(black bars) and negative (grey bars) control samples. Experimental conditions: BSA 2%; anti-H-
IgG-AP 1:150,000; 3-IP 1.0 mM; Ag+ 0.4 mM. The positive and negative sera were diluted at 1:10. 
(Average data ± standard deviation are indicated (n=3)) 
 
 
 
 
 
 
 
 
 
 
II.RESEARCH AND DEVELOPMENT 
 
136  
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Fig. 3. Effect of the secondary labelled antibody on the analytical signal. (a) AGA-IgA positive 
(black bars) and negative (grey bars) control samples (1:2). (b) AGA-IgG positive (black bars) and 
negative (grey bars) control samples (1:2). Experimental conditions: 1 mg mL-1 gliadin adsorbed on 
the hybrid-modified electrode surface; casein 2% (a); BSA 2% (b); 3-IP 1.0 mM; Ag+ 0.4 mM. 
(Average data ± standard deviation are indicated (n=3)). 
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Fig. 4. Cyclic voltammograms obtained for an optimized assay. (a) AGA-IgA positive (solid line) 
and negative (dashed line) control samples (1:2). (b) AGA-IgG positive (solid line) and negative 
(dashed line) control samples (1:2). Experimental conditions: 1 mg mL-1 gliadin adsorbed on the 
hybrid-modified electrode surface; (a) casein 2% and anti-H-IgA-AP 1:25,000; (b) BSA 2% and 
anti-H-IgG-AP 1:50,000; 3-IP 1.0 mM; Ag+ 0.4 mM. Cyclic voltammetric scan from - 0.002 V to + 
0.4 V at a scan rate of 50 mV s-1. 
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3.2. Study of non specific adsorption and sensor biofunctionality 
Regardless of the blocking agents’ efficiencies the presence of several different 
immunoglobulins and other proteins in the serum samples can lead to non specific 
binding (NSB) and difficult the analytical detection of the designed immunosensor. 
Moreover, it is also important to ensure that both the antigen and the secondary labelled 
antibody specifically react with the target immunoglobulin (i.e. AGA class A and G). 
Hence, the background signal was evaluated using positive and negative serum samples 
for both AGA-IgA and IgG detection. The results (Fig. 5) showed that the analytes of 
interest, the human antibodies, are effectively captured by the antigen since the obtained 
ip for a positive sample assayed with a gliadin-modified electrode is clearly different from 
the ip obtained with a BSA-modified electrode (without gliadin). The analytical signal 
obtained with the sensor in the absence of gliadin for positive and negative samples is 
approximately equal and is similar to a negative sample assayed with the complete 
immunosensing strategy. These current intensities, in the order of 5-10 µA, therefore 
result from NSB.  
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Fig. 5. Effect of non-specific adsorption on the analytical signal for the evaluation of (a) AGA IgA 
and (b) AGA IgG content in CD positive (+) and negative (-) serum samples with gliadin-modified 
(black bar) and BSA-modified (without gliadin) (grey bar) electrodes. Experimental conditions as in 
Fig. 3. (Average data ± standard deviation are indicated (n=3)). 
 
3.3. Precision studies 
The precision of the methodology was evaluated in terms of repeatability and 
reproducibility using a real positive sample. The repeatability was evaluated by 
performing five successive inter-electrodic measurements using separate immunosensors 
and the reproducibility was assessed through 2 inter-day evaluations (interval of one 
month). Relative standard deviation (RSD) values for the detection of AGA IgA (0.033) 
and for the detection of AGA IgG (0.035) were obtained when the repeatability was 
assayed. Regarding the reproducibility studies, the RSD values achieved for the detection 
of AGA IgA and AGA IgG were 0.025 and 0.002, respectively. The result indicates that the 
method provides precise results. 
 
 
 
3.4. Calibration plot  
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Calibrator serum solutions provided by the acquired ELISA kits for AGA IgA and AGA 
IgG detection are real patient samples and contain antibody concentrations within the 
range of clinical interest. Under the optimized conditions and using these human serum 
sample calibrators (1:2 diluted), the following linear relationships between ip and the 
immunonoglobulin content (in arbitrary units) were obtained: 
 ip (µA) = (0.21 ± 0.13) [AGA IgA] + (5.06 ± 0.63) r = 0.997, n = 6 
ip (µA) = (0.49 ± 0.18) [AGA IgG] + (8.72 ± 0.87) r = 0.997, n = 6 
The limits of detection (LOD) and the limits of quantification (LOQ) were calculated from 
the calibration plots using the equations: LOD=3s/m and LOQ=10s/m (where s is the 
standard deviation of the intercept and m is the slope of the calibration plot) [27]. In case 
of AGA IgA detection, the LOD and LOQ values obtained were 9.1 U mL-1 and 30.4 U mL-1, 
respectively. In case of AGA IgG detection, LOD and LOQ were found to be 9.0 U mL-1 and 
31.2 U mL-1, respectively. 
 
3.5. Immunosensor assessment for the quantification of antigliadin antibodies in real 
samples 
For the evaluation of the adequacy of the developed immunosensor in real samples, 10 
different real serum samples were analyzed and the results were compared with those 
obtained with a commercial ELISA assay. According to the ELISA kit’s instructions, serum 
calibrators are ready to use and patient’s samples should be diluted 1:101. Serum 
calibrators assayed by the immunosensor were diluted 1:2. Therefore, in order to ensure 
the correct comparison of the results obtained with the immunosensor and the ELISA 
assay, patient’s samples analyzed by the immunosensor were diluted 1:200. The ip 
obtained with the immunosensor was extrapolated to the calibrator’s linear ranges to 
convert the current data in arbitrary units. The recommended cut-off value by the kit 
fabricants was used to determine the clinical relevance of the results. The results obtained 
with the immunosensor were compared with those obtained with the ELISA test (Fig. 6). 
The data obtained indicate that samples 1, 2, 3 and 4 belong to CD patients, sample 5 to a 
CD patient with selective IgA deficiency but with positive results when class G antibodies 
were analyzed and the remaining samples correspond to healthy individuals. All the 
samples were qualitatively classified the same (positive or negative) by both analytical 
tools. Therefore, regarding the qualitative analysis both methods were in agreement. On 
the other hand, in the quantitative analysis of the immunoglobulin’s content a straight 
correlation between the results was not observed. In fact in almost every case, except for 
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S7 and S9 (Fig. 6a) and S7 (Fig. 6b), the immunosensor measures a higher amount of 
AGAs. These differences could be due to the different sample dilutions. While ELISA is 
performed according to the instructions of the manufacturer, the electrochemical 
immunoassay is performed with similar conditions to those used in the ELISA, trying to 
mimic it. Possibly these parameters should be optimized for the immunosensor regardless 
of the ELISA’s conditions. Nonetheless, the methodologies have different characteristics, 
so the similarity achieved in the measurements is very acceptable.  
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a 
 
b 
 
Fig. 6. Comparison of results obtained for real samples assayed with the proposed electrochemical 
immunosensors and with a standard ELISA kit. (a) AGA IgA and (b) AGA IgG. The presented cut-
off levels (11-17 U mL-1) are the recommended by the ELISA kits. 
 
 
0
10
20
30
40
50
60
70
80
90
100
110
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10
A
nt
ib
od
ie
s a
rb
ria
ry
 u
ni
ts
 (U
 m
L-
1 )
Electrochemical immunosensor
ELISA
0
20
40
60
80
100
120
140
160
180
200
220
240
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10
A
nt
ib
od
ie
s a
rb
ria
ry
 u
ni
ts
 (U
 m
L-
1 )
Electrochemical immunosensor
ELISA
 SCREENING FOR ANTI-GLIADIN ANTIBODIES 
 
 143 
 
4. Conclusions 
A novel electrochemical immunosensor based on a nanohybrid analytical transducer 
platform for the detection of human antibodies directed against gliadin in real samples 
was developed. Several parameters involved in the immunosensing strategy, such as the 
blocking agent and the antigen and AP labelled anti-human IgA and IgG antibody 
concentrations, were optimized leading to an excellent analytical performance with no 
significant non-specific adsorptions. Precision studies also indicate that the proposed 
methodology is reproducible and presents a good repeatability. Real patient’s samples 
were analyzed with the electrochemical immunosensor and the results obtained were 
corroborated with a commercial ELISA kit. A correlation between the average values 
obtained with the sensor (in arbitrary units) and those obtained with the ELISA was also 
investigated. The results showed some disparity, since the content of AGA IgA and IgG in 
the sera obtained by the sensor was, in general, higher than that obtained with the ELISA. 
However, in a methodology that intends to be a first-line diagnostic test for an 
autoimmune disease the qualitative analysis is much more important than the quantitive 
analysis. Therefore, in comparison with the conventional ELISA-based analysis, the 
developed electrochemical immunosensor is a reliable, low cost and simple methodology, 
being a perfect option as first platform for future transference to a point-of-care analytical 
device for celiac disease diagnosis. The implementation of this methodology to the 
development of an electrochemical bi-immunosensor for the simultaneous detection of 
autoantibodies against gliadin and tissue transglutaminase will be evaluated. 
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Abstract 
Celiac disease (CD) is a gluten-induced autoimmune enteropathy characterized by the 
presence of antibodies against gliadin (AGA) and anti-tissue transglutaminase (anti-tTG) 
antibodies. A disposable electrochemical dual immunosensor for the simultaneous 
detection of IgA and IgG type AGA and anti-tTG antibodies in real patient’s samples is 
presented. The proposed immunosensor is based on a dual screen-printed carbon 
electrode, with two working electrodes, nanostructured with a carbon-metal hybrid system 
that worked as the transducer surface. The immunosensing strategy consisted of the 
immobilization of gliadin and tTG (i.e. CD specific antigens) on the nanostructured 
electrode surface. The electrochemical detection of the human antibodies present in the 
assayed serum samples was carried out through the antigen-antibody interaction and 
recorded using alkaline phosphatase labelled anti-human antibodies and a mixture of 3-
indoxyl phosphate with silver ions was used as the substrate. The analytical signal was 
based on the anodic redissolution of enzymatically generated silver by cyclic voltammetry. 
The results obtained were corroborated with commercial ELISA kits indicating that the 
developed sensor can be a good alternative to the traditional methods allowing a 
decentralization of the analyses towards a point-of-care strategy. 
 
Keywords: Celiac disease; Tissue transglutaminase; Gliadin; Electrochemical 
immunosensors; Nanomaterials; Multiplexed detection. 
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Abbreviations 
CD – celiac disease  
EIs – electrochemical immunosensors 
AGA – anti-gliadin antibodies  
Anti-H-IgA-AP – anti-human IgA antibodies conjugated with alkaline phosphatase  
Anti-H-IgG-AP – anti-human IgG antibodies conjugated with alkaline phosphatase  
SPCEs – screen-printed carbon electrodes 
MWCNTs – carboxylated multiwalled carbon nanotubes  
NPAus – gold nanoparticles 
 
1. Introduction 
Celiac disease (CD) is a disorder of the small intestine caused by an inappropriate 
immune response to wheat gluten and similar proteins of barley and rye in genetically 
susceptible individuals [1]. The humoral autoimmune response leads to an abnormal 
intestinal mucosa characterized by villous atrophy and crypt hyperplasia, resulting in 
malabsorption related problems [2]. Common serological changes of this condition 
include the appearance of antibodies against gliadin (AGA) and anti-tissue 
transglutaminase (anti-tTG) antibodies; which are specific serological markers of the 
disease. Is reported that immunoglobulin A (IgA) anti-tTG antibody detection has 
sensitivity higher than 90% and specificity higher than 95%;  IgA AGA detection presents 
a sensitivity of about 80% and a specificity ranging from 80 to 90% [3]. The IgA isotype is 
considered to be the most specific; however, selective IgA deficiency affects about 2–5% of 
patients diagnosed with CD [4]. In these cases, the determination of the immunoglobulin 
G (IgG) class of antibodies is considered [5]. 
 The gold standard diagnosis for CD which relies on a intestinal biopsy has been 
changing over the last few decades, especially due to the advent of serological tests with 
high sensitivity and specificity [1].  Serological markers can be used in front-line detection 
strategy to rule out the pathology.  
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Nowadays, analytical techniques are moving towards the development of more simple, 
fast, and point-of-care (POC) analyses. Therefore, electrochemical biosensors are playing a 
growing part in many fields in which a more accurate, sensitive, fast, low cost and, 
specially, in situ analysis is required [6]. Electrochemical biosensors are in many cases the 
best option for diagnostics given their high selectivity and sensitivity which allows early 
detection of many diseases. Among the different types of electrodes that are employed in 
the construction of electrochemical biosensors, screen-printed electrodes (SPEs) are of 
special interest. Their properties, such as simplicity and low cost, versatility of design, 
small dimensions and possibility of incorporation in portable systems, as well as adequate 
electroanalytical characteristics, have progressively introduced SPEs in fields such as 
environmental analysis, food quality control, and clinical diagnostics [7, 8]. 
 In recent years, the development of electrochemical transducers that make use of 
electrode surface modifications with nanomaterials became an exciting area of 
development for modern analytical science [9, 10, 11]. The use of nanomaterials extends 
the potentialities of these electrodes by improving their original electrochemical 
properties. For this reason, carbon nanostructure/ metal nanoparticle hybrid systems 
have been recently exploited as last generation transducers for the development of 
biosensors [12, 13, 14], because a synergic effect of each material property is obtained [15]. 
Within the electrochemical biosensors field, electrochemical immunosensors (EIs) 
combining the specificity inherent to antigen–antibody interactions with the high 
sensitivity of electrochemical transduction [16], can be an excellent alternative to 
conventional immunochemical tests. Therefore, a dual immunosensor for the 
simultaneous detection of AGA and anti-tTG antibodies was developed.  A dual screen-
printed carbon electrode (SPCE) nanostructured with a carbon-gold hybrid system was 
employed as the transducer surface. The immunosensing strategy consisted of the 
immobilization of gliadin and tTG (i.e. CD specific antigens) on the nanostructured 
electrode surface followed by the electrochemical detection of the human antibodies 
present in real serum samples. The antigen-antibody interaction was recorded using 
alkaline phosphatase labelled anti-human antibodies and a mixture of 3-indoxyl 
phosphate with silver ions (3-IP/Ag+) was used as the substrate [17].  The analytical signal 
was based on the anodic redissolution of enzymatically generated silver by cyclic 
voltammetry. As far as we are concerned, there is no record of an EI for the simultaneous 
detection of the referred antibodies. 
 The published works regarding EIs for CD clinical diagnosis that are currently 
available are focused on the detection of just one of the biomarkers. [12, 13, 18-25]. 
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2. Materials and methods 
 
2.1. Instrumentation 
Voltammetric analysis was performed with an Autolab PGSTAT 12 (Eco Chimie B.V., The 
Netherlands) potentiostat interfaced to an AMD K-6 266 MHz computer system and ntrolled 
by Autolab GPES 4.8 software (version for Windows 98). Dual SPCEs and a specific 
connector were purchased from DropSens (Spain). The dual SPCEs comprises two ellipse-
shaped carbon working electrodes (6.3mm2 each one), a carbon counter electrode and a silver 
pseudo-reference electrode, all of them screen-printed on a ceramic substrate (3.4cm × 1.0 
cm).  
 
2.2. Reagents and solutions 
Carboxyl modified multiwalled carbon nanotubes (MWCNTs) were purchased from 
Nanocyl (Belgium). Standard gold tetrachloroaurate (AuCl4−) and silver nitrate were 
obtained from Merck (Germany). Biosynth (Switzerland) supplied the 3-indoxyl 
phosphate disodium salt. Human tissue transglutaminase (recombinantly produced in 
insect cells) was purchased from Zedira (Germany). Wheat gliadin was provided by Sigma 
(Spain). Goat anti-human IgG (Fc specific) conjugated with alkaline phosphatase (anti-H-
IgG-AP) was purchased from Sigma (Spain) and goat anti-human IgA (alpha chain 
specific) labelled with alkaline phosphatase (anti-H-IgA-AP) was provided by Invitrogen 
(Spain). The validation of the developed procedure was performed with anonymous sera 
samples collected in the “Hospital Universitario Central de Asturias” (Spain), which were 
analysed by Varelisa Celikey, Varelisa Celikey IgG, VARELISA Gliadin IgA Antibodies and 
VARELISA Gliadin IgG Antibodies ELISA kits, all supplied by Phadia (Germany). Each kit 
contained six standard serum samples (0, 3, 7, 16, 40 and 100 U mL−1) and a positive and 
a negative control. The kit’s manufacturers proposed a range of values with clinical 
significance for the analysis of the samples. According to the kit’s instructions an equivocal 
result should be considered between 5 and 8 U mL−1 in the case of anti-tTG IgA detection 
(Varelisa Celikey); between 7 and 10 U mL−1 for anti-tTG IgG determination (Varelisa 
Celikey IgG) and for VARELISA Gliadin IgA Antibodies and VARELISA Gliadin IgG 
Antibodies the range of 11 and 17 U mL−1 was recommended as equivocal. Below and above 
these values the samples are classified as negative or positive, respectively, for CD. 
Ultrapure water obtained with a Millipore Direct-QTM purification system from Millipore 
Ibérica S.A. (Spain) was used throughout this work. All chemicals employed were of 
analytical reagent grade. Working solutions of tTG and gliadin were prepared in a 0.1 M 
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Tris-HNO3 pH 7.2 buffer. Working solutions of the secondary alkaline phosphatase 
labelled antibodies were prepared in 0.1 M Tris-HNO3 pH 7.2 containing 2 mM Mg(NO3)2. 
A solution containing 1.0 mM 3-IP and 0.4 mM silver nitrate was prepared daily in 0.1 M 
Tris-HNO3 pH 9.8 and 20 mM Mg(NO3)2 and stored in opaque tubes at 4ºC.  The 
MWCNTs solutions were prepared by dilution of the concentrated solution with a mixture 
of DMF:water (1:1). The gold tetrachloroaurate solution was prepared in 0.1 M HCl. 
 
2.3. Electrodes nanostructuration 
 
Single-use dual SPCEs were modified with 2 µL of a 0.1 mg mL−1 MWCNTs dispersion 
and the solution was left to dry at room temperature until its complete evaporation. Then, 
the MWCNTs-modified electrode was carefully washed with water and dried at room 
temperature. The coating process was followed by in situ electrochemical deposition of 
gold nanoparticles (NPAus) by applying a constant current intensity of − 5 µA for 60 s in 
an acidic solution of 0.1 mM AuCl4− [15]. 
 
2.4. Construction of the dual immunosensor and electrochemical detection 
The immunosensing strategy (Fig. 1) comprise the following steps: the dual SPCE–
MWCNT–NPAus working electrodes (WE) were coated with 4 µL of 1 mg mL-1 gliadin 
solution (WE1) and with 4 µL of a 0.1 µg.µL−1 tTG solution (WE2) and left to incubate 
overnight at 4 ◦C. The electrodes were washed using 0.1M Tris–HNO3 pH 7.2 buffer. Free 
surface sites were blocked with 60 µL of a bovine serum albumin (BSA) solution for 30 min, 
followed by a second washing step with the same buffer. Then, the immunosensor was 
incubated with human serum samples for 60 min followed by a washing step with a 0.1 M 
Tris–HNO3 pH 7.2 buffer containing 2 mM Mg(NO3)2. Finally, the immunosensor was 
incubated with an anti-H-IgA-AP (1:25,000) or an anti-H-IgG-AP (1:50,000) solution (both 
volumes of 60 µL) for 60 min and washed with a 0.1 M Tris pH 9.8 buffer containing 20 mM 
2 mM Mg(NO3)2. The enzymatic reaction was carried out by dropping a 60 µL aliquot of a 
solution containing 1.0 mM 3-IP and 0.4 mM silver nitrate on the immunosensor’s surface. 
The enzymatically deposition of metallic silver catalysed by alkaline phosphatase (AP) was 
already reported [17].  After 20 min of reaction, a cyclic voltammogram was recorded from – 
0.002 V to + 0.4V, at scan rate of 50 mV s-1, to obtain the electrochemical oxidation current 
of the enzymatically deposited silver. 
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Fig. 1. Schematic representation of the immunosensing strategy followed for the analytical 
detection of CD serological markers. 
 
3. Results and discussion 
3.1. Optimization studies 
For the optimization procedure were taken in account two important factors of the 
immunosensing strategy: the antigen´s concentration and the influence of the 
concentration of the labelled secondary antibody on the analytical signal. Regarding the 
detection of anti-tTG IgA (Fig. 2 a1)  and AgA IgA (Fig. 2 b1) the optimal amount of tTG 
and gliadin to be immobilized on the surface was 0.1 µg µL-1  and 1 mg mL-1, respectively, 
because for this values was verified the best relation between the analytical and the 
background signal. In case of anti-tTG IgG (Fig. 2 a2) and AGA IgG (Fig. 2 b2), equal 
optimum amounts of tTG and gliadin to be immobilized on the surface were selected for 
the same reasons.  
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Fig. 2. Effect of the different concentrations of the antigen (tTG: a1 and a2; gliadin: b1 and b2) on 
the analytical signal for the detection of the corresponding immunoglobulins class A (a1 and b1) 
and class G (a2 and b2). Experimental conditions: BSA 2%; positive (grey bars) and negative (white 
bars) control samples (1:2); anti-H-IgA-AP 1:30,000 (a1 and b1) and anti-H-IgG-AP 1:50,000 (a2 
and b2); 3-IP 1.0 mM; Ag+ 0.4 mM. Average data ± standard deviations are indicated (n = 3). 
 
The influence of the secondary labelled antibody on the analytical signal was also 
investigated. The influence of four different concentrations of anti-H-IgA-AP antibody 
(1:5000; 1:10,000; 1:25,000; 1:50,000) and anti-H-IgG-AP (1:10,000; 1:25,000; 
1:50,000; 1:100,000) were investigated using a positive and a negative control samples. As 
can be observed in Fig. 3, in all cases, as the analytical signal corresponding to the assay 
with the positive control (grey squares) increases, the signal obtained with the negative 
control (white squares) also increases due to the augment of non-specific binding.  
Therefore, the best compromise between both signals was achieved for a dilution of 
1:25,000 in the case of anti-H-IgA-AP and 1:50,000 for anti-H-IgG-AP. Finally, in order to 
minimize non-specific adsorption, albumin (2%) was employed as blocking agent (results 
not shown). These optimized conditions were used throughout the work. Typical cyclic 
voltammograms obtained for the detection of AGA IgA and anti-tTG IgA and AGA IgG and 
anti-tTG IgG in positive and negative samples, in optimized conditions, can be observed in 
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Fig. 4. This figure also gives the results obtained with a sample whose donor is a celiac 
patient with selective IgA deficiency. As can be observed the dual-sensor gives a signal 
corresponding to a negative sample in case of IgA detection and a positive result when 
immunoglobulin G are assayed. 
0
5
10
15
20
25
30
35
40
45
50
0 2 4 6 8 10 12
i p
/ 
µA
[anti-H-IgA-AP] 
0
5
10
15
20
25
30
35
40
45
50
0 2 4 6 8 10 12
i p
/ 
µA
[anti-H-IgG-AP] 
0
10
20
30
40
50
60
70
80
90
0 2 4 6 8 10 12
i p
/ 
µA
[anti-H-IgA-AP] 
0
5
10
15
20
25
30
35
0 2 4 6 8 10 12
i p
/ 
µA
[anti-H-IgG-AP] 
b2
a1
a2
b1
Anti-tTG IgA detection AGA IgA detection
Anti-tTG IgG detection AGA IgG detection
1:100,000                    1:50,000                     1:25,000                      1:10,0001:100,000                    1:50,000                     1:25,000                      1:10,000
1:50,000                      1:25,000                        1:10,000                        1:50001:50,000                      1:25,000                        1:10,000                        1:5000
 
Fig. 3. Influence of the secondary AP-labelled antibody on the analytical signal. Experimental 
conditions: tTG 0.1 µg µL−1; gliadin 1 mg mL-1; BSA 2%; positive (grey squares) and negative (white 
squares) control samples (1:5); 3-IP 1.0 mM; Ag+ 0.4 mM. Average data ± standard deviations are 
indicated (n = 3). 
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Fig.4. Cyclic voltammograms obtained for an optimized assay: (a1) AGA-IgA positive (solid line) 
and anti-tTG IgA positive (dashed line) samples; (b1) AGA-IgA negative (solid line) and anti-tTG 
IgA negative (dashed line) samples. (a2) AGA-IgG positive (solid line) and anti-tTG IgG positive 
(dashed line) samples; (b2) AGA-IgG negative (solid line) and anti-tTG IgG negative (dashed line) 
samples. In (c) are presented cyclic voltammograms obtained in the analysis of a sample of a CD 
patient with selective IgA deficiency: (c1) AGA-IgA detection (solid line) and anti-tTG IgA detection 
(dashed line); (c2) AGA-IgG detection (solid line) and anti-tTG IgG detection (dashed line) 
samples. Experimental conditions: tTG 0.1 µg µL−1; gliadin 1 mg mL-1; BSA 2%; serum samples 
diluted 1:200; anti-H-IgA-AP 1:25,000 (a) and anti-H-IgA-AP 1:50,000 (b); 3-IP 1.0 mM; Ag+ 0.4 
mM.  
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3.2. Precision studies 
The precision of the methodology was evaluated in terms of reproducibility which was 
assessed through 3 inter-day evaluations. In case of IgA detection, relative standard 
deviation (RSD%) values of 7.50 % and 3.72 % were obtained for AGA and anti-tTG 
detection, respectively. RSD (%) values of 7.18 % and 4.32 % were obtained for the 
detection of AGA and anti-tTG type G immunoglobulins, respectively. 
 
3.3. Calibration plot 
Calibrator serum solutions provided by the acquired ELISA kits are real patient 
samples and contain antibody concentrations within the range of clinical interest. Under 
the optimized conditions and using these human sera sample calibrators (1:2 diluted), a 
linearity between peak current intensity and the immunonoglobulin content (in arbitrary 
units) was achieved between 0 and 100 U mL-1. The linear relationships of the method is 
given by the following equations:  
Logip(µA)=(4.7x10-1 ± 8.5x10-4)Log[tTG IgA] + (7.1 x10-1 ± 1.3 x10-3) r=0.995, n=6 
Logip(µA)=(6.3x10-1 ± 2.3x10-3)Log[tTG IgG] + (3.2 x10-1 ± 5.6 x10-3) r=0.998, n=6 
Logip(µA)=(6.5x10-1 ± 5.2x10-3)Log[AGA IgA] - (2.0 x10-2 ± 7.1 x10-3) r=0.986, n=6 
Logip(µA)=(6.0x10-1 ± 2.7x10-2)Log[AGA IgG] - (3.3 x10-1 ± 4.0 x10-2) r=0.994, n=6 
The limits of detection (LOD) and the limits of quantification (LOQ) were calculated 
from the calibration plots using the equations: LOD = 3 s/m and LOQ = 10 s/m (where s is 
the standard deviation of the intercept and m is the slope of the calibration plot) [26]. In 
case of tTG IgA detection, the LOD and LOQ values obtained were 2.45 U mL−1 and 20.42 
U mL−1, respectively. In case of tTG IgG detection, LOD and LOQ were found to be 2.95 U 
mL−1 and 37.15 U mL−1 respectively. LOD and LOQ values were 3.16 U mL−1 and 46.77 U 
mL−1 for AGA IgA detection and 2.82 U mL−1 and 32.36 U mL−1, respectively, for AGA IgG 
determination. 
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3.4. Comparison of the response of the dual sensor with the commercial ELISA 
In order to establish an agreement between the dual sensor and a commercial 
methodology available, the performance of the electrochemical immunosensor was 
evaluated against the already referred ELISAs. Twelve different real samples were 
analysed with both methodologies. In order to correlate the results obtained with the 
sensor with the data obtained with the ELISA, the currents obtained with the 
electrochemical immunosensor for each sample were extrapolated to the corresponding 
calibration plot (Section 3.3.) to obtain equivalent arbitrary units to those found when 
analysing the same samples by commercial ELISA kits. The results, presented in Fig. 5, 
showed that three samples were positive for celiac disease (S1–S3) and the other three 
(S4-S6) were negative. The results revealed that with the dual sensor gave were obtained, 
in general, some slightly higher values than the obtained with the spectrofotometric assay. 
Nevertheless, the comparison of the results between the electrochemical immunosensor 
and commercial kits indicate an excellent degree of correlation between both 
methodologies. 
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Fig.5. Comparison of results obtained for real samples assayed with a standard ELISA kit (grey 
bars) and the proposed dual-electrochemical immunosensor (white bars). The dual sensor 
performed a simultaneous detection of immunoglobulins type A (tTG (a1) and AGA (b1)) and  
immunoglobulins type G (tTG (a2) and AGA (b2)). The presented cut-off levels (a1: 5-8 U mL-1; a2: 
7-10 U mL-1, b1 and b2: 11-17 U mL-1) are the recommended by the ELISA kits. Sensor’s 
experimental conditions as in Fig. 4.   
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3.5. Assessment of real serum samples with the dual-electrochemical immunosensor 
In CD clinical diagnosis the most important analytical aspect is verifying the presence or 
the absence of CD serological markers in patient´s samples. Therefore a qualitative 
analysis based on a binary yes/no format is sufficient to determine the analytical 
parameters of this autoimmune condition. To achieved this goal, a cut-off line (see Fig. 6. 
horizontal dotted and dashed lines) was determine as the average peak current intensity 
plus three times the standard deviation obtained for 15 negative samples of healthy 
individuals. The dual immunosensor was then applied to the simultaneous analysis of 12 
different human sera samples from CD patients and healthy individuals for the detection 
of the serological markers in study. The results are presented in Fig. 6 and show that six 
samples were positive for celiac disease (1–6) and the other six samples (7-12) assayed 
remained below the cut-off line. The results were corroborated with the commercial ElISA 
kits. 
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Fig.6. Evaluation of 6 positive and 6 negative human samples for the simultaneous detection of 
class A immunoglobulins, tTG  IgA (a1) and AGA IgA (b1), and  class G immunoglobulins, tTG IgG 
(a2) and AGA IgG (b2), using the optimized electrochemical immunosensor. Optimized conditions 
as in Fig. 4. (average data ± standard deviations are indicated (n = 3)).  
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4. Conclusions 
The new tendencies in analytical chemistry are moving towards the development of 
simple, fast and in situ diagnostic devices. Electrochemical immunosensors offer exciting 
opportunities for numerous decentralized clinical applications and the development of 
disposable screen-printed electrodes was an important contribution due to their electrical 
properties and small size. Therefore, in this work, a disposable dual-electrochemical 
immunosensor for the simultaneous detection of two significant serological markers of 
celiac disease was developed. Aspects as the optimization of the recognition element (e.g. 
antigen), the detection labelled antibody and the reproducibility of the sensor were 
investigated. The sensor unequivocally assayed 12 real samples from healthy and celiac 
individuals, whose veracity was corroborated with a commercial ElISA Kit. Moreover, a 
correlation between the average values obtained with the sensor (in arbitrary units) and 
those obtained with the ELISA for the same samples was also achieved. The results show 
that both methodologies are in good agreement. The proposed sensor is a sensitive and 
effective methodology to the simultaneous determination of IgA and IgG antibodies 
against gliadin and tissue-transglutaminase. In future, the reduction of the steps in the 
construction of the sensors will be evaluated.  
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Brief introduction 
Celiac disease (CD) is caused by a genetically determined specific immune response to 
antigens present in gluten. Gliadins, namely, α-gliadins, are considered the main agent in 
the autoimmune response [1]. This immune response may be focused on a limited region 
of the  α-gliadin component of gluten, and previous studies have suggested that the 
generation of epitopes for recognition by CD4+ T cells requires deamidation of the protein 
by tissue transglutaminase (tTG). tTG catalyzes gliadin deamidation in the intestinal 
mucosa of celiac disease patients, resulting in deamidated gliadin peptides (DGP) which 
are recognized by human leucocyte antigen, HLA-DQ2, receptors of immune cells. 
However, it had not previously been shown that candidate epitope peptides could be 
generated from gluten in vivo, or that these epitopes were selective products of 
physiological digestion of gluten by tissue transglutaminase [2].  
By mimicking the enzymatic gastrointestinal digestion of a representative α-gliadin 
was found that a 33-mer peptide (LQLQPFPQPQLPYP QPQLPYPQPQLPYPQPQPF; α2-
gliadin 56–88) containing known peptide epitopes is generated by digestion with 
intestinal enzymes in vivo and in vitro, producing a highly stimulatory antigen for CD4+ T 
cells [3]. This fragment was resistant to further breakdown by luminal proteases and 
intestinal brush-border enzymes due to its high proline content. The 33-mer contains six 
partly overlapping copies of three DQ2-restricted T cell alpha epitopes [4].  
The detection of anti- gliadin antibodies (AGA) begin to be in disuse because AGA test 
lacks of specificity in comparasion with anti-tTG antibodies assays.  This disadvantage was 
overcome by the introduction of DGP as antigen. Therefore deamidated gliadin antibodies, 
especially class G immunoglobulins (IgG), are specific for CD and their detection of 
outmust interest [5]. At the moment, there are any publications in literature regarding 
electrochemical immunosensors for CD diagnosis using anti-deamidated gliadin 
antibodies as serological markers. Therefore, an experimental work to achieve this 
purpose has been started within the scope of this dissertation; however the results 
presented here still are preliminary. 
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Experimental 
 Apparatus and reagents 
Voltammetric analysis was performed with an Autolab PGSTAT 12 (Eco Chimie B.V, 
The Netherlands) potentiostat/galvanostat interfaced to an AMD K-6 266 MHz computer 
system and controlled by Autolab GPES 4.8 software (version for Windows 98). Screen-
printed carbon electrodes (SPCEs) and a specific connector were purchased from 
DropSens (Spain). Carboxyl modified multiwalled carbon nanotubes (MWCNTs) were 
purchased from Nanocyl (Belgium). Standard gold tetrachloroaurate (AuCl4−) and silver 
nitrate were obtained from Merck (Germany). Biosynth (Switzerland) supplied the 3-
indoxyl phosphate disodium salt (3-IP). A fusion protein of 4 deamidated gliadin peptides 
(33 kDa) (DGPx4: carrier-33merDGP - 26merDGP - DQ2-γ1 - DQ2-γ2) was purchased 
from Zedira (Germany). Goat anti-human IgG (Fc specific) conjugated with alkaline 
phosphatase (anti-H-IgG-AP) was purchased from Sigma (Spain). The sensor was assayed 
with anonymous sera samples collected in the “Hospital Universitario Central de Asturias” 
(Spain), previously analysed with VARELISA Gliadin IgG Antibodies ELISA kit supplied 
by Phadia (Germany). Ultrapure water obtained with a Millipore Direct-QTM purification 
system from Millipore Ibérica S.A. (Spain) was used throughout this work. All chemicals 
employed were of analytical reagent grade.  
 
Procedure 
Single-use SPCEs were modified with 4 µL of a 0.1 mg mL−1 MWCNTs dispersion and the 
solution was left to dry at room temperature until its complete evaporation. Then, the 
MWCNTs-modified electrodes were carefully washed with water and dried at room 
temperature. The coating process was followed by in situ electrochemical deposition of gold 
nanoparticles (NPAus) by applying a constant current intensity of −5  µA for 60 s in an acidic 
solution of 0.1 mM AuCl4− [6]. 
 
The immunosensing strategy comprises the following steps: 
- The SPCE–MWCNT–NPAus working electrodes (WE) were coated with 10 µL of 0.30  
µg.µL−1 DPGx4 solution  and left to incubate overnight at 4 ◦C. 
-Washing of the electrode using 0.1M Tris–HNO3 pH 7.2 buffer. 
- Free surface sites were blocked with 40 µL of 2% bovine serum albumin (BSA) solution for 
30 min. 
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- The immunosensor was incubated with human serum samples for 60 min followed by a 
washing step with a 0.1 M Tris–HNO3 pH 7.2 buffer containing 2 mM Mg(NO3)2.  
- Finally, the immunosensor was incubated with an anti-H-IgG-AP (1:50,000) solution (40 
µL) for 60 min and washed with a 0.1 M Tris pH 9.8 buffer containing 20 mM Mg(NO3)2.  
- The enzymatic reaction was carried out by dropping a 40 µL aliquot of a solution 
containing 1.0 mM 3-IP and 0.4 mM silver nitrate on the immunosensor surface. The 
enzymatically deposition of metallic silver catalyzed by alkaline phosphatase (AP) was 
already reported [7].  
- After 20 min of reaction, a cyclic voltammogram was recorded from –0.002 V to +0.4V, 
at scan rate of 50 mV s-1, to obtain the electrochemical oxidation current of the 
enzymatically deposited silver. 
 
Results and discussion 
The aim ofthis work was the development of an EI for the detection of anti-DGP in 
human serum samples. For that purpose, DGP were immobilized on the nanostructured 
electrode surface working as the capture element of the sensing phase. A carrier protein 
linked with DGP was chosen instead of an deamidated α-gliadin, because this peptide with 
only 33 amino acids (aa56-88) is too small (approximately 4 Da). Therefore, its 
immobilization onto a solid transducer surface is very difficult, even in spite of the 
presence of nanomaterials that amplify the analytical signal. In this way, a carrier fusion 
protein with approximately 33 kDa is more likely to be useful to this immobilization 
strategy, ensuring the success of the immobilization strategy. The DGPx4 is a fusion 
protein of 2 different deamidated gliadin peptides and 2 DQ2-epitopes, fused with a 
carrier protein to be used as antigen for the detection of antibodies specific for deamidated 
gliadin [8].  
The influence of the concentrations of the capture element and of the secondary 
labeled antibody on the analytical signal and was investigated. The best relation between 
analytical and background signal was achieved for a DPGx4 concentration of 0.30 µg µL-1 
and a dilution of 1:50000 was achieved for anti-H-IgG-AP. Free surface sites were 
effectively blocked with BSA (2%). These optimized experimental conditions were used to 
the assessment of serological markers in real serum samples. Figure 1 shows typical cyclic 
voltammograms obtained for the detection of anti-DGP antibodies in positive and negative 
samples, under optimized experimental conditions. There is a significant difference 
between the analytical signals obtained in the presence and in the absence of the capture 
element (i.e. DGPx4) in the immunosensing architecture. 
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Figure 1. Cyclic voltammograms obtained for the detection of anti-gliadin deamidated antibodies 
in positive and negative samples, using a transducer surface with the capture element (DGPx4) 
immobilized (solid lines) and with no capture element immobilized (dashed lines). The analytical 
signal obtained with the absence of a sample was also investigated. Experimental conditions: 
DPGx4 0.30 µg µL-1, serum samples diluted 1:200; anti-H-IgG-AP 1:50000; 3-IP 1.0 mM; Ag+ 0.4 
mM. Cyclic voltammetric scans from −0.02 V to +0.4 V at a scan rate of 50 mV s−1.   
 
Afterwards, the immunosensor was applied in the assessment of the antibodies of interest 
in real serum samples. For that purpose, a cut-off line  was determine as the average peak 
current intensity plus three times the standard deviation obtained for 15 negative samples 
of healthy individuals. Ten different serum samples (5 positive and 5 negative) previously 
analyzed with an ELISA kit, were assayed with the immunosensor for the detection of 
anti-DGPx4 class G antibodies. The results presented in Figure 2 revealed that the EI, in 
development, presents a good qualitative correlation with the reference methods for CD 
diagnosis. 
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Figure 2.  Evaluation of 5 negative     and 5 positive     human serum samples for the detection of 
class G immunoglobulins generated against deamidated gliadin peptides, using the optimized 
electrochemical immunosensor. Optimized conditions as in Figure 1 (average data ± standard 
deviations are indicated (n = 3)). 
 
 
Conclusions  
These results demonstrate the usefulness of this new electrochemical immunosensor 
for the detection of anti-DPG antibodies. Nevertheless, these results are preliminary and a 
more complete validation procedure has to be carried out. 
 In future would be interesting to use dual-screen printed electrodes to endorse the 
detection of antibodies against IgG, DPG in combination with IgA tissue transglutaminase 
in order to facilitate diagnostic work-up and the follow-up of this autoimmune condition. 
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In this thesis, electrochemical immunosensors (EIs) for cealic desease (CD) diagnosis 
were developed through the combination of traditional immunochemical methods with 
modern electrochemical transducers. The association of favourable characteristics like the 
high specificity of the traditional immunochemical methods and the short analysis times 
and low limits of detection of the electroanalytical techniques resulted in faster, simpler 
and more sensitive analysis. In the pursued of achieving this main goal, several diferent 
partial goals were attained along the process. 
 Baring in mind that the development of the transducer surface is a crucial step in 
the construction of a biosensor device, several approaches were tested. Therefore, 
different transducer formats (SPCEs; SPCE-MWCNTs; SPCE-NPAus; SPCE-MWCNT-
NPAus; SPCE-CNFs; SPCE-CNF-NPAus) were evaluated and their biofunctionality was 
tested by employing the highly specific strepatividin/biotin complex. The transducers 
modified with a hybrid conjugation of carbon nanotubes and gold nanoparticles showed 
the best results, and were used in all the subsequent studies. Moreover, this hybrid 
transducer surface, once modified with streptavidin, offered a stable surface for at least 30 
days, which is ideal for use in solid-phase assays with biotinylated molecules (such as 
antibodies, enzymes, DNA, etc..), and is a direct response to requests from researchers in 
the biosensor field. The results of this study were important not only to decide which was 
the best transducer surface to work with, but also to increase the knowledge of the 
development and optimization of nanostructured screen-printed biosensors, providing a 
stronger basis for the development and optimization of EIs. Thus, besides the application 
of the resulting transducers in the subsequent steps of the present work they are also 
expected to be useful in (bio)analytical chemistry as a whole and in electroanalysis in 
particular.  
After selecting the most adequate transducer surface, the sensing phases of the EIs 
were constructed relying on antigen-antibody interactions. The fact that antibodies can be 
produced specifically against many biological analytes of interest improves the EIs 
versatility. 
EIs for clinical diagnosis of CD, through the detection of antibodies (classes A and G), 
directed against gliadin and tissue transglutaminase were the ones first developed. 
Because of sucessful results, the separated EIs were transfered to a multiplexed detection 
platform in order to perform a simultaneous detection of both CD serological markers. 
Dual-SPCE-MWCNT-NPAus were employed and a more complete screening of CD was 
acomplished. Finally, the study of an EI for the detection of anti- deaminated gliadin IgG 
antibodies was also inciated. The initial results are very promising. In all the developed 
sensors the recognition elements were successfully immobilized on the nanohybrid SPCE 
surface and different human serum samples were analyzed. Corroboration of the results 
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with commercial ELISA kits indicated that the proposed EIs are trustful analytical 
screening tools. Therefore, new disposable platforms for CD diagnosis were sucessfuly 
developed in this dissertation. 
In comparison with other reported biosensors (optical or electrochemical), the EIs 
developed in this dissertation have the clear advantage of being constructed on disposable 
SPEs, which avoids some problems such as memory effects and tedious cleaning 
processes, typical of classical solid electrodes. Moreover, these SPEs were not homemade 
but industrially produced, which largely reduces the possibility of irreproducibility in their 
format. The use of SPEs as electrodic transducer surfaces, being small-sized, easy to 
handle and able to be incorporated in portable ready-to-use devices (e.g. similar to the 
ones of glucose sensors) is the best option, in this field, to decentralize clinical 
applications. Moreover, the studies presented in this dissertation were performed with 
human serum samples, which ensure the adequate evaluation of the sensitivity and 
specificity of the methodologies and also indicates that matrix effects are controlled. 
Moreover, to the best of our knowledge, these are the first studies regarding the 
employment of electrochemical immunosensors for simultaneous detection of AGA and 
anti-tTG antibodies as well as for the detection of anti-DGP antibodies. 
Nevertheless, in future studies, it would be important to reduce the time of the 
immunosensing architecture steps. To achieve a point-of-care technology the analysis has 
to be performed in a simple and rapid way. In this dissertation the development of the 
methodology is presented, so now it would be interesting to pursue this line of research. 
At the start of this doctoral research project, the development of an EI for detection of 
gluten traces in “gluten-free” food samples was also foreseen. However, this was not 
possible in the given time frame. Thus, the other future prespective would be the 
development of that EI to analyse gluten in foodstuffs which are naturally gluten-free or in 
products from which gluten has been eliminated, in order to ensure a safe diet for celiac 
patients. In this way, EIs can be useful analytical tools for the two biggest problems that 
are related to celiac disease: the diagnostic/follow-up and the quality control of gluten-free 
food. With the experimental work carried out in this doctoral thesis, new advances in the 
field of electrochemical biosensing were accomplished. The end of this dissertation is not 
necessarily a finalization of a project, instead it's a starting point for future challenges. 
 
 
 
